date generated: 2022-08-23

Background

Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch

Input profiles

Here is the first few lines of the input profile.

##                   KO        drug
## 5_8S_rRNA -0.4520464  13.3741078
## 7SK       -2.2982399   8.2273400
## A1BG      -3.3008939   6.5685508
## A1BG-AS1   0.3211569   2.0363758
## A1CF      -0.7352419  -0.3352928
## A2M       30.2687300 -19.6839168
Here are some metrics about the input data profile:
Profile metrics
Profile metrics
num_genes_in_profile 24473
duplicated_genes_present 0
num_profile_genes_in_sets 8850
num_profile_genes_not_in_sets 15623
profile_pearson_correl 0.06908
profile_spearman_correl 0.09129

Here is a plot of the input profiles. Note the dynamic ranges.

Here is the contour plot of the profile including all detected genes.

Input genesets

Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt
Gene sets metrics
Gene sets metrics
num_genesets 2512
num_genesets_excluded 1047
num_genesets_included 1465

Gene sets by quadrant


Number of significant gene sets (FDR<0.05)= 928

Interactive enrichment scatterplot

All sets with FDR<0.05. Try hovering over the points.

Top N sets irrespective of FDR. Try hovering over the points.

A heatmap of S values for top results


A plot of effect size versus significance


Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.

Results table

Top N= 52 gene sets
set setSize pMANOVA p.adjustMANOVA s.dist s.KO s.drug p.KO p.drug
CLEC7A (Dectin-1) induces NFAT activation 11 3.38e-06 1.31e-05 0.897 -0.3080 -0.842 7.70e-02 1.30e-06
Cohesin Loading onto Chromatin 10 1.94e-05 6.18e-05 0.865 -0.1960 -0.842 2.83e-01 3.98e-06
MET activates RAP1 and RAC1 11 1.26e-05 4.27e-05 0.856 -0.3990 -0.758 2.20e-02 1.35e-05
Syndecan interactions 19 5.07e-10 4.45e-09 0.844 0.2160 -0.816 1.04e-01 7.21e-10
Peptide chain elongation 87 2.79e-43 3.40e-41 0.830 -0.4220 0.715 9.35e-12 8.26e-31
Viral mRNA Translation 87 3.07e-43 3.46e-41 0.830 -0.4200 0.715 1.17e-11 7.10e-31
APC truncation mutants have impaired AXIN binding 14 1.34e-06 5.64e-06 0.828 -0.3480 -0.752 2.43e-02 1.10e-06
AXIN missense mutants destabilize the destruction complex 14 1.34e-06 5.64e-06 0.828 -0.3480 -0.752 2.43e-02 1.10e-06
Signaling by AMER1 mutants 14 1.34e-06 5.64e-06 0.828 -0.3480 -0.752 2.43e-02 1.10e-06
Signaling by APC mutants 14 1.34e-06 5.64e-06 0.828 -0.3480 -0.752 2.43e-02 1.10e-06
Signaling by AXIN mutants 14 1.34e-06 5.64e-06 0.828 -0.3480 -0.752 2.43e-02 1.10e-06
Truncations of AMER1 destabilize the destruction complex 14 1.34e-06 5.64e-06 0.828 -0.3480 -0.752 2.43e-02 1.10e-06
Laminin interactions 23 1.23e-11 1.39e-10 0.827 0.2690 -0.782 2.58e-02 8.23e-11
ERKs are inactivated 13 4.26e-06 1.60e-05 0.821 -0.3330 -0.751 3.74e-02 2.76e-06
Receptor Mediated Mitophagy 11 2.63e-05 8.10e-05 0.819 -0.7760 -0.263 8.30e-06 1.31e-01
S33 mutants of beta-catenin aren’t phosphorylated 15 7.71e-07 3.45e-06 0.811 -0.2600 -0.768 8.08e-02 2.62e-07
S37 mutants of beta-catenin aren’t phosphorylated 15 7.71e-07 3.45e-06 0.811 -0.2600 -0.768 8.08e-02 2.62e-07
S45 mutants of beta-catenin aren’t phosphorylated 15 7.71e-07 3.45e-06 0.811 -0.2600 -0.768 8.08e-02 2.62e-07
Signaling by CTNNB1 phospho-site mutants 15 7.71e-07 3.45e-06 0.811 -0.2600 -0.768 8.08e-02 2.62e-07
Signaling by GSK3beta mutants 15 7.71e-07 3.45e-06 0.811 -0.2600 -0.768 8.08e-02 2.62e-07
T41 mutants of beta-catenin aren’t phosphorylated 15 7.71e-07 3.45e-06 0.811 -0.2600 -0.768 8.08e-02 2.62e-07
Mucopolysaccharidoses 11 1.36e-05 4.58e-05 0.799 0.7560 -0.258 1.41e-05 1.38e-01
Defective EXT1 causes exostoses 1, TRPS2 and CHDS 13 1.43e-06 5.93e-06 0.799 0.3580 -0.714 2.55e-02 8.23e-06
Defective EXT2 causes exostoses 2 13 1.43e-06 5.93e-06 0.799 0.3580 -0.714 2.55e-02 8.23e-06
Establishment of Sister Chromatid Cohesion 11 5.26e-05 1.53e-04 0.795 -0.2980 -0.737 8.65e-02 2.30e-05
Eukaryotic Translation Termination 91 2.19e-41 1.89e-39 0.794 -0.4020 0.684 3.27e-11 1.32e-29
Eukaryotic Translation Elongation 92 1.82e-41 1.67e-39 0.790 -0.4120 0.674 8.16e-12 4.97e-29
Formation of a pool of free 40S subunits 99 1.26e-44 1.68e-42 0.789 -0.4440 0.652 2.03e-14 3.21e-29
Signaling by Hippo 20 1.90e-08 1.19e-07 0.781 -0.1620 -0.764 2.09e-01 3.23e-09
Synthesis of PIPs at the early endosome membrane 16 1.36e-06 5.69e-06 0.773 -0.2980 -0.713 3.91e-02 7.87e-07
Synthesis of PIPs at the late endosome membrane 11 1.09e-04 2.94e-04 0.771 -0.3830 -0.670 2.78e-02 1.20e-04
HDMs demethylate histones 22 1.14e-08 7.46e-08 0.771 -0.3580 -0.683 3.61e-03 2.94e-08
Unwinding of DNA 12 5.50e-05 1.60e-04 0.770 0.6030 0.480 2.99e-04 4.02e-03
Activation of RAC1 13 2.04e-05 6.47e-05 0.770 -0.3400 -0.690 3.36e-02 1.63e-05
Selenocysteine synthesis 91 1.38e-38 8.77e-37 0.768 -0.3550 0.681 4.60e-09 2.66e-29
Cell-extracellular matrix interactions 16 2.20e-06 8.89e-06 0.766 -0.4180 -0.642 3.77e-03 8.63e-06
MET activates PTK2 signaling 18 6.80e-08 3.72e-07 0.765 0.1550 -0.749 2.56e-01 3.71e-08
Signaling by PDGFRA extracellular domain mutants 12 4.81e-05 1.41e-04 0.763 -0.2630 -0.716 1.14e-01 1.74e-05
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants 12 4.81e-05 1.41e-04 0.763 -0.2630 -0.716 1.14e-01 1.74e-05
Beta-catenin phosphorylation cascade 17 8.19e-07 3.66e-06 0.762 -0.2730 -0.711 5.12e-02 3.79e-07
tRNA processing in the mitochondrion 20 6.21e-08 3.42e-07 0.755 0.1600 0.738 2.16e-01 1.09e-08
Response of EIF2AK4 (GCN2) to amino acid deficiency 99 6.60e-41 5.37e-39 0.755 -0.4230 0.625 3.36e-13 5.07e-27
ERK/MAPK targets 22 2.93e-08 1.77e-07 0.751 -0.3520 -0.663 4.27e-03 7.08e-08
Non-integrin membrane-ECM interactions 41 1.27e-16 2.25e-15 0.751 0.2000 -0.724 2.68e-02 1.00e-15
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) 93 6.86e-38 4.02e-36 0.749 -0.4240 0.617 1.55e-12 6.83e-25
Complex I biogenesis 57 8.21e-22 2.23e-20 0.740 -0.1230 0.729 1.09e-01 1.49e-21
Defective B4GALT7 causes EDS, progeroid type 18 1.10e-07 5.83e-07 0.739 0.3710 -0.639 6.44e-03 2.71e-06
Formation of the ternary complex, and subsequently, the 43S complex 50 7.28e-20 1.67e-18 0.731 -0.5010 0.532 8.83e-10 7.23e-11
Signaling by PDGFR in disease 19 5.53e-07 2.59e-06 0.726 -0.1980 -0.698 1.35e-01 1.36e-07
MET promotes cell motility 29 1.04e-10 1.03e-09 0.725 -0.0110 -0.725 9.19e-01 1.37e-11
Regulation of gene expression by Hypoxia-inducible Factor 10 4.08e-04 9.76e-04 0.721 -0.0291 -0.720 8.74e-01 7.95e-05
Deadenylation of mRNA 22 1.59e-07 8.27e-07 0.720 -0.4910 -0.526 6.62e-05 1.96e-05


Results (complete table)


Click HERE to show results for all gene sets

Complete results
set setSize pMANOVA p.adjustMANOVA s.dist s.KO s.drug p.KO p.drug
CLEC7A (Dectin-1) induces NFAT activation 11 3.38e-06 1.31e-05 0.8970 -3.08e-01 -0.842000 7.70e-02 1.30e-06
Cohesin Loading onto Chromatin 10 1.94e-05 6.18e-05 0.8650 -1.96e-01 -0.842000 2.83e-01 3.98e-06
MET activates RAP1 and RAC1 11 1.26e-05 4.27e-05 0.8560 -3.99e-01 -0.758000 2.20e-02 1.35e-05
Syndecan interactions 19 5.07e-10 4.45e-09 0.8440 2.16e-01 -0.816000 1.04e-01 7.21e-10
Peptide chain elongation 87 2.79e-43 3.40e-41 0.8300 -4.22e-01 0.715000 9.35e-12 8.26e-31
Viral mRNA Translation 87 3.07e-43 3.46e-41 0.8300 -4.20e-01 0.715000 1.17e-11 7.10e-31
APC truncation mutants have impaired AXIN binding 14 1.34e-06 5.64e-06 0.8280 -3.48e-01 -0.752000 2.43e-02 1.10e-06
AXIN missense mutants destabilize the destruction complex 14 1.34e-06 5.64e-06 0.8280 -3.48e-01 -0.752000 2.43e-02 1.10e-06
Signaling by AMER1 mutants 14 1.34e-06 5.64e-06 0.8280 -3.48e-01 -0.752000 2.43e-02 1.10e-06
Signaling by APC mutants 14 1.34e-06 5.64e-06 0.8280 -3.48e-01 -0.752000 2.43e-02 1.10e-06
Signaling by AXIN mutants 14 1.34e-06 5.64e-06 0.8280 -3.48e-01 -0.752000 2.43e-02 1.10e-06
Truncations of AMER1 destabilize the destruction complex 14 1.34e-06 5.64e-06 0.8280 -3.48e-01 -0.752000 2.43e-02 1.10e-06
Laminin interactions 23 1.23e-11 1.39e-10 0.8270 2.69e-01 -0.782000 2.58e-02 8.23e-11
ERKs are inactivated 13 4.26e-06 1.60e-05 0.8210 -3.33e-01 -0.751000 3.74e-02 2.76e-06
Receptor Mediated Mitophagy 11 2.63e-05 8.10e-05 0.8190 -7.76e-01 -0.263000 8.30e-06 1.31e-01
S33 mutants of beta-catenin aren’t phosphorylated 15 7.71e-07 3.45e-06 0.8110 -2.60e-01 -0.768000 8.08e-02 2.62e-07
S37 mutants of beta-catenin aren’t phosphorylated 15 7.71e-07 3.45e-06 0.8110 -2.60e-01 -0.768000 8.08e-02 2.62e-07
S45 mutants of beta-catenin aren’t phosphorylated 15 7.71e-07 3.45e-06 0.8110 -2.60e-01 -0.768000 8.08e-02 2.62e-07
Signaling by CTNNB1 phospho-site mutants 15 7.71e-07 3.45e-06 0.8110 -2.60e-01 -0.768000 8.08e-02 2.62e-07
Signaling by GSK3beta mutants 15 7.71e-07 3.45e-06 0.8110 -2.60e-01 -0.768000 8.08e-02 2.62e-07
T41 mutants of beta-catenin aren’t phosphorylated 15 7.71e-07 3.45e-06 0.8110 -2.60e-01 -0.768000 8.08e-02 2.62e-07
Mucopolysaccharidoses 11 1.36e-05 4.58e-05 0.7990 7.56e-01 -0.258000 1.41e-05 1.38e-01
Defective EXT1 causes exostoses 1, TRPS2 and CHDS 13 1.43e-06 5.93e-06 0.7990 3.58e-01 -0.714000 2.55e-02 8.23e-06
Defective EXT2 causes exostoses 2 13 1.43e-06 5.93e-06 0.7990 3.58e-01 -0.714000 2.55e-02 8.23e-06
Establishment of Sister Chromatid Cohesion 11 5.26e-05 1.53e-04 0.7950 -2.98e-01 -0.737000 8.65e-02 2.30e-05
Eukaryotic Translation Termination 91 2.19e-41 1.89e-39 0.7940 -4.02e-01 0.684000 3.27e-11 1.32e-29
Eukaryotic Translation Elongation 92 1.82e-41 1.67e-39 0.7900 -4.12e-01 0.674000 8.16e-12 4.97e-29
Formation of a pool of free 40S subunits 99 1.26e-44 1.68e-42 0.7890 -4.44e-01 0.652000 2.03e-14 3.21e-29
Signaling by Hippo 20 1.90e-08 1.19e-07 0.7810 -1.62e-01 -0.764000 2.09e-01 3.23e-09
Synthesis of PIPs at the early endosome membrane 16 1.36e-06 5.69e-06 0.7730 -2.98e-01 -0.713000 3.91e-02 7.87e-07
Synthesis of PIPs at the late endosome membrane 11 1.09e-04 2.94e-04 0.7710 -3.83e-01 -0.670000 2.78e-02 1.20e-04
HDMs demethylate histones 22 1.14e-08 7.46e-08 0.7710 -3.58e-01 -0.683000 3.61e-03 2.94e-08
Unwinding of DNA 12 5.50e-05 1.60e-04 0.7700 6.03e-01 0.480000 2.99e-04 4.02e-03
Activation of RAC1 13 2.04e-05 6.47e-05 0.7700 -3.40e-01 -0.690000 3.36e-02 1.63e-05
Selenocysteine synthesis 91 1.38e-38 8.77e-37 0.7680 -3.55e-01 0.681000 4.60e-09 2.66e-29
Cell-extracellular matrix interactions 16 2.20e-06 8.89e-06 0.7660 -4.18e-01 -0.642000 3.77e-03 8.63e-06
MET activates PTK2 signaling 18 6.80e-08 3.72e-07 0.7650 1.55e-01 -0.749000 2.56e-01 3.71e-08
Signaling by PDGFRA extracellular domain mutants 12 4.81e-05 1.41e-04 0.7630 -2.63e-01 -0.716000 1.14e-01 1.74e-05
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants 12 4.81e-05 1.41e-04 0.7630 -2.63e-01 -0.716000 1.14e-01 1.74e-05
Beta-catenin phosphorylation cascade 17 8.19e-07 3.66e-06 0.7620 -2.73e-01 -0.711000 5.12e-02 3.79e-07
tRNA processing in the mitochondrion 20 6.21e-08 3.42e-07 0.7550 1.60e-01 0.738000 2.16e-01 1.09e-08
Response of EIF2AK4 (GCN2) to amino acid deficiency 99 6.60e-41 5.37e-39 0.7550 -4.23e-01 0.625000 3.36e-13 5.07e-27
ERK/MAPK targets 22 2.93e-08 1.77e-07 0.7510 -3.52e-01 -0.663000 4.27e-03 7.08e-08
Non-integrin membrane-ECM interactions 41 1.27e-16 2.25e-15 0.7510 2.00e-01 -0.724000 2.68e-02 1.00e-15
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) 93 6.86e-38 4.02e-36 0.7490 -4.24e-01 0.617000 1.55e-12 6.83e-25
Complex I biogenesis 57 8.21e-22 2.23e-20 0.7400 -1.23e-01 0.729000 1.09e-01 1.49e-21
Defective B4GALT7 causes EDS, progeroid type 18 1.10e-07 5.83e-07 0.7390 3.71e-01 -0.639000 6.44e-03 2.71e-06
Formation of the ternary complex, and subsequently, the 43S complex 50 7.28e-20 1.67e-18 0.7310 -5.01e-01 0.532000 8.83e-10 7.23e-11
Signaling by PDGFR in disease 19 5.53e-07 2.59e-06 0.7260 -1.98e-01 -0.698000 1.35e-01 1.36e-07
MET promotes cell motility 29 1.04e-10 1.03e-09 0.7250 -1.10e-02 -0.725000 9.19e-01 1.37e-11
Regulation of gene expression by Hypoxia-inducible Factor 10 4.08e-04 9.76e-04 0.7210 -2.91e-02 -0.720000 8.74e-01 7.95e-05
Deadenylation of mRNA 22 1.59e-07 8.27e-07 0.7200 -4.91e-01 -0.526000 6.62e-05 1.96e-05
Interleukin-6 signaling 11 3.64e-04 8.89e-04 0.7160 -3.18e-01 -0.642000 6.81e-02 2.26e-04
Regulation of PTEN mRNA translation 12 2.08e-04 5.35e-04 0.7160 -4.54e-01 -0.554000 6.49e-03 8.83e-04
Platelet sensitization by LDL 15 2.23e-05 7.00e-05 0.7110 -2.78e-01 -0.654000 6.24e-02 1.14e-05
L13a-mediated translational silencing of Ceruloplasmin expression 109 3.24e-39 2.26e-37 0.7020 -4.66e-01 0.525000 3.94e-17 2.32e-21
FOXO-mediated transcription of cell cycle genes 15 1.84e-05 5.97e-05 0.6970 -3.90e-02 -0.696000 7.94e-01 3.06e-06
Caspase activation via Dependence Receptors in the absence of ligand 10 1.11e-03 2.41e-03 0.6950 -2.83e-01 -0.635000 1.22e-01 5.07e-04
DCC mediated attractive signaling 14 4.56e-05 1.34e-04 0.6940 -7.57e-02 -0.690000 6.24e-01 7.81e-06
CTLA4 inhibitory signaling 17 1.05e-05 3.60e-05 0.6930 -3.05e-01 -0.623000 2.93e-02 8.78e-06
Gastrin-CREB signalling pathway via PKC and MAPK 17 1.16e-05 3.97e-05 0.6920 -3.40e-01 -0.603000 1.52e-02 1.66e-05
Competing endogenous RNAs (ceRNAs) regulate PTEN translation 11 7.22e-04 1.64e-03 0.6910 -4.38e-01 -0.534000 1.18e-02 2.15e-03
GTP hydrolysis and joining of the 60S ribosomal subunit 110 3.32e-38 2.03e-36 0.6900 -4.42e-01 0.530000 1.11e-15 6.60e-22
Other semaphorin interactions 15 8.68e-06 3.06e-05 0.6890 3.59e-01 -0.588000 1.59e-02 7.98e-05
Defective B3GAT3 causes JDSSDHD 18 9.01e-07 3.96e-06 0.6870 3.76e-01 -0.575000 5.69e-03 2.43e-05
Downstream signal transduction 29 5.13e-09 3.61e-08 0.6860 -3.18e-01 -0.608000 3.03e-03 1.44e-08
Signaling by FGFR3 fusions in cancer 10 1.28e-03 2.75e-03 0.6780 -1.64e-01 -0.658000 3.69e-01 3.13e-04
Defective B3GALT6 causes EDSP2 and SEMDJL1 18 1.31e-06 5.63e-06 0.6770 3.75e-01 -0.564000 5.92e-03 3.38e-05
Signaling by Activin 15 7.85e-05 2.18e-04 0.6760 -5.34e-01 -0.414000 3.40e-04 5.44e-03
rRNA processing in the mitochondrion 24 8.25e-08 4.43e-07 0.6740 4.17e-02 0.673000 7.24e-01 1.14e-08
Adenylate cyclase inhibitory pathway 12 3.49e-04 8.58e-04 0.6700 -8.82e-02 -0.664000 5.97e-01 6.71e-05
Synthesis of PIPs at the Golgi membrane 15 7.24e-05 2.04e-04 0.6700 -2.52e-01 -0.621000 9.07e-02 3.14e-05
RORA activates gene expression 18 9.75e-06 3.38e-05 0.6670 -1.79e-01 -0.643000 1.89e-01 2.34e-06
RHO GTPases activate KTN1 11 1.20e-03 2.60e-03 0.6650 -3.84e-01 -0.543000 2.75e-02 1.81e-03
SRP-dependent cotranslational protein targeting to membrane 110 3.90e-35 1.97e-33 0.6620 -3.93e-01 0.533000 9.93e-13 4.19e-22
Cap-dependent Translation Initiation 117 2.43e-37 1.32e-35 0.6620 -4.23e-01 0.509000 2.56e-15 1.77e-21
Eukaryotic Translation Initiation 117 2.43e-37 1.32e-35 0.6620 -4.23e-01 0.509000 2.56e-15 1.77e-21
STAT5 activation downstream of FLT3 ITD mutants 10 2.20e-03 4.43e-03 0.6610 -3.03e-01 -0.588000 9.75e-02 1.28e-03
Signaling by KIT in disease 19 7.69e-06 2.73e-05 0.6590 -2.17e-01 -0.623000 1.02e-01 2.62e-06
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants 19 7.69e-06 2.73e-05 0.6590 -2.17e-01 -0.623000 1.02e-01 2.62e-06
Signaling by FLT3 fusion proteins 19 4.96e-06 1.85e-05 0.6570 -5.33e-02 -0.655000 6.88e-01 7.73e-07
Reduction of cytosolic Ca++ levels 12 1.99e-04 5.13e-04 0.6560 4.23e-01 -0.502000 1.12e-02 2.59e-03
Regulation of signaling by CBL 18 1.73e-05 5.69e-05 0.6560 -2.42e-01 -0.609000 7.58e-02 7.56e-06
Signal transduction by L1 21 3.76e-06 1.44e-05 0.6500 -2.66e-01 -0.593000 3.49e-02 2.54e-06
ALK mutants bind TKIs 12 5.44e-04 1.27e-03 0.6470 -4.16e-02 -0.646000 8.03e-01 1.06e-04
PKA activation 16 2.75e-05 8.39e-05 0.6460 1.45e-01 -0.630000 3.17e-01 1.29e-05
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S 58 5.49e-18 1.13e-16 0.6460 -5.21e-01 0.382000 6.74e-12 4.78e-07
Erythropoietin activates Phosphoinositide-3-kinase (PI3K) 11 1.15e-03 2.50e-03 0.6450 -8.01e-02 -0.640000 6.45e-01 2.36e-04
YAP1- and WWTR1 (TAZ)-stimulated gene expression 12 7.09e-04 1.62e-03 0.6420 -1.11e-01 -0.633000 5.04e-01 1.48e-04
PKA-mediated phosphorylation of CREB 18 1.23e-05 4.18e-05 0.6380 6.90e-02 -0.634000 6.12e-01 3.14e-06
Nephrin family interactions 20 9.91e-06 3.42e-05 0.6370 -2.26e-01 -0.596000 8.06e-02 3.99e-06
Mitochondrial iron-sulfur cluster biogenesis 13 1.73e-04 4.50e-04 0.6350 -4.37e-01 0.462000 6.39e-03 3.96e-03
Membrane binding and targetting of GAG proteins 14 2.14e-04 5.50e-04 0.6350 -6.34e-01 -0.032300 4.00e-05 8.34e-01
Synthesis And Processing Of GAG, GAGPOL Polyproteins 14 2.14e-04 5.50e-04 0.6350 -6.34e-01 -0.032300 4.00e-05 8.34e-01
Translation initiation complex formation 57 4.76e-17 8.61e-16 0.6340 -5.12e-01 0.373000 2.15e-11 1.12e-06
CREB1 phosphorylation through the activation of Adenylate Cyclase 10 1.71e-03 3.56e-03 0.6320 1.95e-01 -0.602000 2.86e-01 9.85e-04
GRB2:SOS provides linkage to MAPK signaling for Integrins 12 1.31e-03 2.80e-03 0.6320 -3.49e-01 -0.527000 3.66e-02 1.57e-03
Biotin transport and metabolism 11 8.11e-04 1.83e-03 0.6310 5.61e-01 -0.290000 1.28e-03 9.61e-02
Formation of ATP by chemiosmotic coupling 18 1.94e-05 6.18e-05 0.6270 -4.48e-02 0.626000 7.42e-01 4.27e-06
MAPK targets/ Nuclear events mediated by MAP kinases 31 4.32e-08 2.46e-07 0.6270 -3.15e-01 -0.542000 2.42e-03 1.73e-07
Signal regulatory protein family interactions 11 2.40e-03 4.78e-03 0.6260 -2.94e-01 -0.553000 9.18e-02 1.48e-03
Role of LAT2/NTAL/LAB on calcium mobilization 13 5.82e-04 1.35e-03 0.6250 -1.01e-01 -0.616000 5.27e-01 1.18e-04
RHOV GTPase cycle 37 8.06e-10 6.87e-09 0.6240 -1.36e-01 -0.609000 1.51e-01 1.41e-10
Prolonged ERK activation events 14 3.85e-04 9.29e-04 0.6230 -1.54e-01 -0.604000 3.17e-01 9.13e-05
Ephrin signaling 19 3.10e-05 9.41e-05 0.6230 -2.58e-01 -0.567000 5.18e-02 1.86e-05
Selenoamino acid metabolism 115 5.95e-32 2.64e-30 0.6180 -3.36e-01 0.519000 4.63e-10 6.31e-22
p130Cas linkage to MAPK signaling for integrins 12 1.86e-03 3.83e-03 0.6160 -3.77e-01 -0.488000 2.39e-02 3.42e-03
The activation of arylsulfatases 10 1.91e-03 3.91e-03 0.6160 4.17e-01 -0.454000 2.25e-02 1.29e-02
Signaling by FLT3 ITD and TKD mutants 16 1.83e-04 4.76e-04 0.6150 -2.16e-01 -0.576000 1.35e-01 6.60e-05
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 125 8.79e-33 4.03e-31 0.6150 -1.21e-01 0.603000 1.91e-02 2.15e-31
Ribosomal scanning and start codon recognition 57 4.22e-16 7.19e-15 0.6150 -4.88e-01 0.374000 1.87e-10 1.03e-06
HS-GAG degradation 19 7.84e-06 2.77e-05 0.6120 4.24e-01 -0.441000 1.36e-03 8.62e-04
Respiratory electron transport 103 4.70e-27 1.64e-25 0.6100 -1.60e-01 0.589000 4.90e-03 4.56e-25
VEGFR2 mediated cell proliferation 19 2.74e-05 8.38e-05 0.6090 -4.60e-02 -0.607000 7.28e-01 4.58e-06
Mitotic Telophase/Cytokinesis 13 1.14e-03 2.48e-03 0.6090 -2.51e-01 -0.554000 1.17e-01 5.37e-04
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs 11 1.38e-03 2.94e-03 0.6070 -5.43e-01 0.273000 1.83e-03 1.18e-01
Major pathway of rRNA processing in the nucleolus and cytosol 180 4.38e-48 7.14e-46 0.6070 -4.42e-01 0.415000 1.15e-24 6.33e-22
rRNA processing in the nucleus and cytosol 190 1.23e-50 2.57e-48 0.6060 -4.52e-01 0.404000 4.72e-27 6.93e-22
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) 113 2.07e-30 8.41e-29 0.6060 -3.92e-01 0.462000 5.64e-13 1.93e-17
Nonsense-Mediated Decay (NMD) 113 2.07e-30 8.41e-29 0.6060 -3.92e-01 0.462000 5.64e-13 1.93e-17
RHO GTPases Activate WASPs and WAVEs 36 8.07e-09 5.40e-08 0.6060 -2.40e-01 -0.556000 1.28e-02 7.57e-09
Interleukin-15 signaling 14 3.64e-04 8.89e-04 0.6060 6.72e-02 -0.602000 6.64e-01 9.64e-05
Miscellaneous transport and binding events 23 3.63e-06 1.39e-05 0.6050 -5.55e-02 -0.603000 6.45e-01 5.57e-07
Regulation of RUNX1 Expression and Activity 18 1.01e-04 2.75e-04 0.6030 -2.52e-01 -0.547000 6.39e-02 5.81e-05
Assembly Of The HIV Virion 16 1.68e-04 4.39e-04 0.6020 -6.01e-01 -0.028600 3.10e-05 8.43e-01
Heme signaling 42 5.08e-10 4.45e-09 0.6010 -2.39e-01 -0.552000 7.42e-03 6.08e-10
Spry regulation of FGF signaling 16 3.46e-04 8.50e-04 0.6010 -4.80e-01 -0.361000 8.77e-04 1.24e-02
Frs2-mediated activation 12 2.00e-03 4.07e-03 0.6010 -1.74e-01 -0.575000 2.96e-01 5.63e-04
EGR2 and SOX10-mediated initiation of Schwann cell myelination 25 2.63e-06 1.04e-05 0.6000 -1.93e-01 -0.568000 9.51e-02 8.71e-07
RHOU GTPase cycle 40 4.02e-10 3.66e-09 0.5990 -1.03e-02 -0.599000 9.10e-01 5.39e-11
Signaling by BMP 23 1.21e-05 4.13e-05 0.5970 -3.55e-01 -0.480000 3.17e-03 6.74e-05
RHOF GTPase cycle 41 1.50e-10 1.46e-09 0.5970 8.37e-02 -0.591000 3.54e-01 5.78e-11
Estrogen-dependent nuclear events downstream of ESR-membrane signaling 22 1.97e-05 6.25e-05 0.5960 -3.27e-01 -0.498000 7.83e-03 5.18e-05
Signaling by WNT in cancer 33 7.53e-08 4.09e-07 0.5950 -2.51e-01 -0.539000 1.27e-02 8.22e-08
Golgi Cisternae Pericentriolar Stack Reorganization 14 1.17e-03 2.55e-03 0.5920 -4.24e-01 -0.413000 5.97e-03 7.43e-03
CD209 (DC-SIGN) signaling 19 8.89e-05 2.43e-04 0.5910 -2.55e-01 -0.534000 5.46e-02 5.65e-05
Erythropoietin activates RAS 13 1.70e-03 3.55e-03 0.5910 -2.54e-01 -0.534000 1.13e-01 8.63e-04
Synthesis of active ubiquitin: roles of E1 and E2 enzymes 30 3.20e-07 1.56e-06 0.5900 -5.63e-01 -0.175000 9.25e-08 9.71e-02
rRNA processing 214 9.34e-54 2.74e-51 0.5890 -3.97e-01 0.435000 1.09e-23 4.38e-28
FCGR3A-mediated phagocytosis 56 1.53e-12 1.94e-11 0.5890 -2.61e-01 -0.528000 7.44e-04 7.96e-12
Leishmania phagocytosis 56 1.53e-12 1.94e-11 0.5890 -2.61e-01 -0.528000 7.44e-04 7.96e-12
Parasite infection 56 1.53e-12 1.94e-11 0.5890 -2.61e-01 -0.528000 7.44e-04 7.96e-12
SLBP independent Processing of Histone Pre-mRNAs 10 3.65e-03 6.97e-03 0.5860 -5.02e-01 0.303000 6.02e-03 9.69e-02
DNA strand elongation 32 2.68e-07 1.32e-06 0.5860 4.59e-01 0.365000 7.01e-06 3.58e-04
RAF-independent MAPK1/3 activation 22 1.85e-05 5.97e-05 0.5850 -1.43e-01 -0.567000 2.44e-01 4.05e-06
Zinc transporters 14 1.14e-03 2.48e-03 0.5850 -2.24e-01 -0.540000 1.46e-01 4.62e-04
ATF4 activates genes in response to endoplasmic reticulum stress 26 4.79e-07 2.26e-06 0.5830 -4.53e-01 0.367000 6.33e-05 1.20e-03
Nucleotide biosynthesis 12 3.67e-03 7.00e-03 0.5810 -4.82e-01 -0.324000 3.83e-03 5.17e-02
Regulation of localization of FOXO transcription factors 12 1.54e-03 3.24e-03 0.5800 2.06e-01 -0.542000 2.16e-01 1.15e-03
HS-GAG biosynthesis 27 6.29e-07 2.89e-06 0.5800 1.32e-01 -0.565000 2.37e-01 3.75e-07
Signaling by Leptin 10 7.15e-03 1.31e-02 0.5790 -8.57e-02 -0.573000 6.39e-01 1.70e-03
MET receptor recycling 10 9.22e-03 1.66e-02 0.5790 -2.63e-01 -0.515000 1.50e-01 4.77e-03
RHOJ GTPase cycle 54 6.18e-13 8.46e-12 0.5780 9.79e-02 -0.570000 2.13e-01 4.18e-13
GAB1 signalosome 15 8.90e-04 1.99e-03 0.5760 -2.23e-01 -0.531000 1.35e-01 3.72e-04
Mitochondrial translation elongation 90 3.60e-21 9.26e-20 0.5750 -1.63e-01 0.551000 7.65e-03 1.50e-19
N-Glycan antennae elongation 14 1.75e-03 3.62e-03 0.5740 -3.79e-01 -0.432000 1.41e-02 5.18e-03
Lysosphingolipid and LPA receptors 11 6.23e-03 1.15e-02 0.5740 -5.11e-01 -0.261000 3.31e-03 1.34e-01
Mitochondrial translation initiation 90 5.71e-21 1.42e-19 0.5720 -1.61e-01 0.549000 8.28e-03 2.15e-19
Aflatoxin activation and detoxification 14 1.43e-03 3.02e-03 0.5720 1.75e-01 0.544000 2.57e-01 4.21e-04
MECP2 regulates neuronal receptors and channels 17 2.74e-04 6.95e-04 0.5710 -6.83e-02 -0.567000 6.26e-01 5.16e-05
Regulation of expression of SLITs and ROBOs 166 3.50e-39 2.33e-37 0.5700 -3.56e-01 0.445000 2.19e-15 4.05e-23
Activation of gene expression by SREBF (SREBP) 42 7.43e-09 5.04e-08 0.5680 -3.37e-01 -0.458000 1.54e-04 2.86e-07
Downregulation of SMAD2/3:SMAD4 transcriptional activity 28 4.01e-06 1.52e-05 0.5680 -3.74e-01 -0.428000 6.15e-04 8.87e-05
A tetrasaccharide linker sequence is required for GAG synthesis 24 3.10e-06 1.21e-05 0.5670 3.25e-01 -0.465000 5.89e-03 7.89e-05
RHOH GTPase cycle 35 5.00e-08 2.80e-07 0.5660 -2.49e-02 -0.565000 7.99e-01 6.96e-09
BMAL1:CLOCK,NPAS2 activates circadian gene expression 26 8.42e-06 2.97e-05 0.5660 -2.41e-01 -0.511000 3.31e-02 6.32e-06
Circadian Clock 67 1.05e-13 1.52e-12 0.5650 -2.65e-01 -0.499000 1.72e-04 1.54e-12
Regulation of FOXO transcriptional activity by acetylation 10 1.20e-02 2.11e-02 0.5640 -2.95e-01 -0.481000 1.06e-01 8.47e-03
Insulin processing 25 6.46e-06 2.34e-05 0.5620 2.24e-03 -0.562000 9.85e-01 1.14e-06
Apoptotic cleavage of cellular proteins 34 3.50e-08 2.05e-07 0.5620 1.90e-01 -0.529000 5.47e-02 9.48e-08
Netrin-1 signaling 45 1.13e-09 9.39e-09 0.5610 -1.21e-01 -0.548000 1.59e-01 1.96e-10
CS/DS degradation 13 1.34e-03 2.84e-03 0.5610 5.11e-01 -0.233000 1.43e-03 1.46e-01
Signaling by ALK fusions and activated point mutants 55 3.21e-11 3.49e-10 0.5590 -2.34e-01 -0.508000 2.65e-03 7.25e-11
Signaling by ALK in cancer 55 3.21e-11 3.49e-10 0.5590 -2.34e-01 -0.508000 2.65e-03 7.25e-11
Mitochondrial translation termination 90 5.11e-20 1.21e-18 0.5590 -1.51e-01 0.538000 1.33e-02 1.05e-18
Citric acid cycle (TCA cycle) 22 8.12e-05 2.24e-04 0.5570 -4.51e-01 -0.326000 2.48e-04 8.06e-03
Uptake and function of anthrax toxins 11 7.80e-03 1.42e-02 0.5570 -1.91e-01 -0.523000 2.73e-01 2.66e-03
Influenza Viral RNA Transcription and Replication 134 3.21e-30 1.27e-28 0.5550 -3.86e-01 0.398000 1.09e-14 1.59e-15
RAC2 GTPase cycle 85 1.86e-17 3.51e-16 0.5540 -6.36e-02 -0.550000 3.10e-01 1.71e-18
RAC3 GTPase cycle 89 4.30e-18 9.00e-17 0.5540 -8.72e-02 -0.547000 1.55e-01 4.58e-19
Signaling by Erythropoietin 24 2.94e-05 8.95e-05 0.5530 -1.99e-01 -0.517000 9.19e-02 1.18e-05
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer 45 6.16e-09 4.28e-08 0.5530 -4.00e-01 -0.382000 3.36e-06 9.34e-06
Chondroitin sulfate biosynthesis 19 7.00e-05 1.98e-04 0.5530 3.50e-01 -0.428000 8.18e-03 1.25e-03
Antigen Presentation: Folding, assembly and peptide loading of class I MHC 25 2.47e-05 7.69e-05 0.5520 -2.82e-01 -0.475000 1.47e-02 3.91e-05
RHOQ GTPase cycle 58 1.84e-12 2.27e-11 0.5520 4.17e-02 -0.550000 5.83e-01 4.17e-13
RUNX3 regulates NOTCH signaling 14 2.15e-03 4.34e-03 0.5510 -1.40e-01 -0.533000 3.64e-01 5.51e-04
Diseases associated with glycosaminoglycan metabolism 35 2.97e-08 1.79e-07 0.5510 2.73e-01 -0.479000 5.21e-03 9.35e-07
Signaling by FGFR4 in disease 11 9.34e-03 1.68e-02 0.5500 -2.40e-01 -0.495000 1.68e-01 4.47e-03
Regulation of cholesterol biosynthesis by SREBP (SREBF) 55 7.08e-11 7.20e-10 0.5490 -2.15e-01 -0.505000 5.84e-03 9.09e-11
Response of EIF2AK1 (HRI) to heme deficiency 15 7.54e-04 1.70e-03 0.5480 -5.20e-01 0.174000 4.89e-04 2.43e-01
Growth hormone receptor signaling 20 1.39e-04 3.70e-04 0.5460 -4.84e-02 -0.544000 7.08e-01 2.51e-05
STAT3 nuclear events downstream of ALK signaling 10 9.72e-03 1.73e-02 0.5430 1.14e-01 -0.531000 5.32e-01 3.61e-03
Translocation of SLC2A4 (GLUT4) to the plasma membrane 50 4.90e-10 4.35e-09 0.5410 -9.61e-02 -0.533000 2.39e-01 6.95e-11
Regulation of commissural axon pathfinding by SLIT and ROBO 10 1.14e-02 2.01e-02 0.5400 4.05e-02 -0.539000 8.25e-01 3.18e-03
Mitochondrial translation 96 6.75e-20 1.57e-18 0.5390 -1.48e-01 0.518000 1.21e-02 1.55e-18
FOXO-mediated transcription of cell death genes 15 2.32e-03 4.63e-03 0.5390 -4.65e-01 -0.272000 1.80e-03 6.80e-02
RHOC GTPase cycle 72 2.08e-14 3.27e-13 0.5390 -5.20e-03 -0.539000 9.39e-01 2.54e-15
Recycling pathway of L1 27 8.83e-06 3.10e-05 0.5380 -4.56e-02 -0.536000 6.81e-01 1.41e-06
Signaling by NODAL 19 5.24e-04 1.23e-03 0.5380 -3.62e-01 -0.398000 6.34e-03 2.66e-03
Mitophagy 28 6.80e-06 2.42e-05 0.5350 -5.32e-01 -0.047600 1.07e-06 6.63e-01
Vif-mediated degradation of APOBEC3G 52 2.64e-11 2.95e-10 0.5340 -4.31e-01 0.315000 7.39e-08 8.41e-05
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A 50 6.88e-11 7.09e-10 0.5340 -4.25e-01 0.323000 2.00e-07 7.81e-05
p53-Independent DNA Damage Response 50 6.88e-11 7.09e-10 0.5340 -4.25e-01 0.323000 2.00e-07 7.81e-05
p53-Independent G1/S DNA damage checkpoint 50 6.88e-11 7.09e-10 0.5340 -4.25e-01 0.323000 2.00e-07 7.81e-05
ROS sensing by NFE2L2 55 1.02e-11 1.18e-10 0.5340 -4.83e-01 0.226000 5.60e-10 3.69e-03
KSRP (KHSRP) binds and destabilizes mRNA 17 3.75e-04 9.07e-04 0.5320 -4.47e-01 0.289000 1.42e-03 3.89e-02
Regulation of KIT signaling 15 2.63e-03 5.20e-03 0.5320 -2.44e-01 -0.473000 1.02e-01 1.52e-03
Disassembly of the destruction complex and recruitment of AXIN to the membrane 30 5.16e-06 1.91e-05 0.5320 -1.54e-01 -0.509000 1.45e-01 1.38e-06
rRNA modification in the nucleus and cytosol 60 2.08e-12 2.52e-11 0.5310 -5.05e-01 0.163000 1.24e-11 2.94e-02
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane 22 1.35e-04 3.60e-04 0.5290 -5.13e-01 -0.129000 3.08e-05 2.95e-01
Tie2 Signaling 17 1.29e-03 2.76e-03 0.5280 -2.28e-01 -0.476000 1.04e-01 6.72e-04
TICAM1,TRAF6-dependent induction of TAK1 complex 11 1.29e-02 2.25e-02 0.5280 -4.93e-01 -0.189000 4.66e-03 2.77e-01
RAF activation 33 2.44e-06 9.72e-06 0.5270 -2.18e-01 -0.480000 3.02e-02 1.78e-06
COPI-mediated anterograde transport 79 5.32e-14 8.12e-13 0.5270 -2.53e-01 -0.462000 1.02e-04 1.17e-12
APC/C:Cdc20 mediated degradation of Cyclin B 24 2.14e-05 6.76e-05 0.5270 -2.16e-01 0.480000 6.68e-02 4.62e-05
Regulation of activated PAK-2p34 by proteasome mediated degradation 48 3.40e-10 3.15e-09 0.5270 -4.38e-01 0.293000 1.54e-07 4.48e-04
Autodegradation of the E3 ubiquitin ligase COP1 49 2.15e-10 2.06e-09 0.5260 -4.25e-01 0.309000 2.54e-07 1.79e-04
Downregulation of TGF-beta receptor signaling 26 5.37e-05 1.56e-04 0.5250 -3.95e-01 -0.346000 4.95e-04 2.29e-03
Transport of the SLBP Dependant Mature mRNA 36 1.24e-06 5.35e-06 0.5240 -4.04e-01 -0.334000 2.73e-05 5.26e-04
Protein methylation 15 2.89e-03 5.67e-03 0.5230 -4.93e-01 -0.175000 9.48e-04 2.40e-01
Interleukin-27 signaling 10 2.01e-02 3.31e-02 0.5230 -1.65e-01 -0.496000 3.66e-01 6.59e-03
RND1 GTPase cycle 42 1.49e-08 9.52e-08 0.5220 1.22e-01 -0.508000 1.72e-01 1.22e-08
Signaling by TGF-beta Receptor Complex 74 9.30e-13 1.23e-11 0.5220 -3.43e-01 -0.394000 3.29e-07 4.71e-09
Signaling by cytosolic FGFR1 fusion mutants 18 7.09e-04 1.62e-03 0.5210 -5.62e-02 -0.518000 6.80e-01 1.40e-04
PERK regulates gene expression 31 1.33e-06 5.64e-06 0.5210 -4.78e-01 0.205000 3.99e-06 4.82e-02
Processive synthesis on the lagging strand 15 3.65e-03 6.97e-03 0.5200 4.33e-01 0.287000 3.66e-03 5.42e-02
MAPK3 (ERK1) activation 10 2.24e-02 3.67e-02 0.5190 -2.09e-01 -0.475000 2.52e-01 9.29e-03
G-protein mediated events 48 5.57e-09 3.89e-08 0.5180 -6.95e-02 -0.514000 4.05e-01 7.30e-10
Postmitotic nuclear pore complex (NPC) reformation 27 4.27e-05 1.26e-04 0.5180 -4.42e-01 -0.270000 6.92e-05 1.53e-02
Cellular response to starvation 150 2.14e-29 8.05e-28 0.5180 -3.22e-01 0.406000 9.62e-12 9.26e-18
Transport of the SLBP independent Mature mRNA 35 2.53e-06 1.00e-05 0.5180 -3.88e-01 -0.342000 7.04e-05 4.54e-04
Synthesis of PIPs at the plasma membrane 50 3.81e-09 2.82e-08 0.5170 -1.14e-01 -0.504000 1.63e-01 6.82e-10
RHOG GTPase cycle 74 1.84e-13 2.59e-12 0.5160 -3.51e-02 -0.514000 6.02e-01 1.91e-14
Stabilization of p53 53 9.56e-11 9.52e-10 0.5150 -4.25e-01 0.291000 8.54e-08 2.43e-04
Signaling by VEGF 99 1.95e-17 3.61e-16 0.5150 -8.45e-02 -0.508000 1.46e-01 2.18e-18
Integrin signaling 24 1.21e-04 3.25e-04 0.5150 -1.94e-01 -0.477000 9.98e-02 5.16e-05
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers 28 1.04e-05 3.59e-05 0.5150 6.77e-02 -0.510000 5.35e-01 2.96e-06
VEGFA-VEGFR2 Pathway 91 4.15e-16 7.15e-15 0.5140 -7.20e-02 -0.509000 2.35e-01 4.25e-17
Leading Strand Synthesis 14 6.05e-03 1.12e-02 0.5130 4.26e-01 0.287000 5.81e-03 6.29e-02
Polymerase switching 14 6.05e-03 1.12e-02 0.5130 4.26e-01 0.287000 5.81e-03 6.29e-02
FCGR3A-mediated IL10 synthesis 32 4.09e-06 1.54e-05 0.5130 -7.50e-02 -0.508000 4.63e-01 6.58e-07
SUMOylation of SUMOylation proteins 35 3.03e-06 1.18e-05 0.5130 -4.10e-01 -0.308000 2.63e-05 1.61e-03
RHOBTB1 GTPase cycle 23 2.21e-04 5.67e-04 0.5130 -4.41e-01 -0.261000 2.47e-04 3.00e-02
Vpr-mediated nuclear import of PICs 34 4.88e-06 1.82e-05 0.5120 -3.83e-01 -0.339000 1.09e-04 6.25e-04
Platelet calcium homeostasis 24 3.77e-05 1.12e-04 0.5110 2.30e-01 -0.457000 5.10e-02 1.07e-04
Fcgamma receptor (FCGR) dependent phagocytosis 82 9.39e-14 1.38e-12 0.5110 -2.19e-01 -0.461000 6.15e-04 4.84e-13
COPI-independent Golgi-to-ER retrograde traffic 33 5.40e-06 1.97e-05 0.5110 -2.05e-01 -0.468000 4.15e-02 3.30e-06
FCERI mediated Ca+2 mobilization 28 2.54e-05 7.84e-05 0.5100 -1.16e-01 -0.497000 2.88e-01 5.26e-06
Signaling by SCF-KIT 41 2.32e-07 1.18e-06 0.5100 -1.54e-01 -0.486000 8.79e-02 7.00e-08
PKA activation in glucagon signalling 15 2.33e-03 4.65e-03 0.5090 8.80e-02 -0.501000 5.55e-01 7.70e-04
DAG and IP3 signaling 37 6.07e-07 2.81e-06 0.5070 -1.19e-02 -0.507000 9.00e-01 9.38e-08
PLC beta mediated events 44 5.86e-08 3.27e-07 0.5060 -6.47e-02 -0.502000 4.57e-01 8.07e-09
Ca-dependent events 33 3.31e-06 1.29e-05 0.5060 -3.51e-02 -0.505000 7.27e-01 5.11e-07
Activated NTRK2 signals through FRS2 and FRS3 11 1.73e-02 2.90e-02 0.5060 -1.33e-01 -0.488000 4.45e-01 5.06e-03
APC/C:Cdc20 mediated degradation of Securin 66 8.36e-13 1.12e-11 0.5060 -3.68e-01 0.347000 2.36e-07 1.06e-06
MAP kinase activation 62 3.43e-10 3.16e-09 0.5040 -2.83e-01 -0.418000 1.18e-04 1.27e-08
Regulation of actin dynamics for phagocytic cup formation 58 9.15e-10 7.66e-09 0.5040 -1.96e-01 -0.464000 9.64e-03 9.31e-10
PI Metabolism 77 8.85e-13 1.18e-11 0.5030 -1.70e-01 -0.474000 1.01e-02 6.17e-13
MET activates RAS signaling 11 1.73e-02 2.91e-02 0.5030 -1.03e-01 -0.492000 5.55e-01 4.67e-03
Hyaluronan uptake and degradation 10 2.27e-02 3.70e-02 0.5020 5.02e-01 0.022200 5.98e-03 9.03e-01
RUNX2 regulates osteoblast differentiation 22 3.20e-04 7.96e-04 0.5010 -1.02e-01 -0.491000 4.09e-01 6.74e-05
Transcriptional activation of mitochondrial biogenesis 53 1.16e-08 7.56e-08 0.5010 -3.33e-01 -0.374000 2.66e-05 2.46e-06
Constitutive Signaling by Overexpressed ERBB2 11 1.41e-02 2.42e-02 0.5010 5.76e-02 -0.498000 7.41e-01 4.25e-03
HIV elongation arrest and recovery 32 5.19e-06 1.91e-05 0.5000 -5.00e-01 0.016000 9.78e-07 8.75e-01
Pausing and recovery of HIV elongation 32 5.19e-06 1.91e-05 0.5000 -5.00e-01 0.016000 9.78e-07 8.75e-01
RHOB GTPase cycle 69 2.01e-12 2.46e-11 0.5000 9.99e-02 -0.490000 1.51e-01 1.98e-12
PECAM1 interactions 11 1.71e-02 2.88e-02 0.4970 -2.91e-02 -0.496000 8.67e-01 4.35e-03
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription 31 2.48e-05 7.69e-05 0.4950 -4.33e-01 -0.241000 3.02e-05 2.02e-02
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors 11 1.31e-02 2.27e-02 0.4940 2.06e-01 -0.449000 2.37e-01 9.90e-03
RND3 GTPase cycle 41 1.42e-07 7.41e-07 0.4930 1.27e-01 -0.477000 1.59e-01 1.26e-07
Extra-nuclear estrogen signaling 66 1.59e-10 1.53e-09 0.4930 -1.99e-01 -0.451000 5.14e-03 2.35e-10
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 17 3.12e-03 6.08e-03 0.4930 -2.28e-01 -0.437000 1.03e-01 1.82e-03
Signaling by TGFB family members 98 6.70e-15 1.07e-13 0.4930 -3.24e-01 -0.371000 2.90e-08 2.12e-10
Regulation of RUNX3 expression and activity 54 7.29e-10 6.32e-09 0.4930 -4.58e-01 0.183000 5.93e-09 2.02e-02
TBC/RABGAPs 43 6.20e-07 2.86e-06 0.4920 -3.46e-01 -0.350000 8.54e-05 7.21e-05
SCF-beta-TrCP mediated degradation of Emi1 53 7.99e-10 6.84e-09 0.4920 -4.19e-01 0.257000 1.27e-07 1.20e-03
Vpu mediated degradation of CD4 50 2.77e-09 2.12e-08 0.4900 -4.07e-01 0.274000 6.34e-07 8.11e-04
Autodegradation of Cdh1 by Cdh1:APC/C 64 9.86e-12 1.15e-10 0.4900 -3.54e-01 0.339000 9.46e-07 2.72e-06
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 72 4.45e-13 6.18e-12 0.4900 -3.66e-01 0.326000 8.04e-08 1.71e-06
RHOD GTPase cycle 52 4.60e-09 3.32e-08 0.4890 5.43e-02 -0.486000 4.98e-01 1.27e-09
Transport of Ribonucleoproteins into the Host Nucleus 32 2.67e-05 8.19e-05 0.4890 -3.19e-01 -0.371000 1.80e-03 2.79e-04
Pausing and recovery of Tat-mediated HIV elongation 30 1.76e-05 5.73e-05 0.4890 -4.88e-01 0.027600 3.67e-06 7.93e-01
Tat-mediated HIV elongation arrest and recovery 30 1.76e-05 5.73e-05 0.4890 -4.88e-01 0.027600 3.67e-06 7.93e-01
VLDLR internalisation and degradation 11 1.39e-02 2.39e-02 0.4880 2.40e-01 -0.425000 1.68e-01 1.46e-02
Cargo concentration in the ER 31 1.74e-05 5.71e-05 0.4880 -5.14e-02 -0.486000 6.20e-01 2.85e-06
Hyaluronan metabolism 14 5.33e-03 9.99e-03 0.4870 4.73e-01 -0.117000 2.18e-03 4.50e-01
Regulation of Apoptosis 51 2.62e-09 2.02e-08 0.4870 -4.15e-01 0.255000 2.98e-07 1.60e-03
Regulated proteolysis of p75NTR 11 1.82e-02 3.03e-02 0.4870 4.49e-02 -0.484000 7.96e-01 5.39e-03
Signaling by MET 66 7.37e-11 7.45e-10 0.4860 -2.43e-02 -0.485000 7.32e-01 8.78e-12
Heparan sulfate/heparin (HS-GAG) metabolism 48 8.73e-09 5.79e-08 0.4850 2.78e-01 -0.398000 8.49e-04 1.84e-06
mRNA decay by 3’ to 5’ exoribonuclease 16 2.01e-03 4.07e-03 0.4850 -3.11e-01 0.372000 3.11e-02 9.91e-03
Caspase-mediated cleavage of cytoskeletal proteins 12 1.13e-02 2.00e-02 0.4850 1.35e-01 -0.466000 4.20e-01 5.17e-03
Molecules associated with elastic fibres 25 1.02e-04 2.75e-04 0.4850 9.30e-02 -0.476000 4.21e-01 3.77e-05
Degradation of DVL 55 7.35e-10 6.33e-09 0.4850 -4.25e-01 0.234000 5.01e-08 2.70e-03
Interactions of Vpr with host cellular proteins 37 6.60e-06 2.37e-05 0.4850 -3.44e-01 -0.341000 2.87e-04 3.33e-04
CD28 co-stimulation 29 6.81e-05 1.93e-04 0.4840 -1.88e-01 -0.446000 8.03e-02 3.20e-05
Josephin domain DUBs 10 2.90e-02 4.61e-02 0.4830 -4.83e-01 0.011300 8.21e-03 9.50e-01
Negative regulation of NOTCH4 signaling 54 1.04e-09 8.69e-09 0.4830 -3.83e-01 0.293000 1.09e-06 1.91e-04
EPHB-mediated forward signaling 34 1.78e-05 5.79e-05 0.4820 -2.69e-01 -0.400000 6.58e-03 5.38e-05
Removal of the Flap Intermediate 14 1.09e-02 1.93e-02 0.4820 4.16e-01 0.242000 6.98e-03 1.17e-01
TGF-beta receptor signaling activates SMADs 32 3.78e-05 1.13e-04 0.4810 -3.65e-01 -0.314000 3.52e-04 2.14e-03
Influenza Infection 153 7.01e-26 2.28e-24 0.4800 -3.57e-01 0.320000 2.24e-14 7.58e-12
CaM pathway 31 1.91e-05 6.12e-05 0.4800 2.04e-02 -0.479000 8.44e-01 3.83e-06
Calmodulin induced events 31 1.91e-05 6.12e-05 0.4800 2.04e-02 -0.479000 8.44e-01 3.83e-06
Signaling by NTRK3 (TRKC) 16 5.33e-03 9.99e-03 0.4800 -1.67e-01 -0.450000 2.48e-01 1.84e-03
The role of GTSE1 in G2/M progression after G2 checkpoint 58 3.30e-10 3.08e-09 0.4790 -3.92e-01 0.275000 2.38e-07 2.85e-04
Nuclear events stimulated by ALK signaling in cancer 19 2.25e-03 4.51e-03 0.4790 -4.26e-01 -0.219000 1.31e-03 9.79e-02
Sema3A PAK dependent Axon repulsion 16 4.75e-03 8.95e-03 0.4780 -8.09e-02 -0.471000 5.76e-01 1.11e-03
Signaling by PDGF 51 3.43e-08 2.01e-07 0.4770 -4.95e-02 -0.474000 5.40e-01 4.55e-09
Transport of Mature mRNAs Derived from Intronless Transcripts 43 1.36e-06 5.69e-06 0.4770 -3.94e-01 -0.268000 7.65e-06 2.36e-03
L1CAM interactions 92 3.02e-14 4.66e-13 0.4760 -2.88e-02 -0.475000 6.33e-01 3.10e-15
Elastic fibre formation 35 4.03e-06 1.52e-05 0.4760 9.77e-02 -0.466000 3.17e-01 1.83e-06
Regulation of IFNA signaling 12 2.37e-02 3.85e-02 0.4750 -2.82e-01 -0.382000 9.03e-02 2.18e-02
p75NTR signals via NF-kB 16 5.94e-03 1.11e-02 0.4750 -4.43e-01 -0.171000 2.14e-03 2.36e-01
Lagging Strand Synthesis 20 2.01e-03 4.07e-03 0.4750 3.72e-01 0.295000 3.97e-03 2.23e-02
Formation of HIV elongation complex in the absence of HIV Tat 44 2.67e-07 1.32e-06 0.4750 -4.74e-01 0.025900 5.22e-08 7.66e-01
NEP/NS2 Interacts with the Cellular Export Machinery 32 5.08e-05 1.48e-04 0.4740 -3.31e-01 -0.340000 1.18e-03 8.85e-04
VEGFR2 mediated vascular permeability 27 8.57e-05 2.36e-04 0.4740 5.46e-02 -0.471000 6.23e-01 2.27e-05
Cristae formation 31 2.43e-05 7.57e-05 0.4720 -4.86e-02 0.469000 6.39e-01 6.06e-06
APC/C:Cdc20 mediated degradation of mitotic proteins 74 1.65e-12 2.07e-11 0.4720 -3.51e-01 0.315000 1.72e-07 2.76e-06
Hh mutants are degraded by ERAD 54 3.17e-09 2.38e-08 0.4710 -4.04e-01 0.243000 2.79e-07 2.03e-03
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins 75 1.46e-12 1.89e-11 0.4700 -3.59e-01 0.303000 7.46e-08 5.60e-06
Metal ion SLC transporters 22 8.27e-04 1.86e-03 0.4700 -8.64e-02 -0.462000 4.83e-01 1.77e-04
Interleukin-3, Interleukin-5 and GM-CSF signaling 38 5.07e-06 1.88e-05 0.4700 -9.98e-02 -0.459000 2.87e-01 9.64e-07
Transport of Mature mRNA Derived from an Intronless Transcript 42 2.92e-06 1.15e-05 0.4690 -3.81e-01 -0.273000 1.93e-05 2.16e-03
Activation of the TFAP2 (AP-2) family of transcription factors 11 3.54e-02 5.51e-02 0.4680 -3.91e-01 -0.258000 2.47e-02 1.39e-01
CDT1 association with the CDC6:ORC:origin complex 57 1.21e-09 9.92e-09 0.4680 -3.38e-01 0.323000 1.01e-05 2.43e-05
Abortive elongation of HIV-1 transcript in the absence of Tat 23 4.02e-04 9.66e-04 0.4670 -4.61e-01 0.077700 1.30e-04 5.19e-01
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand 37 9.31e-06 3.24e-05 0.4670 -1.32e-01 -0.448000 1.66e-01 2.39e-06
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases 14 1.18e-02 2.08e-02 0.4660 -8.72e-02 -0.458000 5.72e-01 3.03e-03
Formation of HIV-1 elongation complex containing HIV-1 Tat 42 8.74e-07 3.86e-06 0.4660 -4.64e-01 0.034700 1.89e-07 6.97e-01
HIV Transcription Elongation 42 8.74e-07 3.86e-06 0.4660 -4.64e-01 0.034700 1.89e-07 6.97e-01
Tat-mediated elongation of the HIV-1 transcript 42 8.74e-07 3.86e-06 0.4660 -4.64e-01 0.034700 1.89e-07 6.97e-01
mRNA decay by 5’ to 3’ exoribonuclease 15 8.97e-03 1.62e-02 0.4650 -4.54e-01 -0.101000 2.33e-03 4.99e-01
RAC1 GTPase cycle 176 5.03e-26 1.67e-24 0.4650 4.44e-02 -0.463000 3.09e-01 2.75e-26
AUF1 (hnRNP D0) binds and destabilizes mRNA 53 7.57e-09 5.11e-08 0.4640 -3.83e-01 0.261000 1.37e-06 9.89e-04
VxPx cargo-targeting to cilium 19 2.71e-03 5.33e-03 0.4640 -1.13e-01 -0.450000 3.95e-01 6.85e-04
Oncogenic MAPK signaling 75 5.44e-11 5.73e-10 0.4630 -7.07e-02 -0.458000 2.90e-01 6.81e-12
Chondroitin sulfate/dermatan sulfate metabolism 48 4.57e-08 2.58e-07 0.4630 2.95e-01 -0.356000 4.08e-04 1.93e-05
Keratan sulfate biosynthesis 24 5.37e-04 1.25e-03 0.4620 -7.45e-02 -0.456000 5.27e-01 1.09e-04
IRE1alpha activates chaperones 50 3.90e-07 1.87e-06 0.4620 -2.62e-01 -0.381000 1.34e-03 3.19e-06
Regulation of ornithine decarboxylase (ODC) 49 4.03e-08 2.32e-07 0.4620 -4.01e-01 0.230000 1.22e-06 5.39e-03
Folding of actin by CCT/TriC 10 4.03e-02 6.18e-02 0.4620 -4.62e-01 -0.009740 1.15e-02 9.57e-01
Cholesterol biosynthesis 24 7.17e-04 1.63e-03 0.4610 -4.31e-01 -0.164000 2.57e-04 1.65e-01
Rev-mediated nuclear export of HIV RNA 35 3.50e-05 1.05e-04 0.4610 -3.74e-01 -0.269000 1.27e-04 5.86e-03
CDC42 GTPase cycle 153 1.05e-22 3.02e-21 0.4590 1.07e-01 -0.447000 2.26e-02 1.32e-21
Interleukin-35 Signalling 12 2.94e-02 4.67e-02 0.4590 -2.21e-01 -0.402000 1.86e-01 1.58e-02
Ovarian tumor domain proteases 37 2.37e-05 7.40e-05 0.4580 -3.15e-01 -0.333000 9.25e-04 4.61e-04
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis 53 1.24e-08 8.05e-08 0.4580 -3.78e-01 0.259000 1.94e-06 1.12e-03
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) 32 1.00e-04 2.72e-04 0.4580 -3.25e-01 -0.323000 1.48e-03 1.57e-03
Regulation of Glucokinase by Glucokinase Regulatory Protein 32 1.00e-04 2.72e-04 0.4580 -3.25e-01 -0.323000 1.48e-03 1.57e-03
ER to Golgi Anterograde Transport 131 1.75e-17 3.37e-16 0.4570 -1.73e-01 -0.423000 6.41e-04 5.72e-17
SUMOylation of ubiquitinylation proteins 39 1.39e-05 4.64e-05 0.4570 -3.42e-01 -0.303000 2.20e-04 1.05e-03
Signal amplification 28 3.29e-04 8.11e-04 0.4550 -2.64e-01 -0.371000 1.55e-02 6.77e-04
Ubiquitin-dependent degradation of Cyclin D 50 4.03e-08 2.32e-07 0.4550 -3.66e-01 0.271000 7.51e-06 9.15e-04
Cross-presentation of soluble exogenous antigens (endosomes) 45 2.31e-07 1.18e-06 0.4550 -3.78e-01 0.253000 1.12e-05 3.28e-03
RHO GTPases activate IQGAPs 11 3.52e-02 5.49e-02 0.4540 -5.48e-02 -0.450000 7.53e-01 9.70e-03
NIK–>noncanonical NF-kB signaling 57 5.45e-09 3.82e-08 0.4530 -4.02e-01 0.211000 1.55e-07 5.94e-03
Transport to the Golgi and subsequent modification 161 5.55e-21 1.40e-19 0.4530 -1.71e-01 -0.420000 1.78e-04 3.44e-20
Interleukin receptor SHC signaling 21 1.42e-03 3.00e-03 0.4530 1.52e-02 -0.453000 9.04e-01 3.26e-04
N-glycan antennae elongation in the medial/trans-Golgi 25 8.58e-04 1.93e-03 0.4530 -2.91e-01 -0.347000 1.17e-02 2.65e-03
Activation of BAD and translocation to mitochondria 15 1.24e-02 2.17e-02 0.4530 -1.50e-01 -0.428000 3.14e-01 4.14e-03
RET signaling 37 1.90e-05 6.12e-05 0.4520 -1.29e-01 -0.434000 1.74e-01 4.99e-06
NOTCH4 Activation and Transmission of Signal to the Nucleus 11 2.45e-02 3.97e-02 0.4520 3.47e-01 -0.290000 4.64e-02 9.53e-02
RUNX2 regulates bone development 29 1.61e-04 4.24e-04 0.4520 -6.12e-02 -0.448000 5.69e-01 2.98e-05
Signalling to ERKs 33 7.38e-05 2.07e-04 0.4520 -1.75e-01 -0.417000 8.18e-02 3.44e-05
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint 72 3.21e-11 3.49e-10 0.4520 -3.41e-01 0.296000 5.74e-07 1.36e-05
Nuclear import of Rev protein 34 7.17e-05 2.02e-04 0.4510 -3.58e-01 -0.275000 3.02e-04 5.53e-03
Intra-Golgi and retrograde Golgi-to-ER traffic 179 4.86e-23 1.43e-21 0.4510 -1.67e-01 -0.419000 1.14e-04 3.49e-22
Constitutive Signaling by AKT1 E17K in Cancer 26 6.77e-04 1.55e-03 0.4490 -2.31e-01 -0.385000 4.11e-02 6.70e-04
Signaling by EGFR 48 9.16e-07 4.02e-06 0.4490 -1.29e-01 -0.430000 1.21e-01 2.46e-07
Dectin-1 mediated noncanonical NF-kB signaling 59 4.29e-09 3.13e-08 0.4490 -4.05e-01 0.194000 7.27e-08 9.81e-03
Degradation of AXIN 53 2.88e-08 1.75e-07 0.4490 -3.98e-01 0.209000 5.45e-07 8.50e-03
Processing and activation of SUMO 10 6.27e-02 9.11e-02 0.4490 -3.22e-01 -0.313000 7.78e-02 8.68e-02
Defective CFTR causes cystic fibrosis 58 7.11e-09 4.89e-08 0.4490 -4.16e-01 0.169000 4.27e-08 2.61e-02
mRNA Splicing - Minor Pathway 52 3.23e-08 1.91e-07 0.4490 -3.11e-01 0.323000 1.03e-04 5.51e-05
Alpha-protein kinase 1 signaling pathway 11 3.94e-02 6.06e-02 0.4490 -4.41e-01 -0.084500 1.14e-02 6.28e-01
Sodium/Calcium exchangers 10 3.76e-02 5.79e-02 0.4480 2.24e-01 -0.388000 2.20e-01 3.34e-02
Dermatan sulfate biosynthesis 10 4.00e-02 6.14e-02 0.4480 1.55e-01 -0.420000 3.95e-01 2.13e-02
Signaling by ALK 26 4.49e-04 1.07e-03 0.4480 -5.61e-02 -0.444000 6.20e-01 8.71e-05
Interleukin-7 signaling 23 7.17e-04 1.63e-03 0.4480 9.62e-02 -0.437000 4.24e-01 2.81e-04
Deadenylation-dependent mRNA decay 53 2.51e-07 1.25e-06 0.4480 -4.27e-01 -0.135000 7.48e-08 9.02e-02
Cell-Cell communication 105 2.33e-14 3.63e-13 0.4480 -2.52e-02 -0.447000 6.55e-01 2.40e-15
NOTCH2 intracellular domain regulates transcription 11 3.76e-02 5.79e-02 0.4470 -2.84e-02 -0.446000 8.70e-01 1.05e-02
Cdc20:Phospho-APC/C mediated degradation of Cyclin A 71 7.49e-11 7.52e-10 0.4470 -3.37e-01 0.293000 8.99e-07 1.93e-05
EPHA-mediated growth cone collapse 15 1.56e-02 2.66e-02 0.4470 -2.29e-01 -0.383000 1.25e-01 1.01e-02
STING mediated induction of host immune responses 15 1.53e-02 2.62e-02 0.4460 -3.97e-01 -0.203000 7.74e-03 1.73e-01
Interactions of Rev with host cellular proteins 37 3.83e-05 1.14e-04 0.4460 -3.67e-01 -0.253000 1.11e-04 7.64e-03
Export of Viral Ribonucleoproteins from Nucleus 33 1.23e-04 3.27e-04 0.4460 -2.96e-01 -0.333000 3.22e-03 9.30e-04
Synthesis of bile acids and bile salts via 27-hydroxycholesterol 11 4.54e-02 6.87e-02 0.4450 -4.14e-01 -0.163000 1.74e-02 3.48e-01
XBP1(S) activates chaperone genes 48 2.04e-06 8.29e-06 0.4440 -2.47e-01 -0.369000 3.04e-03 9.55e-06
RHOA GTPase cycle 146 3.70e-20 8.89e-19 0.4440 8.18e-02 -0.436000 8.77e-02 8.34e-20
Formation of the Early Elongation Complex 33 3.73e-05 1.12e-04 0.4430 -4.30e-01 0.106000 1.91e-05 2.90e-01
Formation of the HIV-1 Early Elongation Complex 33 3.73e-05 1.12e-04 0.4430 -4.30e-01 0.106000 1.91e-05 2.90e-01
Nuclear Events (kinase and transcription factor activation) 60 9.77e-08 5.23e-07 0.4430 -3.20e-01 -0.306000 1.83e-05 4.02e-05
Negative regulators of DDX58/IFIH1 signaling 35 7.18e-05 2.02e-04 0.4430 -3.83e-01 -0.222000 8.85e-05 2.28e-02
Regulation of TP53 Activity through Acetylation 29 4.05e-04 9.71e-04 0.4430 -3.36e-01 -0.288000 1.72e-03 7.27e-03
Interleukin-17 signaling 67 1.55e-08 9.85e-08 0.4410 -2.48e-01 -0.364000 4.44e-04 2.46e-07
FLT3 Signaling 35 7.57e-05 2.12e-04 0.4400 -1.92e-01 -0.396000 4.94e-02 5.10e-05
Glycosaminoglycan metabolism 109 1.72e-15 2.86e-14 0.4390 1.92e-01 -0.395000 5.45e-04 9.56e-13
Glutathione conjugation 29 3.04e-04 7.61e-04 0.4380 9.20e-02 0.428000 3.91e-01 6.50e-05
NS1 Mediated Effects on Host Pathways 40 2.66e-05 8.17e-05 0.4380 -3.27e-01 -0.292000 3.49e-04 1.41e-03
PINK1-PRKN Mediated Mitophagy 21 2.10e-03 4.26e-03 0.4370 -4.36e-01 0.036100 5.43e-04 7.75e-01
NOTCH3 Intracellular Domain Regulates Transcription 22 2.01e-03 4.07e-03 0.4360 -3.76e-02 -0.434000 7.60e-01 4.25e-04
Translation 293 3.38e-40 2.60e-38 0.4350 -2.89e-01 0.326000 1.51e-17 7.64e-22
Keratan sulfate/keratin metabolism 29 2.02e-04 5.20e-04 0.4350 5.93e-02 -0.431000 5.80e-01 5.81e-05
GPVI-mediated activation cascade 29 3.42e-04 8.41e-04 0.4350 -9.36e-02 -0.425000 3.83e-01 7.42e-05
p53-Dependent G1 DNA Damage Response 62 4.70e-09 3.36e-08 0.4350 -3.68e-01 0.232000 5.27e-07 1.60e-03
p53-Dependent G1/S DNA damage checkpoint 62 4.70e-09 3.36e-08 0.4350 -3.68e-01 0.232000 5.27e-07 1.60e-03
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known 36 7.69e-05 2.15e-04 0.4350 -2.18e-01 -0.376000 2.34e-02 9.33e-05
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling 26 9.27e-04 2.06e-03 0.4350 -1.52e-01 -0.407000 1.78e-01 3.25e-04
Myogenesis 25 6.74e-04 1.55e-03 0.4350 5.42e-02 -0.431000 6.39e-01 1.88e-04
Adherens junctions interactions 29 1.22e-04 3.25e-04 0.4340 2.81e-01 -0.331000 8.81e-03 2.02e-03
Gap junction trafficking and regulation 20 2.45e-03 4.87e-03 0.4340 1.37e-01 -0.412000 2.89e-01 1.42e-03
Lewis blood group biosynthesis 14 2.65e-02 4.26e-02 0.4330 -2.36e-01 -0.362000 1.26e-01 1.89e-02
Metabolism of polyamines 57 3.42e-08 2.01e-07 0.4320 -3.92e-01 0.182000 3.00e-07 1.78e-02
Regulation of HMOX1 expression and activity 63 7.66e-09 5.15e-08 0.4320 -4.10e-01 0.136000 1.83e-08 6.23e-02
GRB2 events in EGFR signaling 11 5.95e-02 8.71e-02 0.4310 -2.60e-01 -0.344000 1.35e-01 4.82e-02
Constitutive Signaling by EGFRvIII 15 1.70e-02 2.87e-02 0.4310 -7.65e-02 -0.424000 6.08e-01 4.47e-03
Signaling by EGFRvIII in Cancer 15 1.70e-02 2.87e-02 0.4310 -7.65e-02 -0.424000 6.08e-01 4.47e-03
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion 14 2.83e-02 4.52e-02 0.4300 -2.74e-01 -0.332000 7.61e-02 3.16e-02
Cellular response to heat stress 94 4.47e-11 4.74e-10 0.4300 -3.14e-01 -0.294000 1.39e-07 8.51e-07
Antiviral mechanism by IFN-stimulated genes 80 1.52e-09 1.23e-08 0.4300 -3.31e-01 -0.275000 3.17e-07 2.12e-05
Golgi-to-ER retrograde transport 111 4.47e-13 6.18e-12 0.4300 -2.19e-01 -0.370000 6.79e-05 1.60e-11
Toll Like Receptor 3 (TLR3) Cascade 89 1.59e-10 1.53e-09 0.4300 -2.77e-01 -0.328000 6.05e-06 8.53e-08
Neurotoxicity of clostridium toxins 10 7.51e-02 1.07e-01 0.4300 3.85e-01 0.190000 3.49e-02 2.97e-01
Post NMDA receptor activation events 56 2.51e-07 1.25e-06 0.4300 -6.31e-02 -0.425000 4.14e-01 3.70e-08
Regulation of IFNG signaling 13 3.46e-02 5.42e-02 0.4290 -3.87e-01 -0.185000 1.56e-02 2.49e-01
CDK-mediated phosphorylation and removal of Cdc6 71 4.49e-10 4.04e-09 0.4290 -3.11e-01 0.295000 5.75e-06 1.67e-05
MyD88 cascade initiated on plasma membrane 80 1.67e-09 1.31e-08 0.4290 -2.68e-01 -0.334000 3.29e-05 2.31e-07
Toll Like Receptor 10 (TLR10) Cascade 80 1.67e-09 1.31e-08 0.4290 -2.68e-01 -0.334000 3.29e-05 2.31e-07
Toll Like Receptor 5 (TLR5) Cascade 80 1.67e-09 1.31e-08 0.4290 -2.68e-01 -0.334000 3.29e-05 2.31e-07
IRAK2 mediated activation of TAK1 complex 10 7.67e-02 1.09e-01 0.4280 -3.80e-01 -0.198000 3.74e-02 2.79e-01
Translocation of ZAP-70 to Immunological synapse 13 3.65e-02 5.66e-02 0.4280 2.26e-01 0.364000 1.57e-01 2.32e-02
Retrograde transport at the Trans-Golgi-Network 49 1.50e-06 6.22e-06 0.4280 -2.25e-02 -0.427000 7.86e-01 2.29e-07
Notch-HLH transcription pathway 28 4.82e-04 1.14e-03 0.4270 -2.10e-02 -0.426000 8.48e-01 9.43e-05
Receptor-type tyrosine-protein phosphatases 18 1.03e-02 1.82e-02 0.4270 -2.00e-01 -0.377000 1.42e-01 5.62e-03
DARPP-32 events 23 1.52e-03 3.19e-03 0.4260 6.90e-02 -0.420000 5.67e-01 4.83e-04
Signaling by BRAF and RAF1 fusions 58 2.73e-07 1.34e-06 0.4260 -1.15e-01 -0.410000 1.31e-01 6.59e-08
ECM proteoglycans 43 4.73e-06 1.77e-05 0.4250 1.06e-01 -0.412000 2.28e-01 2.97e-06
ISG15 antiviral mechanism 72 1.81e-08 1.14e-07 0.4250 -3.18e-01 -0.282000 3.08e-06 3.53e-05
RHOBTB GTPase Cycle 35 1.72e-04 4.49e-04 0.4250 -2.79e-01 -0.320000 4.28e-03 1.05e-03
Signaling by NTRKs 131 5.79e-15 9.33e-14 0.4240 -2.03e-01 -0.372000 5.92e-05 1.75e-13
FGFR2 alternative splicing 25 7.43e-04 1.68e-03 0.4240 -3.94e-01 0.155000 6.46e-04 1.78e-01
Signaling by ERBB2 ECD mutants 16 1.28e-02 2.24e-02 0.4240 8.55e-03 -0.423000 9.53e-01 3.36e-03
Glycolysis 67 4.30e-08 2.46e-07 0.4240 -1.63e-01 -0.391000 2.10e-02 3.10e-08
Signaling by NTRK1 (TRKA) 113 6.78e-13 9.19e-12 0.4220 -2.05e-01 -0.369000 1.72e-04 1.13e-11
TICAM1, RIP1-mediated IKK complex recruitment 18 1.02e-02 1.82e-02 0.4220 -4.02e-01 -0.128000 3.17e-03 3.46e-01
G1/S DNA Damage Checkpoints 64 8.32e-09 5.54e-08 0.4220 -3.55e-01 0.228000 9.19e-07 1.59e-03
SUMOylation of immune response proteins 11 5.38e-02 7.95e-02 0.4210 -4.21e-01 -0.022400 1.57e-02 8.98e-01
TNFR1-induced proapoptotic signaling 13 4.20e-02 6.42e-02 0.4210 -3.13e-01 -0.282000 5.07e-02 7.85e-02
DAP12 interactions 33 2.83e-04 7.15e-04 0.4210 -1.97e-01 -0.372000 5.04e-02 2.15e-04
Intra-Golgi traffic 43 1.54e-05 5.13e-05 0.4200 -7.85e-02 -0.413000 3.73e-01 2.81e-06
Degradation of GLI1 by the proteasome 57 7.94e-08 4.28e-07 0.4200 -3.68e-01 0.203000 1.55e-06 8.13e-03
Hh mutants abrogate ligand secretion 57 7.78e-08 4.20e-07 0.4200 -3.60e-01 0.215000 2.54e-06 4.93e-03
RNA Polymerase I Promoter Opening 24 9.80e-04 2.16e-03 0.4190 -2.44e-01 0.341000 3.87e-02 3.81e-03
Membrane Trafficking 577 6.20e-62 4.54e-59 0.4190 -1.53e-01 -0.390000 3.46e-10 4.07e-58
FCERI mediated MAPK activation 29 8.16e-04 1.84e-03 0.4180 -1.85e-01 -0.375000 8.42e-02 4.72e-04
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling 89 1.44e-10 1.42e-09 0.4180 -7.35e-02 -0.411000 2.31e-01 2.00e-11
The citric acid (TCA) cycle and respiratory electron transport 173 1.18e-21 3.14e-20 0.4180 -1.52e-01 0.389000 5.42e-04 1.04e-18
SHC1 events in EGFR signaling 12 5.21e-02 7.72e-02 0.4170 -1.57e-01 -0.386000 3.45e-01 2.05e-02
RND2 GTPase cycle 41 1.41e-05 4.71e-05 0.4170 8.75e-02 -0.408000 3.32e-01 6.24e-06
Opioid Signalling 78 2.80e-09 2.13e-08 0.4170 -8.55e-02 -0.408000 1.92e-01 4.59e-10
Negative regulation of the PI3K/AKT network 96 3.32e-11 3.58e-10 0.4150 -7.23e-02 -0.408000 2.21e-01 4.49e-12
Golgi Associated Vesicle Biogenesis 55 1.01e-06 4.41e-06 0.4140 -6.73e-02 -0.408000 3.88e-01 1.61e-07
APC-Cdc20 mediated degradation of Nek2A 26 6.87e-04 1.57e-03 0.4140 -2.25e-01 0.347000 4.73e-02 2.17e-03
Activation of NMDA receptors and postsynaptic events 69 3.22e-08 1.91e-07 0.4140 -7.28e-02 -0.407000 2.96e-01 4.87e-09
Signaling by NTRK2 (TRKB) 24 3.09e-03 6.03e-03 0.4130 -1.67e-01 -0.378000 1.58e-01 1.33e-03
activated TAK1 mediates p38 MAPK activation 18 1.38e-02 2.38e-02 0.4130 -2.01e-01 -0.361000 1.39e-01 8.05e-03
Protein ubiquitination 73 3.11e-08 1.86e-07 0.4130 -3.55e-01 -0.211000 1.56e-07 1.79e-03
Elevation of cytosolic Ca2+ levels 12 4.33e-02 6.60e-02 0.4130 3.73e-02 -0.411000 8.23e-01 1.37e-02
RHO GTPase cycle 433 1.74e-48 3.19e-46 0.4130 -5.48e-05 -0.413000 9.98e-01 2.34e-49
Gap junction degradation 10 8.36e-02 1.17e-01 0.4110 -7.02e-02 -0.405000 7.01e-01 2.64e-02
Phosphorylation of the APC/C 20 4.28e-03 8.12e-03 0.4100 -1.84e-01 0.367000 1.55e-01 4.52e-03
mRNA Capping 29 5.04e-04 1.19e-03 0.4100 -4.03e-01 0.075500 1.75e-04 4.82e-01
Platelet Aggregation (Plug Formation) 29 1.06e-03 2.32e-03 0.4100 -1.67e-01 -0.374000 1.19e-01 4.91e-04
Ca2+ pathway 56 1.02e-06 4.44e-06 0.4090 -5.54e-02 -0.405000 4.73e-01 1.55e-07
Regulation of RUNX2 expression and activity 70 7.42e-09 5.04e-08 0.4090 -3.82e-01 0.145000 3.16e-08 3.60e-02
Regulation of MECP2 expression and activity 29 8.64e-04 1.94e-03 0.4080 -7.05e-02 -0.401000 5.11e-01 1.82e-04
Toll Like Receptor 9 (TLR9) Cascade 90 1.36e-09 1.10e-08 0.4060 -2.50e-01 -0.320000 4.21e-05 1.47e-07
Integrin cell surface interactions 57 2.12e-07 1.09e-06 0.4060 2.19e-01 -0.342000 4.17e-03 8.06e-06
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA 17 1.28e-02 2.24e-02 0.4050 -3.99e-01 0.072800 4.42e-03 6.03e-01
SHC1 events in ERBB2 signaling 20 7.50e-03 1.37e-02 0.4050 -2.98e-02 -0.404000 8.18e-01 1.76e-03
Role of phospholipids in phagocytosis 22 5.81e-03 1.08e-02 0.4050 -1.30e-01 -0.384000 2.92e-01 1.84e-03
Signaling by FGFR1 in disease 36 2.45e-04 6.25e-04 0.4050 -1.58e-01 -0.372000 1.01e-01 1.10e-04
Cell junction organization 75 4.87e-09 3.46e-08 0.4040 7.64e-02 -0.397000 2.53e-01 2.67e-09
FLT3 signaling in disease 28 1.32e-03 2.82e-03 0.4040 -9.71e-02 -0.393000 3.74e-01 3.22e-04
RNA Pol II CTD phosphorylation and interaction with CE 27 9.01e-04 2.01e-03 0.4040 -3.85e-01 0.122000 5.28e-04 2.74e-01
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection 27 9.01e-04 2.01e-03 0.4040 -3.85e-01 0.122000 5.28e-04 2.74e-01
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 13 3.71e-02 5.74e-02 0.4040 6.61e-02 -0.398000 6.80e-01 1.29e-02
ADP signalling through P2Y purinoceptor 1 21 9.19e-03 1.65e-02 0.4030 -2.68e-01 -0.301000 3.36e-02 1.68e-02
The NLRP3 inflammasome 15 3.48e-02 5.44e-02 0.4030 -3.19e-01 -0.246000 3.24e-02 9.85e-02
Sphingolipid de novo biosynthesis 42 6.52e-05 1.86e-04 0.4020 -1.40e-01 -0.377000 1.17e-01 2.36e-05
Regulation of APC/C activators between G1/S and early anaphase 79 8.70e-10 7.36e-09 0.4010 -3.28e-01 0.232000 4.73e-07 3.63e-04
Nuclear Pore Complex (NPC) Disassembly 36 3.56e-04 8.73e-04 0.4010 -2.89e-01 -0.277000 2.64e-03 3.99e-03
MyD88-independent TLR4 cascade 93 1.24e-09 1.01e-08 0.4010 -2.54e-01 -0.310000 2.23e-05 2.40e-07
TRIF(TICAM1)-mediated TLR4 signaling 93 1.24e-09 1.01e-08 0.4010 -2.54e-01 -0.310000 2.23e-05 2.40e-07
Asymmetric localization of PCP proteins 62 1.30e-07 6.85e-07 0.4010 -3.79e-01 0.129000 2.34e-07 8.00e-02
Initial triggering of complement 13 3.71e-02 5.74e-02 0.4000 -1.09e-01 0.385000 4.94e-01 1.64e-02
Regulation of HSF1-mediated heat shock response 78 3.68e-08 2.14e-07 0.4000 -3.08e-01 -0.255000 2.54e-06 9.92e-05
Prolactin receptor signaling 11 8.33e-02 1.17e-01 0.3990 -1.42e-01 -0.373000 4.15e-01 3.23e-02
Gap junction trafficking 18 9.94e-03 1.77e-02 0.3990 1.57e-01 -0.367000 2.50e-01 7.07e-03
Rab regulation of trafficking 120 4.21e-12 5.02e-11 0.3990 -2.45e-01 -0.315000 3.62e-06 2.54e-09
Pentose phosphate pathway 13 5.33e-02 7.89e-02 0.3980 -3.73e-01 -0.139000 1.98e-02 3.86e-01
Synaptic adhesion-like molecules 21 1.01e-02 1.79e-02 0.3980 -2.26e-01 -0.327000 7.28e-02 9.37e-03
COPII-mediated vesicle transport 66 2.86e-07 1.40e-06 0.3970 -9.43e-02 -0.386000 1.85e-01 5.78e-08
HDACs deacetylate histones 52 3.95e-06 1.50e-05 0.3970 -3.97e-01 0.009870 7.25e-07 9.02e-01
APC/C-mediated degradation of cell cycle proteins 86 2.19e-10 2.07e-09 0.3970 -3.16e-01 0.240000 4.01e-07 1.17e-04
Regulation of mitotic cell cycle 86 2.19e-10 2.07e-09 0.3970 -3.16e-01 0.240000 4.01e-07 1.17e-04
COPI-dependent Golgi-to-ER retrograde traffic 78 4.33e-08 2.46e-07 0.3970 -2.24e-01 -0.328000 6.22e-04 5.63e-07
G alpha (z) signalling events 39 8.99e-05 2.46e-04 0.3970 1.24e-02 -0.396000 8.93e-01 1.83e-05
EGFR downregulation 29 1.90e-03 3.91e-03 0.3960 -2.46e-01 -0.311000 2.20e-02 3.77e-03
Formation of RNA Pol II elongation complex 57 2.17e-06 8.78e-06 0.3950 -3.90e-01 -0.068100 3.60e-07 3.74e-01
RNA Polymerase II Transcription Elongation 57 2.17e-06 8.78e-06 0.3950 -3.90e-01 -0.068100 3.60e-07 3.74e-01
Vesicle-mediated transport 606 5.44e-58 1.99e-55 0.3950 -1.36e-01 -0.371000 1.01e-08 3.43e-55
Late Phase of HIV Life Cycle 135 1.15e-13 1.65e-12 0.3940 -3.72e-01 -0.131000 8.16e-14 8.59e-03
Pre-NOTCH Processing in Golgi 18 2.08e-02 3.41e-02 0.3940 -2.14e-01 -0.331000 1.17e-01 1.50e-02
FGFR1 mutant receptor activation 29 1.54e-03 3.23e-03 0.3940 -1.05e-01 -0.380000 3.27e-01 4.03e-04
RAB GEFs exchange GTP for GDP on RABs 88 6.36e-09 4.40e-08 0.3930 -2.06e-01 -0.335000 8.27e-04 5.42e-08
ER Quality Control Compartment (ERQC) 21 1.15e-02 2.02e-02 0.3930 -2.99e-01 -0.255000 1.75e-02 4.30e-02
Activation of NF-kappaB in B cells 65 1.21e-07 6.41e-07 0.3930 -3.76e-01 0.114000 1.56e-07 1.11e-01
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells 14 3.29e-02 5.18e-02 0.3920 1.08e-01 -0.377000 4.83e-01 1.46e-02
Apoptotic execution phase 47 1.06e-05 3.62e-05 0.3910 1.20e-01 -0.373000 1.53e-01 9.87e-06
Viral Messenger RNA Synthesis 44 7.31e-05 2.05e-04 0.3910 -3.62e-01 -0.147000 3.18e-05 9.05e-02
Regulation of pyruvate dehydrogenase (PDH) complex 15 4.28e-02 6.52e-02 0.3910 -2.92e-01 -0.260000 5.03e-02 8.11e-02
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) 14 4.00e-02 6.14e-02 0.3900 3.90e-01 0.001030 1.15e-02 9.95e-01
Negative regulation of MAPK pathway 42 1.15e-04 3.09e-04 0.3900 -1.36e-01 -0.366000 1.29e-01 4.12e-05
CRMPs in Sema3A signaling 16 2.47e-02 3.99e-02 0.3900 1.89e-02 -0.389000 8.96e-01 7.04e-03
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation 85 2.08e-08 1.29e-07 0.3890 -2.38e-01 -0.307000 1.43e-04 9.57e-07
Glutamate and glutamine metabolism 13 4.86e-02 7.28e-02 0.3890 3.68e-02 -0.387000 8.19e-01 1.56e-02
PKMTs methylate histone lysines 45 8.74e-05 2.40e-04 0.3890 -2.84e-01 -0.266000 9.74e-04 2.04e-03
Thrombin signalling through proteinase activated receptors (PARs) 27 3.65e-03 6.97e-03 0.3890 -2.44e-01 -0.302000 2.82e-02 6.51e-03
NOTCH1 Intracellular Domain Regulates Transcription 47 4.53e-05 1.33e-04 0.3880 -1.40e-01 -0.361000 9.64e-02 1.82e-05
RNA polymerase II transcribes snRNA genes 71 1.96e-07 1.01e-06 0.3870 -3.79e-01 -0.077900 3.36e-08 2.56e-01
MyD88 dependent cascade initiated on endosome 86 2.40e-08 1.47e-07 0.3860 -2.46e-01 -0.296000 7.74e-05 1.99e-06
Toll Like Receptor 7/8 (TLR7/8) Cascade 86 2.40e-08 1.47e-07 0.3860 -2.46e-01 -0.296000 7.74e-05 1.99e-06
Trafficking of GluR2-containing AMPA receptors 16 2.01e-02 3.32e-02 0.3850 3.06e-01 -0.234000 3.39e-02 1.06e-01
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation 34 3.81e-04 9.21e-04 0.3850 -3.79e-01 0.070700 1.32e-04 4.75e-01
G1/S-Specific Transcription 29 2.57e-03 5.10e-03 0.3850 3.25e-01 0.207000 2.45e-03 5.39e-02
SUMOylation of DNA replication proteins 46 8.22e-05 2.26e-04 0.3840 -3.21e-01 -0.212000 1.68e-04 1.28e-02
RNA Polymerase II Transcription Termination 65 1.41e-07 7.36e-07 0.3840 -2.99e-01 0.241000 3.01e-05 7.73e-04
Degradation of GLI2 by the proteasome 57 1.10e-06 4.75e-06 0.3840 -3.25e-01 0.205000 2.23e-05 7.47e-03
DAP12 signaling 26 4.58e-03 8.65e-03 0.3830 -1.47e-01 -0.354000 1.96e-01 1.80e-03
Mitochondrial protein import 64 2.31e-07 1.18e-06 0.3820 -2.03e-01 0.324000 4.91e-03 7.42e-06
SUMOylation of intracellular receptors 27 1.92e-03 3.94e-03 0.3820 1.08e-01 -0.367000 3.33e-01 9.71e-04
FCERI mediated NF-kB activation 75 4.56e-08 2.58e-07 0.3820 -3.79e-01 0.050100 1.40e-08 4.53e-01
Negative regulation of FGFR1 signaling 29 2.96e-03 5.79e-03 0.3820 -2.98e-01 -0.239000 5.55e-03 2.56e-02
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism 11 8.06e-02 1.14e-01 0.3820 8.32e-02 -0.373000 6.33e-01 3.23e-02
Formation of TC-NER Pre-Incision Complex 53 5.23e-06 1.91e-05 0.3810 -3.69e-01 0.096700 3.36e-06 2.23e-01
Metabolism of Angiotensinogen to Angiotensins 11 7.75e-02 1.10e-01 0.3810 3.59e-01 -0.128000 3.91e-02 4.62e-01
Dissolution of Fibrin Clot 12 6.30e-02 9.14e-02 0.3810 1.08e-01 -0.365000 5.16e-01 2.84e-02
HIV Life Cycle 147 6.78e-14 1.01e-12 0.3810 -3.61e-01 -0.123000 4.29e-14 9.88e-03
CLEC7A (Dectin-1) signaling 97 9.10e-10 7.66e-09 0.3810 -3.79e-01 -0.039800 1.10e-10 4.98e-01
Retrograde neurotrophin signalling 14 3.66e-02 5.67e-02 0.3810 1.90e-01 -0.330000 2.18e-01 3.26e-02
LDL clearance 16 2.30e-02 3.74e-02 0.3810 1.86e-01 -0.332000 1.99e-01 2.14e-02
Transcription of the HIV genome 69 3.36e-07 1.63e-06 0.3800 -3.80e-01 -0.021800 4.85e-08 7.54e-01
Budding and maturation of HIV virion 28 3.35e-03 6.48e-03 0.3800 -3.47e-01 -0.156000 1.48e-03 1.54e-01
Disorders of Developmental Biology 13 4.86e-02 7.28e-02 0.3800 1.48e-01 -0.350000 3.54e-01 2.90e-02
Disorders of Nervous System Development 13 4.86e-02 7.28e-02 0.3800 1.48e-01 -0.350000 3.54e-01 2.90e-02
Loss of function of MECP2 in Rett syndrome 13 4.86e-02 7.28e-02 0.3800 1.48e-01 -0.350000 3.54e-01 2.90e-02
Pervasive developmental disorders 13 4.86e-02 7.28e-02 0.3800 1.48e-01 -0.350000 3.54e-01 2.90e-02
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism 12 5.73e-02 8.41e-02 0.3800 2.69e-01 -0.268000 1.07e-01 1.07e-01
alpha-linolenic acid (ALA) metabolism 12 5.73e-02 8.41e-02 0.3800 2.69e-01 -0.268000 1.07e-01 1.07e-01
Interleukin-2 family signaling 34 5.64e-04 1.31e-03 0.3800 2.00e-02 -0.379000 8.40e-01 1.29e-04
Defective GALNT12 causes CRCS1 10 1.36e-01 1.80e-01 0.3800 2.18e-01 0.311000 2.33e-01 8.86e-02
Signaling by NOTCH1 72 2.46e-07 1.23e-06 0.3800 -5.90e-02 -0.375000 3.86e-01 3.69e-08
PI3K/AKT Signaling in Cancer 89 1.12e-08 7.41e-08 0.3790 -1.06e-01 -0.364000 8.44e-02 2.99e-09
AKT phosphorylates targets in the cytosol 14 5.40e-02 7.98e-02 0.3780 -7.82e-02 -0.370000 6.13e-01 1.65e-02
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha 64 3.92e-07 1.88e-06 0.3780 -3.44e-01 0.156000 1.91e-06 3.05e-02
ATF6 (ATF6-alpha) activates chaperone genes 10 1.13e-01 1.54e-01 0.3770 -3.77e-01 0.025200 3.92e-02 8.90e-01
RNA Polymerase III Transcription Termination 23 6.86e-03 1.26e-02 0.3770 -3.77e-01 0.017100 1.76e-03 8.87e-01
CD28 dependent PI3K/Akt signaling 18 2.57e-02 4.14e-02 0.3770 -1.14e-01 -0.359000 4.02e-01 8.34e-03
Glycosphingolipid metabolism 42 6.19e-05 1.77e-04 0.3760 3.18e-01 -0.201000 3.67e-04 2.45e-02
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA 17 2.26e-02 3.69e-02 0.3760 -3.63e-01 0.096500 9.54e-03 4.91e-01
Signaling by FGFR2 IIIa TM 19 1.36e-02 2.35e-02 0.3750 -3.50e-01 0.137000 8.35e-03 3.01e-01
PPARA activates gene expression 108 4.30e-10 3.89e-09 0.3750 -1.30e-01 -0.352000 1.91e-02 2.56e-10
Activation of the pre-replicative complex 33 1.74e-03 3.61e-03 0.3740 2.29e-01 0.295000 2.27e-02 3.31e-03
Regulation of TP53 Degradation 35 1.20e-03 2.60e-03 0.3730 -3.00e-01 -0.222000 2.11e-03 2.32e-02
Cell-cell junction organization 50 1.13e-05 3.85e-05 0.3730 2.15e-01 -0.305000 8.64e-03 1.92e-04
Endosomal/Vacuolar pathway 12 9.77e-02 1.34e-01 0.3720 -1.66e-01 -0.333000 3.18e-01 4.60e-02
Nuclear Envelope Breakdown 53 4.21e-05 1.24e-04 0.3720 -2.37e-01 -0.287000 2.86e-03 3.03e-04
Asparagine N-linked glycosylation 278 3.87e-24 1.16e-22 0.3720 -1.41e-01 -0.344000 4.89e-05 4.83e-23
Signaling by RAF1 mutants 35 8.89e-04 1.99e-03 0.3720 -7.94e-02 -0.363000 4.16e-01 2.01e-04
Potential therapeutics for SARS 81 2.35e-07 1.19e-06 0.3710 -2.55e-01 -0.269000 7.11e-05 2.84e-05
TRAF3-dependent IRF activation pathway 14 6.66e-02 9.60e-02 0.3700 -1.48e-01 -0.340000 3.39e-01 2.78e-02
DNA methylation 26 3.21e-03 6.24e-03 0.3700 -1.54e-01 0.336000 1.73e-01 3.02e-03
Interleukin-20 family signaling 19 2.74e-02 4.37e-02 0.3700 -2.00e-01 -0.311000 1.32e-01 1.89e-02
Regulation of lipid metabolism by PPARalpha 110 5.92e-10 5.16e-09 0.3690 -1.28e-01 -0.346000 2.06e-02 3.40e-10
HuR (ELAVL1) binds and stabilizes mRNA 10 1.15e-01 1.55e-01 0.3690 1.07e-01 -0.353000 5.57e-01 5.32e-02
Assembly of the pre-replicative complex 90 1.93e-09 1.50e-08 0.3690 -2.19e-01 0.297000 3.38e-04 1.10e-06
Diseases of signal transduction by growth factor receptors and second messengers 404 1.35e-33 6.38e-32 0.3680 -1.69e-01 -0.327000 5.80e-09 1.06e-29
GLI3 is processed to GLI3R by the proteasome 57 3.47e-06 1.34e-05 0.3680 -3.21e-01 0.180000 2.76e-05 1.85e-02
Inflammasomes 19 2.84e-02 4.53e-02 0.3680 -3.06e-01 -0.205000 2.11e-02 1.22e-01
Translation of Replicase and Assembly of the Replication Transcription Complex 13 6.88e-02 9.86e-02 0.3680 1.33e-02 -0.368000 9.34e-01 2.17e-02
Carnitine metabolism 11 1.04e-01 1.43e-01 0.3680 9.71e-03 -0.368000 9.56e-01 3.47e-02
Clathrin-mediated endocytosis 135 9.09e-12 1.06e-10 0.3680 -1.69e-01 -0.326000 6.80e-04 5.67e-11
Cytosolic iron-sulfur cluster assembly 13 8.09e-02 1.14e-01 0.3680 1.13e-01 0.350000 4.82e-01 2.89e-02
HATs acetylate histones 99 3.21e-09 2.40e-08 0.3680 -3.62e-01 -0.060900 4.50e-10 2.95e-01
PI3K events in ERBB2 signaling 14 6.84e-02 9.81e-02 0.3670 -1.24e-01 -0.345000 4.20e-01 2.53e-02
RNA Polymerase III Abortive And Retractive Initiation 41 2.69e-04 6.85e-04 0.3660 -3.66e-01 -0.022300 5.06e-05 8.05e-01
RNA Polymerase III Transcription 41 2.69e-04 6.85e-04 0.3660 -3.66e-01 -0.022300 5.06e-05 8.05e-01
RHO GTPases activate CIT 19 3.06e-02 4.85e-02 0.3650 -2.56e-01 -0.261000 5.38e-02 4.87e-02
UCH proteinases 90 4.12e-09 3.02e-08 0.3650 -3.31e-01 0.153000 5.58e-08 1.22e-02
Attenuation phase 23 1.37e-02 2.37e-02 0.3650 -1.58e-01 -0.329000 1.90e-01 6.36e-03
Signaling by ROBO receptors 210 1.76e-20 4.30e-19 0.3640 -2.91e-01 0.219000 3.63e-13 4.27e-08
Insulin receptor signalling cascade 48 8.22e-05 2.26e-04 0.3640 -4.07e-02 -0.362000 6.25e-01 1.45e-05
mRNA Splicing - Major Pathway 179 1.87e-17 3.51e-16 0.3640 -3.13e-01 0.187000 5.22e-13 1.66e-05
NF-kB is activated and signals survival 13 8.12e-02 1.14e-01 0.3640 -3.57e-01 -0.069700 2.58e-02 6.64e-01
Signaling by FGFR3 38 9.76e-04 2.15e-03 0.3640 -2.16e-01 -0.293000 2.13e-02 1.79e-03
Assembly of active LPL and LIPC lipase complexes 12 8.78e-02 1.23e-01 0.3630 3.66e-02 -0.361000 8.26e-01 3.03e-02
EPH-ephrin mediated repulsion of cells 48 5.92e-05 1.70e-04 0.3620 4.72e-02 -0.359000 5.72e-01 1.66e-05
WNT5A-dependent internalization of FZD4 15 4.44e-02 6.75e-02 0.3620 9.55e-02 -0.349000 5.22e-01 1.91e-02
EPH-Ephrin signaling 91 2.93e-08 1.77e-07 0.3620 -7.37e-02 -0.355000 2.24e-01 4.91e-09
ESR-mediated signaling 170 5.47e-14 8.26e-13 0.3620 -2.19e-01 -0.288000 8.17e-07 8.87e-11
Chromatin modifying enzymes 222 3.74e-18 7.95e-17 0.3610 -3.16e-01 -0.175000 4.33e-16 7.25e-06
Chromatin organization 222 3.74e-18 7.95e-17 0.3610 -3.16e-01 -0.175000 4.33e-16 7.25e-06
Association of TriC/CCT with target proteins during biosynthesis 37 1.32e-03 2.82e-03 0.3610 -2.45e-01 -0.265000 9.89e-03 5.21e-03
NOTCH4 Intracellular Domain Regulates Transcription 19 1.93e-02 3.19e-02 0.3600 1.25e-01 -0.338000 3.47e-01 1.07e-02
Cobalamin (Cbl, vitamin B12) transport and metabolism 18 3.20e-02 5.05e-02 0.3600 -3.57e-01 -0.050500 8.80e-03 7.11e-01
Metabolism of RNA 677 2.53e-61 1.24e-58 0.3600 -3.20e-01 0.166000 5.42e-46 1.74e-13
Regulation of TP53 Expression and Degradation 36 1.67e-03 3.49e-03 0.3600 -2.66e-01 -0.242000 5.67e-03 1.21e-02
mRNA Splicing 187 1.09e-17 2.18e-16 0.3580 -2.99e-01 0.196000 1.57e-12 3.59e-06
Amine ligand-binding receptors 22 9.60e-03 1.72e-02 0.3580 2.36e-01 -0.269000 5.54e-02 2.88e-02
HCMV Early Events 80 7.37e-07 3.36e-06 0.3570 -3.03e-01 -0.189000 2.84e-06 3.39e-03
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation 10 1.39e-01 1.84e-01 0.3570 3.53e-01 -0.048500 5.30e-02 7.91e-01
RUNX1 regulates transcription of genes involved in differentiation of HSCs 87 1.47e-08 9.48e-08 0.3560 -2.95e-01 0.199000 1.96e-06 1.31e-03
Sialic acid metabolism 31 4.34e-03 8.23e-03 0.3560 -1.90e-01 -0.301000 6.68e-02 3.76e-03
Processing of Capped Intron-Containing Pre-mRNA 238 1.80e-21 4.70e-20 0.3550 -3.32e-01 0.125000 9.00e-19 8.85e-04
Transport of Mature Transcript to Cytoplasm 81 1.61e-07 8.33e-07 0.3550 -3.53e-01 0.036400 4.02e-08 5.71e-01
Fatty acyl-CoA biosynthesis 35 1.26e-03 2.70e-03 0.3540 1.93e-02 -0.353000 8.44e-01 2.99e-04
Regulation of mRNA stability by proteins that bind AU-rich elements 87 3.13e-08 1.86e-07 0.3540 -3.36e-01 0.109000 5.79e-08 7.86e-02
AKT phosphorylates targets in the nucleus 10 1.45e-01 1.90e-01 0.3530 4.70e-02 -0.350000 7.97e-01 5.53e-02
SHC1 events in ERBB4 signaling 12 1.19e-01 1.60e-01 0.3520 -1.10e-01 -0.334000 5.08e-01 4.49e-02
p75NTR recruits signalling complexes 13 9.50e-02 1.31e-01 0.3520 -3.46e-01 -0.063800 3.08e-02 6.90e-01
Effects of PIP2 hydrolysis 24 1.16e-02 2.05e-02 0.3520 -1.21e-02 -0.351000 9.18e-01 2.89e-03
Extracellular matrix organization 249 5.50e-22 1.52e-20 0.3510 1.28e-01 -0.327000 4.90e-04 5.56e-19
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase 20 1.77e-02 2.95e-02 0.3510 -1.83e-01 0.300000 1.57e-01 2.02e-02
HIV Infection 222 6.65e-18 1.35e-16 0.3510 -3.43e-01 -0.074100 1.09e-18 5.68e-02
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters 17 4.55e-02 6.88e-02 0.3510 -4.70e-02 -0.348000 7.37e-01 1.30e-02
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux 35 2.24e-03 4.49e-03 0.3510 -1.29e-01 -0.326000 1.87e-01 8.33e-04
SUMOylation of chromatin organization proteins 57 6.72e-05 1.91e-04 0.3510 -2.43e-01 -0.252000 1.49e-03 9.77e-04
Switching of origins to a post-replicative state 89 1.60e-08 1.01e-07 0.3510 -2.17e-01 0.276000 4.11e-04 6.93e-06
Blood group systems biosynthesis 18 4.57e-02 6.89e-02 0.3500 -1.65e-01 -0.309000 2.25e-01 2.32e-02
Constitutive Signaling by Aberrant PI3K in Cancer 62 1.38e-05 4.64e-05 0.3500 -4.45e-02 -0.347000 5.45e-01 2.27e-06
Semaphorin interactions 60 1.52e-05 5.07e-05 0.3500 1.82e-03 -0.350000 9.81e-01 2.75e-06
PCNA-Dependent Long Patch Base Excision Repair 21 2.89e-02 4.60e-02 0.3500 2.03e-01 0.285000 1.07e-01 2.40e-02
Resolution of D-Loop Structures 33 3.94e-03 7.48e-03 0.3500 2.41e-01 0.253000 1.66e-02 1.18e-02
WNT ligand biogenesis and trafficking 24 1.31e-02 2.27e-02 0.3490 -3.67e-02 -0.347000 7.55e-01 3.23e-03
SUMOylation of transcription cofactors 44 6.32e-04 1.46e-03 0.3490 -2.22e-01 -0.269000 1.08e-02 2.00e-03
Orc1 removal from chromatin 69 9.86e-07 4.31e-06 0.3490 -2.36e-01 0.257000 7.00e-04 2.21e-04
GRB2 events in ERBB2 signaling 14 9.41e-02 1.30e-01 0.3480 -1.69e-01 -0.304000 2.72e-01 4.90e-02
Cargo recognition for clathrin-mediated endocytosis 97 6.57e-08 3.60e-07 0.3480 -1.36e-01 -0.320000 2.06e-02 4.93e-08
SCF(Skp2)-mediated degradation of p27/p21 60 6.61e-06 2.37e-05 0.3480 -2.73e-01 0.215000 2.51e-04 3.92e-03
Synthesis of very long-chain fatty acyl-CoAs 22 1.39e-02 2.39e-02 0.3480 1.33e-01 -0.321000 2.81e-01 9.08e-03
Negative regulation of TCF-dependent signaling by WNT ligand antagonists 11 1.53e-01 2.00e-01 0.3470 -1.34e-01 -0.320000 4.41e-01 6.59e-02
Cytosolic tRNA aminoacylation 24 1.72e-02 2.89e-02 0.3470 -3.15e-01 -0.145000 7.49e-03 2.19e-01
trans-Golgi Network Vesicle Budding 71 2.73e-06 1.07e-05 0.3470 -1.03e-02 -0.347000 8.81e-01 4.36e-07
NRAGE signals death through JNK 59 1.78e-05 5.80e-05 0.3460 4.38e-02 -0.344000 5.60e-01 4.94e-06
Reactions specific to the complex N-glycan synthesis pathway 10 1.90e-01 2.43e-01 0.3460 -2.88e-01 -0.192000 1.14e-01 2.94e-01
Deactivation of the beta-catenin transactivating complex 41 3.69e-04 8.98e-04 0.3460 1.37e-01 -0.318000 1.30e-01 4.28e-04
RNA Polymerase II Pre-transcription Events 80 8.69e-07 3.86e-06 0.3450 -3.40e-01 -0.059400 1.40e-07 3.58e-01
SUMOylation of RNA binding proteins 47 4.50e-04 1.07e-03 0.3450 -2.78e-01 -0.204000 9.64e-04 1.56e-02
DSCAM interactions 10 1.93e-01 2.47e-01 0.3450 -1.95e-01 -0.284000 2.85e-01 1.20e-01
Host Interactions of HIV factors 124 3.03e-10 2.84e-09 0.3450 -3.44e-01 -0.024300 3.60e-11 6.41e-01
HSF1 activation 26 1.46e-02 2.51e-02 0.3440 -2.32e-01 -0.254000 4.08e-02 2.48e-02
SARS-CoV-2 Infection 70 6.78e-06 2.42e-05 0.3440 -9.37e-02 -0.331000 1.75e-01 1.66e-06
Assembly and cell surface presentation of NMDA receptors 23 2.31e-02 3.77e-02 0.3440 -1.92e-01 -0.286000 1.11e-01 1.78e-02
Condensation of Prophase Chromosomes 34 1.32e-03 2.82e-03 0.3440 -2.51e-01 0.235000 1.14e-02 1.75e-02
Transport of bile salts and organic acids, metal ions and amine compounds 58 2.16e-05 6.79e-05 0.3440 7.21e-02 -0.336000 3.42e-01 9.37e-06
Metabolism of non-coding RNA 53 1.47e-04 3.89e-04 0.3430 -3.19e-01 -0.127000 5.99e-05 1.09e-01
snRNP Assembly 53 1.47e-04 3.89e-04 0.3430 -3.19e-01 -0.127000 5.99e-05 1.09e-01
RAB geranylgeranylation 62 3.75e-05 1.12e-04 0.3430 -1.54e-01 -0.306000 3.58e-02 3.03e-05
SARS-CoV Infections 150 2.75e-11 3.05e-10 0.3420 -1.75e-01 -0.294000 2.07e-04 5.04e-10
Transport of Mature mRNA derived from an Intron-Containing Transcript 72 2.55e-06 1.01e-05 0.3400 -3.37e-01 0.044700 7.35e-07 5.12e-01
TNFR1-induced NFkappaB signaling pathway 26 1.58e-02 2.68e-02 0.3400 -2.73e-01 -0.204000 1.61e-02 7.23e-02
Signaling by ERBB2 in Cancer 24 1.75e-02 2.93e-02 0.3400 -6.50e-02 -0.334000 5.82e-01 4.66e-03
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression 37 9.88e-04 2.17e-03 0.3400 -3.03e-01 0.153000 1.42e-03 1.06e-01
HSF1-dependent transactivation 31 6.44e-03 1.19e-02 0.3390 -1.29e-01 -0.314000 2.13e-01 2.49e-03
Fc epsilon receptor (FCERI) signaling 126 1.67e-09 1.31e-08 0.3390 -3.04e-01 -0.150000 3.80e-09 3.58e-03
Regulation of RAS by GAPs 64 9.56e-06 3.32e-05 0.3390 -3.29e-01 0.082000 5.40e-06 2.56e-01
Defective B3GALTL causes PpS 36 1.22e-03 2.63e-03 0.3390 3.00e-01 -0.158000 1.86e-03 1.01e-01
Unfolded Protein Response (UPR) 89 6.86e-07 3.14e-06 0.3380 -2.97e-01 -0.163000 1.28e-06 7.96e-03
Processing of Capped Intronless Pre-mRNA 28 6.59e-03 1.22e-02 0.3380 -3.31e-01 0.068900 2.40e-03 5.28e-01
Hedgehog ‘on’ state 84 2.42e-07 1.22e-06 0.3370 -3.19e-01 0.109000 4.14e-07 8.40e-02
RHOBTB2 GTPase cycle 23 2.74e-02 4.37e-02 0.3370 -2.64e-01 -0.210000 2.84e-02 8.18e-02
Glucagon signaling in metabolic regulation 26 1.48e-02 2.53e-02 0.3370 -1.06e-01 -0.320000 3.49e-01 4.76e-03
IGF1R signaling cascade 47 2.97e-04 7.47e-04 0.3370 1.76e-02 -0.336000 8.34e-01 6.65e-05
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) 47 2.97e-04 7.47e-04 0.3370 1.76e-02 -0.336000 8.34e-01 6.65e-05
Signaling by Receptor Tyrosine Kinases 468 1.35e-34 6.59e-33 0.3370 -2.07e-02 -0.336000 4.42e-01 9.18e-36
ABC transporters in lipid homeostasis 15 8.39e-02 1.17e-01 0.3360 3.31e-01 0.054300 2.64e-02 7.16e-01
Interferon alpha/beta signaling 56 5.90e-05 1.70e-04 0.3350 -3.30e-01 0.054900 1.93e-05 4.77e-01
mRNA 3’-end processing 56 3.39e-05 1.02e-04 0.3340 -2.63e-01 0.206000 6.60e-04 7.51e-03
Regulation of PTEN stability and activity 67 9.25e-06 3.23e-05 0.3330 -3.26e-01 0.066400 3.90e-06 3.47e-01
O-linked glycosylation of mucins 48 1.94e-04 5.03e-04 0.3310 1.51e-01 -0.295000 7.06e-02 4.04e-04
E3 ubiquitin ligases ubiquitinate target proteins 53 3.03e-04 7.59e-04 0.3310 -2.90e-01 -0.160000 2.56e-04 4.44e-02
Inhibition of DNA recombination at telomere 39 9.43e-04 2.09e-03 0.3310 -2.88e-01 0.164000 1.87e-03 7.67e-02
G alpha (12/13) signalling events 75 2.45e-06 9.72e-06 0.3310 7.84e-02 -0.322000 2.40e-01 1.45e-06
Packaging Of Telomere Ends 24 1.53e-02 2.61e-02 0.3300 -3.13e-01 0.107000 8.03e-03 3.63e-01
Selective autophagy 58 1.67e-04 4.38e-04 0.3300 -2.59e-01 -0.205000 6.48e-04 6.92e-03
PI-3K cascade:FGFR1 18 6.31e-02 9.15e-02 0.3300 -1.35e-01 -0.301000 3.21e-01 2.69e-02
Thromboxane signalling through TP receptor 20 5.00e-02 7.48e-02 0.3300 -2.22e-01 -0.244000 8.54e-02 5.86e-02
Transcriptional regulation by RUNX3 94 6.02e-07 2.80e-06 0.3300 -2.96e-01 -0.146000 7.02e-07 1.42e-02
Activation of the AP-1 family of transcription factors 10 2.24e-01 2.82e-01 0.3300 -2.20e-01 -0.246000 2.29e-01 1.78e-01
NGF-stimulated transcription 38 2.67e-03 5.26e-03 0.3290 -3.17e-01 -0.090300 7.27e-04 3.35e-01
Cellular response to hypoxia 72 5.56e-06 2.03e-05 0.3290 -3.25e-01 0.051400 1.83e-06 4.51e-01
DNA Replication Pre-Initiation 107 7.36e-09 5.04e-08 0.3290 -1.45e-01 0.295000 9.36e-03 1.29e-07
Interleukin-12 signaling 43 9.30e-04 2.06e-03 0.3290 -3.29e-01 -0.012800 1.90e-04 8.85e-01
Downstream signaling events of B Cell Receptor (BCR) 79 1.94e-06 7.93e-06 0.3290 -3.27e-01 0.036500 5.01e-07 5.75e-01
CDC6 association with the ORC:origin complex 11 1.88e-01 2.41e-01 0.3290 1.34e-01 0.300000 4.41e-01 8.50e-02
ER-Phagosome pathway 86 3.29e-07 1.60e-06 0.3290 -3.02e-01 0.130000 1.32e-06 3.66e-02
Signaling by FGFR1 46 9.84e-04 2.16e-03 0.3270 -1.40e-01 -0.296000 1.00e-01 5.11e-04
Degradation of beta-catenin by the destruction complex 83 2.03e-06 8.29e-06 0.3270 -3.25e-01 -0.040200 3.10e-07 5.27e-01
NR1H2 and NR1H3-mediated signaling 43 1.61e-03 3.37e-03 0.3270 -1.45e-01 -0.293000 1.00e-01 8.86e-04
Negative regulation of FGFR3 signaling 27 1.92e-02 3.18e-02 0.3270 -2.33e-01 -0.228000 3.58e-02 4.00e-02
Translesion synthesis by POLI 17 6.27e-02 9.11e-02 0.3260 -2.19e-02 0.326000 8.76e-01 2.01e-02
Fanconi Anemia Pathway 36 3.63e-03 6.96e-03 0.3260 5.24e-02 0.322000 5.87e-01 8.28e-04
Caspase activation via extrinsic apoptotic signalling pathway 25 2.09e-02 3.43e-02 0.3250 -5.92e-02 -0.320000 6.08e-01 5.61e-03
IRS-related events triggered by IGF1R 46 6.60e-04 1.52e-03 0.3250 -3.13e-03 -0.325000 9.71e-01 1.37e-04
Signaling by Rho GTPases 625 3.81e-42 3.72e-40 0.3250 -4.17e-02 -0.322000 7.44e-02 2.52e-43
Intracellular signaling by second messengers 287 9.44e-19 2.09e-17 0.3250 -1.83e-01 -0.269000 9.73e-08 4.49e-15
DDX58/IFIH1-mediated induction of interferon-alpha/beta 66 6.43e-05 1.83e-04 0.3250 -2.79e-01 -0.167000 9.04e-05 1.92e-02
Platelet activation, signaling and aggregation 224 1.18e-15 1.99e-14 0.3240 -5.07e-02 -0.320000 1.91e-01 1.31e-16
Signaling by high-kinase activity BRAF mutants 31 8.07e-03 1.46e-02 0.3240 -3.76e-02 -0.322000 7.17e-01 1.91e-03
Inactivation of APC/C via direct inhibition of the APC/C complex 21 2.72e-02 4.36e-02 0.3240 -1.71e-01 0.275000 1.74e-01 2.92e-02
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components 21 2.72e-02 4.36e-02 0.3240 -1.71e-01 0.275000 1.74e-01 2.92e-02
Signaling by Rho GTPases, Miro GTPases and RHOBTB3 641 1.00e-42 1.05e-40 0.3240 -4.79e-02 -0.320000 3.82e-02 7.99e-44
Transcriptional regulation of white adipocyte differentiation 81 6.52e-06 2.35e-05 0.3240 -1.28e-01 -0.297000 4.71e-02 3.70e-06
Synthesis of IP2, IP, and Ins in the cytosol 14 1.33e-01 1.77e-01 0.3230 -2.08e-01 -0.247000 1.77e-01 1.09e-01
Signaling by FGFR4 37 4.87e-03 9.16e-03 0.3230 -1.95e-01 -0.258000 4.05e-02 6.61e-03
Metabolism of amine-derived hormones 12 1.79e-01 2.31e-01 0.3220 2.58e-01 0.194000 1.22e-01 2.45e-01
Transcriptional Regulation by MECP2 55 1.44e-04 3.81e-04 0.3220 4.85e-02 -0.318000 5.34e-01 4.39e-05
TRAF6 mediated IRF7 activation 16 1.00e-01 1.38e-01 0.3220 -1.67e-01 -0.275000 2.46e-01 5.70e-02
SUMOylation of DNA damage response and repair proteins 76 2.12e-05 6.70e-05 0.3210 -2.17e-01 -0.237000 1.06e-03 3.53e-04
Resolution of D-loop Structures through Holliday Junction Intermediates 32 1.07e-02 1.90e-02 0.3210 2.21e-01 0.233000 3.05e-02 2.23e-02
Digestion and absorption 10 1.89e-01 2.42e-01 0.3210 -1.39e-01 0.289000 4.46e-01 1.13e-01
The role of Nef in HIV-1 replication and disease pathogenesis 23 3.44e-02 5.38e-02 0.3200 -1.02e-01 -0.304000 3.95e-01 1.17e-02
Regulation of beta-cell development 29 7.66e-03 1.40e-02 0.3200 1.74e-01 -0.269000 1.05e-01 1.22e-02
Diseases of carbohydrate metabolism 30 8.99e-03 1.62e-02 0.3200 3.19e-01 -0.026300 2.49e-03 8.03e-01
G beta:gamma signalling through CDC42 16 1.06e-01 1.44e-01 0.3200 -2.26e-01 -0.226000 1.18e-01 1.17e-01
Phospholipid metabolism 186 3.53e-12 4.24e-11 0.3190 -1.47e-01 -0.283000 5.25e-04 2.57e-11
Paradoxical activation of RAF signaling by kinase inactive BRAF 39 3.33e-03 6.44e-03 0.3190 -8.88e-02 -0.306000 3.37e-01 9.24e-04
Signaling by RAS mutants 39 3.33e-03 6.44e-03 0.3190 -8.88e-02 -0.306000 3.37e-01 9.24e-04
Signaling by moderate kinase activity BRAF mutants 39 3.33e-03 6.44e-03 0.3190 -8.88e-02 -0.306000 3.37e-01 9.24e-04
Signaling downstream of RAS mutants 39 3.33e-03 6.44e-03 0.3190 -8.88e-02 -0.306000 3.37e-01 9.24e-04
RNA Polymerase I Promoter Escape 52 1.64e-04 4.31e-04 0.3190 -2.23e-01 0.228000 5.39e-03 4.45e-03
Class I peroxisomal membrane protein import 19 4.28e-02 6.52e-02 0.3190 1.65e-01 -0.272000 2.12e-01 3.99e-02
Interleukin-1 signaling 95 4.85e-07 2.29e-06 0.3190 -3.19e-01 0.000406 7.91e-08 9.95e-01
HIV Transcription Initiation 47 5.12e-04 1.20e-03 0.3180 -3.01e-01 0.103000 3.57e-04 2.23e-01
RNA Polymerase II HIV Promoter Escape 47 5.12e-04 1.20e-03 0.3180 -3.01e-01 0.103000 3.57e-04 2.23e-01
RNA Polymerase II Promoter Escape 47 5.12e-04 1.20e-03 0.3180 -3.01e-01 0.103000 3.57e-04 2.23e-01
RNA Polymerase II Transcription Initiation 47 5.12e-04 1.20e-03 0.3180 -3.01e-01 0.103000 3.57e-04 2.23e-01
RNA Polymerase II Transcription Initiation And Promoter Clearance 47 5.12e-04 1.20e-03 0.3180 -3.01e-01 0.103000 3.57e-04 2.23e-01
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening 47 5.12e-04 1.20e-03 0.3180 -3.01e-01 0.103000 3.57e-04 2.23e-01
PRC2 methylates histones and DNA 34 3.48e-03 6.69e-03 0.3180 -2.11e-01 0.237000 3.28e-02 1.66e-02
Glycogen breakdown (glycogenolysis) 15 9.56e-02 1.32e-01 0.3170 4.87e-02 -0.314000 7.44e-01 3.54e-02
Hedgehog ligand biogenesis 63 3.20e-05 9.70e-05 0.3170 -2.70e-01 0.166000 2.05e-04 2.27e-02
HCMV Infection 104 5.76e-07 2.69e-06 0.3170 -2.52e-01 -0.192000 8.92e-06 6.93e-04
Platelet homeostasis 72 1.53e-05 5.10e-05 0.3170 2.66e-02 -0.316000 6.96e-01 3.53e-06
N-glycan trimming in the ER and Calnexin/Calreticulin cycle 35 7.45e-03 1.36e-02 0.3170 -1.55e-01 -0.277000 1.13e-01 4.62e-03
O-glycosylation of TSR domain-containing proteins 37 2.31e-03 4.62e-03 0.3170 2.69e-01 -0.167000 4.57e-03 7.90e-02
MyD88:MAL(TIRAP) cascade initiated on plasma membrane 94 2.40e-06 9.59e-06 0.3170 -2.08e-01 -0.239000 4.84e-04 6.22e-05
Toll Like Receptor 2 (TLR2) Cascade 94 2.40e-06 9.59e-06 0.3170 -2.08e-01 -0.239000 4.84e-04 6.22e-05
Toll Like Receptor TLR1:TLR2 Cascade 94 2.40e-06 9.59e-06 0.3170 -2.08e-01 -0.239000 4.84e-04 6.22e-05
Toll Like Receptor TLR6:TLR2 Cascade 94 2.40e-06 9.59e-06 0.3170 -2.08e-01 -0.239000 4.84e-04 6.22e-05
Costimulation by the CD28 family 57 2.82e-04 7.13e-04 0.3170 -9.74e-02 -0.301000 2.03e-01 8.23e-05
Activation of ATR in response to replication stress 37 6.12e-03 1.13e-02 0.3170 2.27e-01 0.221000 1.71e-02 1.97e-02
Toll Like Receptor 4 (TLR4) Cascade 121 5.94e-08 3.30e-07 0.3170 -1.98e-01 -0.247000 1.69e-04 2.63e-06
Autophagy 124 4.03e-08 2.32e-07 0.3160 -1.92e-01 -0.251000 2.18e-04 1.35e-06
TNFR2 non-canonical NF-kB pathway 89 5.23e-07 2.46e-06 0.3160 -2.73e-01 0.159000 8.36e-06 9.54e-03
Mitochondrial Fatty Acid Beta-Oxidation 34 9.47e-03 1.70e-02 0.3150 1.94e-01 0.249000 5.07e-02 1.19e-02
FGFRL1 modulation of FGFR1 signaling 11 1.66e-01 2.16e-01 0.3150 1.85e-01 -0.255000 2.87e-01 1.43e-01
Deubiquitination 246 2.48e-15 4.04e-14 0.3150 -2.66e-01 -0.169000 5.99e-13 5.06e-06
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding 34 8.73e-03 1.58e-02 0.3150 -2.88e-01 -0.126000 3.64e-03 2.02e-01
PIP3 activates AKT signaling 251 2.31e-15 3.80e-14 0.3140 -2.09e-01 -0.234000 1.22e-08 1.52e-10
IRF3-mediated induction of type I IFN 12 1.91e-01 2.44e-01 0.3130 -2.85e-01 -0.130000 8.74e-02 4.37e-01
Negative regulation of MET activity 21 5.46e-02 8.05e-02 0.3130 -1.18e-01 -0.290000 3.51e-01 2.15e-02
Listeria monocytogenes entry into host cells 20 6.40e-02 9.24e-02 0.3130 -1.33e-01 -0.283000 3.04e-01 2.84e-02
p75 NTR receptor-mediated signalling 94 1.25e-06 5.36e-06 0.3130 -3.24e-02 -0.311000 5.87e-01 1.85e-07
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants 57 3.22e-04 7.96e-04 0.3120 -7.07e-02 -0.304000 3.56e-01 7.17e-05
Constitutive Signaling by NOTCH1 PEST Domain Mutants 57 3.22e-04 7.96e-04 0.3120 -7.07e-02 -0.304000 3.56e-01 7.17e-05
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer 57 3.22e-04 7.96e-04 0.3120 -7.07e-02 -0.304000 3.56e-01 7.17e-05
Signaling by NOTCH1 PEST Domain Mutants in Cancer 57 3.22e-04 7.96e-04 0.3120 -7.07e-02 -0.304000 3.56e-01 7.17e-05
Signaling by NOTCH1 in Cancer 57 3.22e-04 7.96e-04 0.3120 -7.07e-02 -0.304000 3.56e-01 7.17e-05
DNA Damage Recognition in GG-NER 38 2.66e-03 5.26e-03 0.3110 -2.86e-01 0.123000 2.30e-03 1.88e-01
Formation of the cornified envelope 21 5.33e-02 7.89e-02 0.3110 -7.98e-02 -0.301000 5.27e-01 1.71e-02
Regulation of TLR by endogenous ligand 14 1.51e-01 1.97e-01 0.3110 1.48e-01 0.274000 3.38e-01 7.63e-02
Ub-specific processing proteases 175 4.13e-11 4.42e-10 0.3110 -2.91e-01 -0.110000 2.99e-11 1.23e-02
Signaling by ERBB2 KD Mutants 23 3.72e-02 5.75e-02 0.3100 -2.82e-02 -0.309000 8.15e-01 1.03e-02
Mismatch Repair 15 1.06e-01 1.44e-01 0.3100 3.06e-01 -0.052400 4.03e-02 7.25e-01
IRS-mediated signalling 43 2.19e-03 4.41e-03 0.3100 -3.32e-02 -0.308000 7.07e-01 4.66e-04
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) 14 1.29e-01 1.72e-01 0.3100 3.10e-01 -0.009920 4.47e-02 9.49e-01
Rap1 signalling 15 1.12e-01 1.52e-01 0.3100 7.79e-03 -0.310000 9.58e-01 3.77e-02
RNA Polymerase I Promoter Clearance 71 1.56e-05 5.17e-05 0.3100 -2.71e-01 0.150000 7.83e-05 2.90e-02
RNA Polymerase I Transcription 71 1.56e-05 5.17e-05 0.3100 -2.71e-01 0.150000 7.83e-05 2.90e-02
HCMV Late Events 76 3.86e-05 1.14e-04 0.3090 -2.76e-01 -0.141000 3.25e-05 3.39e-02
Deposition of new CENPA-containing nucleosomes at the centromere 44 1.23e-03 2.64e-03 0.3090 -9.58e-02 0.294000 2.71e-01 7.33e-04
Nucleosome assembly 44 1.23e-03 2.64e-03 0.3090 -9.58e-02 0.294000 2.71e-01 7.33e-04
O-linked glycosylation 95 3.52e-07 1.70e-06 0.3090 1.82e-01 -0.250000 2.16e-03 2.59e-05
NoRC negatively regulates rRNA expression 67 2.83e-05 8.62e-05 0.3090 -2.45e-01 0.188000 5.24e-04 7.90e-03
Synthesis of DNA 118 2.44e-08 1.50e-07 0.3090 -6.24e-02 0.302000 2.42e-01 1.40e-08
RNA Polymerase III Transcription Initiation 36 5.80e-03 1.08e-02 0.3080 -3.08e-01 -0.007570 1.36e-03 9.37e-01
Nonhomologous End-Joining (NHEJ) 43 3.41e-03 6.57e-03 0.3080 -2.67e-01 -0.154000 2.45e-03 8.02e-02
Antigen processing: Ubiquitination & Proteasome degradation 292 4.00e-17 7.32e-16 0.3080 -2.35e-01 -0.200000 4.88e-12 4.23e-09
RNA Polymerase III Transcription Initiation From Type 2 Promoter 27 2.38e-02 3.86e-02 0.3080 -3.03e-01 -0.057100 6.51e-03 6.08e-01
Sensory processing of sound by outer hair cells of the cochlea 43 1.46e-03 3.08e-03 0.3080 1.12e-01 -0.287000 2.06e-01 1.13e-03
Negative epigenetic regulation of rRNA expression 70 1.97e-05 6.25e-05 0.3080 -2.59e-01 0.166000 1.79e-04 1.60e-02
C-type lectin receptors (CLRs) 123 4.96e-08 2.79e-07 0.3070 -3.00e-01 -0.066700 8.92e-09 2.01e-01
Synthesis of PA 32 1.63e-02 2.77e-02 0.3060 -2.24e-01 -0.208000 2.80e-02 4.16e-02
Integration of energy metabolism 93 3.60e-06 1.38e-05 0.3060 -7.54e-02 -0.296000 2.09e-01 7.77e-07
Cytosolic sensors of pathogen-associated DNA 61 3.20e-04 7.96e-04 0.3060 -2.83e-01 -0.117000 1.34e-04 1.15e-01
RNA Polymerase I Transcription Initiation 47 1.03e-03 2.25e-03 0.3050 -2.98e-01 0.067400 4.08e-04 4.24e-01
Translesion synthesis by REV1 16 1.05e-01 1.44e-01 0.3050 1.83e-03 0.305000 9.90e-01 3.46e-02
Toll-like Receptor Cascades 139 2.05e-08 1.28e-07 0.3040 -1.78e-01 -0.247000 2.86e-04 4.97e-07
Glutamate binding, activation of AMPA receptors and synaptic plasticity 27 1.76e-02 2.94e-02 0.3040 1.29e-01 -0.275000 2.44e-01 1.33e-02
Trafficking of AMPA receptors 27 1.76e-02 2.94e-02 0.3040 1.29e-01 -0.275000 2.44e-01 1.33e-02
Cell surface interactions at the vascular wall 97 1.19e-06 5.16e-06 0.3040 1.38e-02 -0.304000 8.14e-01 2.29e-07
Prefoldin mediated transfer of substrate to CCT/TriC 27 1.79e-02 2.98e-02 0.3040 -2.78e-01 0.123000 1.24e-02 2.68e-01
Physiological factors 10 2.75e-01 3.35e-01 0.3040 -1.40e-01 -0.269000 4.43e-01 1.40e-01
DNA Replication 150 4.83e-10 4.31e-09 0.3030 -5.70e-02 0.298000 2.28e-01 2.95e-10
Acyl chain remodelling of PI 10 2.26e-01 2.84e-01 0.3030 2.72e-01 -0.134000 1.36e-01 4.64e-01
Sphingolipid metabolism 84 5.03e-06 1.87e-05 0.3030 8.92e-02 -0.289000 1.58e-01 4.55e-06
Downstream TCR signaling 88 3.70e-06 1.41e-05 0.3020 -2.97e-01 0.056200 1.48e-06 3.62e-01
ABC transporter disorders 73 2.16e-05 6.79e-05 0.3020 -2.72e-01 0.132000 6.00e-05 5.19e-02
PTEN Regulation 140 1.48e-08 9.52e-08 0.3020 -2.83e-01 -0.105000 7.59e-09 3.12e-02
Metabolism of carbohydrates 262 7.77e-17 1.39e-15 0.3020 6.63e-02 -0.294000 6.44e-02 2.26e-16
ADP signalling through P2Y purinoceptor 12 17 1.20e-01 1.61e-01 0.3010 -2.02e-01 -0.224000 1.50e-01 1.10e-01
Nuclear Receptor transcription pathway 46 2.21e-03 4.44e-03 0.3010 -4.40e-02 -0.297000 6.06e-01 4.80e-04
Negative regulation of FGFR4 signaling 27 3.52e-02 5.49e-02 0.3000 -2.28e-01 -0.196000 4.05e-02 7.84e-02
Interaction between L1 and Ankyrins 25 2.47e-02 3.99e-02 0.3000 2.22e-01 -0.201000 5.45e-02 8.16e-02
Death Receptor Signalling 137 2.74e-08 1.67e-07 0.3000 -1.03e-01 -0.281000 3.72e-02 1.29e-08
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways 49 2.40e-03 4.78e-03 0.2990 -2.01e-01 -0.222000 1.48e-02 7.25e-03
Defective pyroptosis 34 7.65e-03 1.40e-02 0.2990 -1.02e-01 0.282000 3.05e-01 4.48e-03
FOXO-mediated transcription 58 5.71e-04 1.33e-03 0.2990 -8.04e-02 -0.288000 2.89e-01 1.46e-04
PI3K Cascade 39 5.46e-03 1.02e-02 0.2990 -1.85e-02 -0.299000 8.41e-01 1.25e-03
Inositol phosphate metabolism 45 3.42e-03 6.58e-03 0.2990 -1.17e-01 -0.275000 1.75e-01 1.39e-03
Signaling by ERBB2 48 2.31e-03 4.62e-03 0.2990 -1.05e-01 -0.280000 2.09e-01 8.02e-04
Cytoprotection by HMOX1 118 6.08e-08 3.36e-07 0.2980 -2.85e-01 0.086500 8.34e-08 1.04e-01
Pyruvate metabolism and Citric Acid (TCA) cycle 52 1.75e-03 3.62e-03 0.2980 -2.35e-01 -0.183000 3.34e-03 2.25e-02
Glutathione synthesis and recycling 12 2.28e-01 2.86e-01 0.2980 1.55e-01 0.255000 3.53e-01 1.27e-01
Mitotic Prophase 103 3.55e-06 1.37e-05 0.2970 -2.45e-01 -0.168000 1.71e-05 3.16e-03
Aberrant regulation of mitotic exit in cancer due to RB1 defects 20 5.80e-02 8.49e-02 0.2970 -1.18e-01 0.273000 3.62e-01 3.46e-02
SIRT1 negatively regulates rRNA expression 29 1.49e-02 2.56e-02 0.2970 -1.88e-01 0.229000 7.91e-02 3.25e-02
Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) 10 2.43e-01 3.02e-01 0.2970 -2.75e-01 0.112000 1.33e-01 5.39e-01
Repression of WNT target genes 14 1.63e-01 2.13e-01 0.2960 -4.28e-02 -0.293000 7.82e-01 5.74e-02
Ion homeostasis 45 1.63e-03 3.42e-03 0.2960 1.42e-01 -0.260000 9.93e-02 2.55e-03
Antimicrobial peptides 23 6.33e-02 9.17e-02 0.2950 1.88e-01 0.228000 1.19e-01 5.85e-02
Leishmania infection 187 6.95e-11 7.12e-10 0.2940 -6.54e-02 -0.287000 1.23e-01 1.23e-11
Transcriptional regulation by small RNAs 68 1.64e-04 4.31e-04 0.2930 -2.93e-01 -0.021000 2.99e-05 7.64e-01
Calnexin/calreticulin cycle 26 4.58e-02 6.91e-02 0.2930 -1.68e-01 -0.240000 1.39e-01 3.39e-02
Cytochrome c-mediated apoptotic response 13 2.16e-01 2.73e-01 0.2930 -2.16e-01 -0.198000 1.78e-01 2.17e-01
Uptake and actions of bacterial toxins 28 2.69e-02 4.32e-02 0.2920 1.80e-04 -0.292000 9.99e-01 7.41e-03
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 33 2.07e-02 3.41e-02 0.2920 -2.34e-01 -0.175000 2.02e-02 8.17e-02
Vasopressin regulates renal water homeostasis via Aquaporins 35 1.02e-02 1.82e-02 0.2920 2.79e-02 -0.291000 7.75e-01 2.92e-03
Signaling by Non-Receptor Tyrosine Kinases 52 1.97e-03 4.02e-03 0.2920 -1.17e-01 -0.267000 1.44e-01 8.56e-04
Signaling by PTK6 52 1.97e-03 4.02e-03 0.2920 -1.17e-01 -0.267000 1.44e-01 8.56e-04
Cargo trafficking to the periciliary membrane 47 3.56e-03 6.84e-03 0.2920 -1.14e-01 -0.268000 1.77e-01 1.45e-03
Diseases of glycosylation 129 1.55e-08 9.85e-08 0.2910 1.99e-01 -0.213000 9.74e-05 2.89e-05
Protein-protein interactions at synapses 78 8.10e-05 2.24e-04 0.2910 -8.76e-02 -0.277000 1.81e-01 2.29e-05
Gap-filling DNA repair synthesis and ligation in GG-NER 25 5.12e-02 7.61e-02 0.2900 1.16e-01 0.266000 3.13e-01 2.13e-02
Downstream signaling of activated FGFR1 28 3.44e-02 5.38e-02 0.2900 -9.10e-02 -0.276000 4.04e-01 1.16e-02
Hemostasis 485 3.73e-27 1.33e-25 0.2900 4.08e-03 -0.290000 8.77e-01 5.28e-28
PI-3K cascade:FGFR3 16 1.32e-01 1.75e-01 0.2900 -6.86e-03 -0.290000 9.62e-01 4.45e-02
Signaling by Nuclear Receptors 236 1.69e-12 2.10e-11 0.2900 -1.78e-01 -0.229000 2.47e-06 1.33e-09
Ion transport by P-type ATPases 47 1.65e-03 3.45e-03 0.2900 1.39e-01 -0.254000 9.90e-02 2.59e-03
Interferon Signaling 172 2.09e-09 1.62e-08 0.2890 -2.60e-01 -0.126000 4.12e-09 4.36e-03
ERBB2 Regulates Cell Motility 13 2.12e-01 2.69e-01 0.2880 -8.51e-02 -0.275000 5.95e-01 8.54e-02
Diseases associated with glycosylation precursor biosynthesis 18 1.17e-01 1.57e-01 0.2870 -7.23e-02 -0.278000 5.95e-01 4.10e-02
RNA Polymerase I Transcription Termination 30 1.80e-02 2.99e-02 0.2870 -2.48e-01 0.144000 1.86e-02 1.74e-01
Endosomal Sorting Complex Required For Transport (ESCRT) 31 2.96e-02 4.69e-02 0.2870 -2.36e-01 -0.163000 2.31e-02 1.16e-01
Negative regulation of NMDA receptor-mediated neuronal transmission 19 1.04e-01 1.42e-01 0.2860 -5.64e-02 -0.280000 6.70e-01 3.44e-02
p38MAPK events 13 2.32e-01 2.90e-01 0.2860 -2.24e-01 -0.177000 1.61e-01 2.69e-01
Diseases associated with O-glycosylation of proteins 60 3.97e-04 9.56e-04 0.2860 2.68e-01 -0.099200 3.30e-04 1.84e-01
TICAM1-dependent activation of IRF3/IRF7 12 1.99e-01 2.54e-01 0.2860 -2.25e-01 0.176000 1.78e-01 2.90e-01
Class I MHC mediated antigen processing & presentation 352 1.25e-17 2.44e-16 0.2850 -1.99e-01 -0.204000 1.23e-10 4.32e-11
RNA Polymerase III Transcription Initiation From Type 3 Promoter 28 3.25e-02 5.11e-02 0.2850 -2.85e-01 -0.001960 9.08e-03 9.86e-01
Glucose metabolism 84 5.55e-05 1.61e-04 0.2840 -6.68e-02 -0.276000 2.90e-01 1.20e-05
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion 34 1.49e-02 2.56e-02 0.2840 2.12e-02 -0.283000 8.30e-01 4.24e-03
Cell death signalling via NRAGE, NRIF and NADE 76 7.93e-05 2.20e-04 0.2840 3.34e-02 -0.282000 6.15e-01 2.12e-05
Regulation of PTEN gene transcription 61 1.20e-03 2.60e-03 0.2840 -1.95e-01 -0.206000 8.31e-03 5.48e-03
Negative regulation of FLT3 13 2.30e-01 2.88e-01 0.2830 -2.60e-01 -0.112000 1.04e-01 4.85e-01
RHO GTPases Activate ROCKs 19 1.22e-01 1.63e-01 0.2830 -1.53e-01 -0.237000 2.47e-01 7.33e-02
Ras activation upon Ca2+ influx through NMDA receptor 18 1.17e-01 1.57e-01 0.2820 -1.17e-02 -0.282000 9.32e-01 3.84e-02
Downstream signaling of activated FGFR3 23 6.75e-02 9.71e-02 0.2820 -3.63e-02 -0.279000 7.63e-01 2.03e-02
Interleukin-12 family signaling 51 2.90e-03 5.68e-03 0.2810 -2.74e-01 -0.065900 7.23e-04 4.16e-01
G-protein beta:gamma signalling 27 5.06e-02 7.55e-02 0.2810 -1.31e-01 -0.249000 2.38e-01 2.52e-02
Macroautophagy 111 5.73e-06 2.08e-05 0.2800 -1.47e-01 -0.239000 7.51e-03 1.37e-05
Signaling by WNT 276 1.42e-13 2.01e-12 0.2800 -1.70e-01 -0.223000 1.15e-06 1.82e-10
FRS-mediated FGFR1 signaling 20 1.14e-01 1.54e-01 0.2800 -1.53e-01 -0.235000 2.36e-01 6.93e-02
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) 26 6.02e-02 8.80e-02 0.2800 2.31e-01 0.158000 4.17e-02 1.63e-01
Signal Transduction 2157 1.77e-97 2.59e-94 0.2780 -6.13e-02 -0.271000 2.50e-06 3.81e-97
Interleukin-6 family signaling 23 6.39e-02 9.23e-02 0.2780 3.79e-02 -0.275000 7.53e-01 2.23e-02
Assembly of the ORC complex at the origin of replication 30 2.23e-02 3.65e-02 0.2770 -2.05e-01 0.187000 5.19e-02 7.66e-02
Condensation of Prometaphase Chromosomes 11 2.69e-01 3.28e-01 0.2770 -4.55e-02 0.273000 7.94e-01 1.17e-01
Metabolism of cofactors 19 1.36e-01 1.80e-01 0.2760 1.94e-01 0.197000 1.44e-01 1.37e-01
Depolymerisation of the Nuclear Lamina 15 1.90e-01 2.43e-01 0.2760 -5.82e-02 -0.270000 6.97e-01 7.04e-02
Signaling by CSF3 (G-CSF) 30 4.37e-02 6.66e-02 0.2760 -1.82e-01 -0.207000 8.44e-02 4.98e-02
MAPK6/MAPK4 signaling 87 6.31e-05 1.80e-04 0.2750 -2.72e-01 -0.042600 1.14e-05 4.92e-01
Synthesis of PE 12 2.53e-01 3.12e-01 0.2750 -2.75e-01 0.001940 9.89e-02 9.91e-01
Aquaporin-mediated transport 37 1.33e-02 2.31e-02 0.2750 3.27e-02 -0.273000 7.31e-01 4.04e-03
Methylation 14 1.75e-01 2.26e-01 0.2750 -1.84e-01 0.204000 2.33e-01 1.85e-01
Acetylcholine binding and downstream events 10 3.54e-01 4.15e-01 0.2750 1.78e-01 0.210000 3.31e-01 2.51e-01
Postsynaptic nicotinic acetylcholine receptors 10 3.54e-01 4.15e-01 0.2750 1.78e-01 0.210000 3.31e-01 2.51e-01
Metabolism of amino acids and derivatives 337 1.43e-18 3.12e-17 0.2750 -1.45e-01 0.234000 5.01e-06 1.59e-13
Late endosomal microautophagy 29 4.41e-02 6.71e-02 0.2740 -2.61e-01 -0.084900 1.50e-02 4.29e-01
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain 20 1.27e-01 1.68e-01 0.2740 -1.91e-01 -0.197000 1.39e-01 1.27e-01
Estrogen-dependent gene expression 107 1.62e-05 5.34e-05 0.2740 -2.07e-01 -0.180000 2.20e-04 1.26e-03
RHO GTPases activate PAKs 21 9.96e-02 1.37e-01 0.2740 -4.79e-02 -0.270000 7.04e-01 3.24e-02
TNF signaling 44 9.71e-03 1.73e-02 0.2740 -2.49e-01 -0.113000 4.21e-03 1.96e-01
Cyclin A:Cdk2-associated events at S phase entry 85 3.45e-05 1.04e-04 0.2730 -2.46e-01 0.119000 8.74e-05 5.71e-02
Positive epigenetic regulation of rRNA expression 67 3.97e-04 9.56e-04 0.2730 -2.66e-01 0.060500 1.64e-04 3.92e-01
Synthesis of substrates in N-glycan biosythesis 61 1.86e-03 3.83e-03 0.2730 -1.47e-01 -0.230000 4.69e-02 1.90e-03
SLC transporter disorders 80 2.77e-04 7.01e-04 0.2730 -1.60e-01 -0.221000 1.36e-02 6.27e-04
Long-term potentiation 20 1.14e-01 1.54e-01 0.2720 -5.01e-02 -0.268000 6.98e-01 3.81e-02
Defects in vitamin and cofactor metabolism 21 8.34e-02 1.17e-01 0.2720 8.71e-02 -0.258000 4.90e-01 4.06e-02
MAPK family signaling cascades 292 9.16e-14 1.36e-12 0.2710 -1.09e-01 -0.248000 1.32e-03 2.59e-13
RNA Polymerase III Chain Elongation 18 1.25e-01 1.66e-01 0.2710 -2.65e-01 0.057600 5.14e-02 6.72e-01
Retinoid metabolism and transport 32 2.19e-02 3.60e-02 0.2710 1.22e-01 -0.242000 2.32e-01 1.77e-02
Defects in cobalamin (B12) metabolism 13 2.41e-01 3.00e-01 0.2710 -2.70e-01 -0.023900 9.16e-02 8.81e-01
Activated NOTCH1 Transmits Signal to the Nucleus 30 3.63e-02 5.65e-02 0.2700 7.09e-03 -0.270000 9.46e-01 1.05e-02
Negative regulation of FGFR2 signaling 30 5.01e-02 7.48e-02 0.2700 -1.86e-01 -0.195000 7.76e-02 6.44e-02
Metabolism of fat-soluble vitamins 36 1.64e-02 2.77e-02 0.2690 6.53e-02 -0.261000 4.98e-01 6.67e-03
RNA Polymerase III Transcription Initiation From Type 1 Promoter 28 4.86e-02 7.28e-02 0.2690 -2.68e-01 -0.020700 1.39e-02 8.50e-01
Cyclin E associated events during G1/S transition 83 5.97e-05 1.71e-04 0.2690 -2.34e-01 0.131000 2.24e-04 3.87e-02
HDR through Homologous Recombination (HRR) 66 1.50e-03 3.17e-03 0.2680 1.77e-01 0.202000 1.31e-02 4.63e-03
Signalling to RAS 20 1.34e-01 1.78e-01 0.2680 -1.21e-01 -0.239000 3.49e-01 6.42e-02
MicroRNA (miRNA) biogenesis 24 7.37e-02 1.05e-01 0.2670 -2.66e-01 0.017200 2.40e-02 8.84e-01
Processing of Intronless Pre-mRNAs 19 1.51e-01 1.97e-01 0.2660 -2.41e-01 -0.114000 6.94e-02 3.89e-01
Post-translational protein modification 1261 1.50e-52 3.66e-50 0.2660 -1.18e-01 -0.238000 1.51e-12 1.84e-46
Pyrimidine salvage 10 3.78e-01 4.39e-01 0.2660 1.70e-01 0.205000 3.52e-01 2.62e-01
Heme biosynthesis 13 2.59e-01 3.17e-01 0.2660 2.63e-01 0.037200 1.01e-01 8.17e-01
G-protein activation 18 1.78e-01 2.30e-01 0.2640 -1.95e-01 -0.179000 1.52e-01 1.90e-01
Cellular response to chemical stress 147 7.05e-08 3.84e-07 0.2640 -2.43e-01 0.105000 3.74e-07 2.85e-02
Cellular hexose transport 17 1.85e-01 2.39e-01 0.2640 2.49e-01 0.085600 7.52e-02 5.41e-01
Oncogene Induced Senescence 31 5.13e-02 7.61e-02 0.2630 -2.18e-01 -0.147000 3.53e-02 1.56e-01
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 26 5.20e-02 7.71e-02 0.2630 -2.12e-01 0.156000 6.16e-02 1.68e-01
PCP/CE pathway 90 1.06e-04 2.85e-04 0.2630 -2.61e-01 -0.033800 1.90e-05 5.79e-01
Neurexins and neuroligins 49 6.07e-03 1.13e-02 0.2630 -1.80e-03 -0.263000 9.83e-01 1.45e-03
IRAK1 recruits IKK complex 10 3.79e-01 4.39e-01 0.2630 -1.12e-01 -0.238000 5.41e-01 1.93e-01
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation 10 3.79e-01 4.39e-01 0.2630 -1.12e-01 -0.238000 5.41e-01 1.93e-01
Formation of apoptosome 11 3.42e-01 4.04e-01 0.2630 -2.44e-01 -0.097800 1.62e-01 5.74e-01
Regulation of the apoptosome activity 11 3.42e-01 4.04e-01 0.2630 -2.44e-01 -0.097800 1.62e-01 5.74e-01
SUMOylation 170 1.09e-07 5.82e-07 0.2620 -1.42e-01 -0.219000 1.34e-03 7.86e-07
eNOS activation 11 3.01e-01 3.63e-01 0.2610 9.04e-02 -0.245000 6.04e-01 1.60e-01
Sulfur amino acid metabolism 25 7.23e-02 1.03e-01 0.2610 -3.56e-02 0.258000 7.58e-01 2.55e-02
Regulation of TP53 Activity through Methylation 19 1.22e-01 1.62e-01 0.2600 -2.14e-01 0.147000 1.06e-01 2.66e-01
Phosphorylation of CD3 and TCR zeta chains 15 2.49e-01 3.09e-01 0.2590 2.03e-01 0.162000 1.74e-01 2.78e-01
TCR signaling 108 1.86e-05 6.01e-05 0.2590 -2.59e-01 -0.003220 3.28e-06 9.54e-01
TP53 Regulates Transcription of DNA Repair Genes 61 1.91e-03 3.91e-03 0.2590 -2.58e-01 0.021100 4.89e-04 7.75e-01
Signaling by EGFR in Cancer 23 1.22e-01 1.62e-01 0.2580 -1.77e-01 -0.188000 1.42e-01 1.18e-01
Interleukin-1 family signaling 124 5.14e-06 1.90e-05 0.2570 -2.56e-01 -0.020900 8.01e-07 6.88e-01
Signaling by FGFR2 66 1.99e-03 4.06e-03 0.2570 -2.43e-01 -0.082800 6.23e-04 2.45e-01
MHC class II antigen presentation 97 5.64e-05 1.63e-04 0.2570 1.95e-02 -0.256000 7.40e-01 1.29e-05
Signaling by ERBB4 50 5.80e-03 1.08e-02 0.2570 5.09e-02 -0.252000 5.33e-01 2.08e-03
Factors involved in megakaryocyte development and platelet production 115 9.18e-06 3.21e-05 0.2560 2.62e-02 -0.255000 6.27e-01 2.28e-06
Resolution of AP sites via the multiple-nucleotide patch replacement pathway 25 1.06e-01 1.45e-01 0.2560 1.70e-01 0.191000 1.41e-01 9.89e-02
Unblocking of NMDA receptors, glutamate binding and activation 18 1.95e-01 2.49e-01 0.2550 -1.27e-01 -0.222000 3.52e-01 1.03e-01
Signaling by the B Cell Receptor (BCR) 106 5.99e-05 1.72e-04 0.2550 -2.34e-01 -0.102000 3.07e-05 6.99e-02
Signaling by FGFR in disease 59 5.20e-03 9.77e-03 0.2550 -1.64e-01 -0.195000 2.96e-02 9.51e-03
Beta-catenin independent WNT signaling 138 4.60e-06 1.73e-05 0.2550 -2.03e-01 -0.154000 3.91e-05 1.74e-03
Adaptive Immune System 639 3.12e-25 9.93e-24 0.2540 -1.21e-01 -0.224000 1.80e-07 3.43e-22
SUMO E3 ligases SUMOylate target proteins 164 4.62e-07 2.19e-06 0.2540 -1.46e-01 -0.208000 1.23e-03 4.15e-06
tRNA Aminoacylation 42 2.36e-02 3.84e-02 0.2540 -2.04e-01 -0.152000 2.19e-02 8.93e-02
Collagen degradation 34 3.72e-02 5.74e-02 0.2540 -9.40e-03 -0.254000 9.24e-01 1.04e-02
Regulation of innate immune responses to cytosolic DNA 14 2.46e-01 3.06e-01 0.2540 -2.50e-01 0.042200 1.05e-01 7.85e-01
Signaling by NOTCH2 32 3.64e-02 5.66e-02 0.2540 1.00e-01 -0.233000 3.27e-01 2.26e-02
NOTCH2 Activation and Transmission of Signal to the Nucleus 22 9.75e-02 1.34e-01 0.2530 1.96e-01 -0.161000 1.12e-01 1.91e-01
Defective C1GALT1C1 causes TNPS 11 3.79e-01 4.39e-01 0.2530 1.75e-01 0.183000 3.15e-01 2.92e-01
MAP2K and MAPK activation 35 3.43e-02 5.38e-02 0.2530 -3.95e-03 -0.253000 9.68e-01 9.62e-03
Regulation of insulin secretion 65 1.80e-03 3.72e-03 0.2530 1.50e-02 -0.252000 8.34e-01 4.39e-04
Neddylation 222 2.81e-09 2.13e-08 0.2520 -2.27e-01 -0.109000 5.04e-09 5.05e-03
Endogenous sterols 22 1.38e-01 1.81e-01 0.2520 -9.38e-02 -0.234000 4.46e-01 5.72e-02
Neurotransmitter receptors and postsynaptic signal transmission 152 3.97e-07 1.90e-06 0.2520 2.03e-02 -0.251000 6.66e-01 8.79e-08
Resolution of Abasic Sites (AP sites) 38 3.64e-02 5.66e-02 0.2520 1.65e-01 0.190000 7.85e-02 4.22e-02
Response to elevated platelet cytosolic Ca2+ 114 1.37e-05 4.60e-05 0.2520 4.01e-02 -0.249000 4.59e-01 4.48e-06
RIP-mediated NFkB activation via ZBP1 16 2.48e-01 3.07e-01 0.2510 -2.03e-01 -0.148000 1.60e-01 3.04e-01
Activation of Matrix Metalloproteinases 25 1.15e-01 1.55e-01 0.2510 -1.82e-01 -0.173000 1.15e-01 1.34e-01
Lysosome Vesicle Biogenesis 34 3.96e-02 6.09e-02 0.2510 2.77e-04 -0.251000 9.98e-01 1.14e-02
FGFR4 ligand binding and activation 10 4.18e-01 4.78e-01 0.2510 2.12e-01 0.133000 2.46e-01 4.65e-01
Dual incision in TC-NER 65 1.26e-03 2.70e-03 0.2510 -2.07e-01 0.140000 3.81e-03 5.01e-02
Nuclear signaling by ERBB4 26 6.84e-02 9.81e-02 0.2510 1.49e-01 -0.201000 1.88e-01 7.57e-02
Formation of Incision Complex in GG-NER 43 1.71e-02 2.88e-02 0.2510 -2.51e-01 -0.003050 4.47e-03 9.72e-01
Triglyceride catabolism 17 1.77e-01 2.28e-01 0.2510 1.16e-01 -0.222000 4.06e-01 1.13e-01
Synthesis, secretion, and deacylation of Ghrelin 13 3.26e-01 3.90e-01 0.2500 1.97e-01 0.155000 2.20e-01 3.34e-01
SUMOylation of transcription factors 19 1.79e-01 2.30e-01 0.2500 -5.78e-02 -0.243000 6.63e-01 6.63e-02
Gene Silencing by RNA 95 1.97e-04 5.09e-04 0.2500 -2.41e-01 -0.066800 4.88e-05 2.60e-01
RHOBTB3 ATPase cycle 10 4.22e-01 4.81e-01 0.2500 -1.44e-01 -0.205000 4.31e-01 2.63e-01
Epigenetic regulation of gene expression 109 2.54e-05 7.84e-05 0.2500 -2.46e-01 0.043400 8.89e-06 4.34e-01
FGFR2 ligand binding and activation 14 2.96e-01 3.57e-01 0.2490 2.24e-01 0.110000 1.48e-01 4.78e-01
Regulation of gene expression in beta cells 13 2.71e-01 3.30e-01 0.2480 2.13e-01 -0.128000 1.84e-01 4.25e-01
NOD1/2 Signaling Pathway 31 6.97e-02 9.97e-02 0.2480 -1.16e-01 -0.219000 2.66e-01 3.45e-02
Translesion synthesis by POLK 17 2.13e-01 2.70e-01 0.2480 3.05e-02 0.246000 8.27e-01 7.90e-02
Interleukin-4 and Interleukin-13 signaling 95 1.69e-04 4.41e-04 0.2480 -1.48e-02 -0.247000 8.03e-01 3.10e-05
Transcription-Coupled Nucleotide Excision Repair (TC-NER) 78 4.30e-04 1.02e-03 0.2480 -2.19e-01 0.115000 8.21e-04 7.81e-02
Glycogen synthesis 15 2.35e-01 2.93e-01 0.2470 6.29e-02 -0.239000 6.73e-01 1.09e-01
Energy dependent regulation of mTOR by LKB1-AMPK 28 9.32e-02 1.29e-01 0.2470 -1.30e-01 -0.210000 2.34e-01 5.41e-02
MTOR signalling 40 3.41e-02 5.36e-02 0.2470 -1.31e-01 -0.209000 1.52e-01 2.20e-02
RAS processing 19 2.01e-01 2.55e-01 0.2460 -1.25e-01 -0.212000 3.45e-01 1.09e-01
Defective GALNT3 causes HFTC 10 4.28e-01 4.87e-01 0.2460 1.15e-01 0.218000 5.30e-01 2.33e-01
Platelet degranulation 109 3.81e-05 1.13e-04 0.2460 3.03e-02 -0.244000 5.85e-01 1.04e-05
Degradation of the extracellular matrix 90 2.72e-04 6.91e-04 0.2460 1.73e-05 -0.246000 1.00e+00 5.46e-05
Scavenging by Class A Receptors 16 2.65e-01 3.24e-01 0.2460 1.75e-01 0.173000 2.25e-01 2.32e-01
Dopamine Neurotransmitter Release Cycle 22 1.53e-01 1.99e-01 0.2460 -2.28e-01 -0.092300 6.44e-02 4.54e-01
Collagen formation 80 3.72e-04 9.02e-04 0.2450 1.90e-01 -0.155000 3.33e-03 1.64e-02
NCAM signaling for neurite out-growth 54 6.65e-03 1.23e-02 0.2450 3.27e-02 -0.243000 6.77e-01 2.02e-03
NCAM1 interactions 34 4.15e-02 6.34e-02 0.2440 2.36e-01 -0.061400 1.74e-02 5.35e-01
Cellular responses to stress 671 3.91e-26 1.33e-24 0.2440 -2.43e-01 -0.003840 4.01e-27 8.65e-01
ZBP1(DAI) mediated induction of type I IFNs 19 2.13e-01 2.70e-01 0.2430 -1.90e-01 -0.152000 1.52e-01 2.51e-01
Downstream signaling of activated FGFR4 23 1.35e-01 1.78e-01 0.2430 -2.97e-02 -0.241000 8.05e-01 4.53e-02
SARS-CoV-1 Infection 49 1.21e-02 2.11e-02 0.2430 1.81e-02 -0.242000 8.26e-01 3.37e-03
G beta:gamma signalling through PI3Kgamma 21 1.75e-01 2.26e-01 0.2420 -8.80e-02 -0.225000 4.85e-01 7.37e-02
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants 19 2.18e-01 2.75e-01 0.2410 -1.47e-01 -0.191000 2.67e-01 1.49e-01
Signaling by Ligand-Responsive EGFR Variants in Cancer 19 2.18e-01 2.75e-01 0.2410 -1.47e-01 -0.191000 2.67e-01 1.49e-01
G2/M Checkpoints 140 1.66e-06 6.85e-06 0.2410 -1.54e-01 0.185000 1.59e-03 1.60e-04
TCF dependent signaling in response to WNT 186 3.89e-07 1.87e-06 0.2410 -1.93e-01 -0.144000 5.69e-06 7.01e-04
tRNA processing in the nucleus 59 6.94e-03 1.27e-02 0.2410 -2.36e-01 -0.048200 1.73e-03 5.22e-01
Peptide hormone metabolism 65 2.67e-03 5.26e-03 0.2400 6.60e-02 -0.231000 3.58e-01 1.28e-03
Pexophagy 11 4.19e-01 4.78e-01 0.2400 -1.49e-01 -0.188000 3.92e-01 2.81e-01
Polymerase switching on the C-strand of the telomere 26 1.14e-01 1.54e-01 0.2390 2.35e-01 0.046600 3.83e-02 6.81e-01
InlB-mediated entry of Listeria monocytogenes into host cell 15 3.07e-01 3.70e-01 0.2390 -1.40e-01 -0.193000 3.47e-01 1.95e-01
Mitochondrial biogenesis 91 6.45e-04 1.49e-03 0.2390 -2.23e-01 -0.084100 2.29e-04 1.65e-01
MAP3K8 (TPL2)-dependent MAPK1/3 activation 16 2.85e-01 3.45e-01 0.2390 -1.90e-01 -0.144000 1.88e-01 3.18e-01
IKK complex recruitment mediated by RIP1 22 1.68e-01 2.17e-01 0.2380 -2.27e-01 -0.072200 6.53e-02 5.58e-01
Degradation of cysteine and homocysteine 11 4.14e-01 4.73e-01 0.2380 9.12e-02 0.220000 6.00e-01 2.06e-01
Separation of Sister Chromatids 168 2.25e-07 1.15e-06 0.2380 -2.15e-01 0.102000 1.48e-06 2.29e-02
Plasma lipoprotein assembly 13 3.64e-01 4.24e-01 0.2380 1.81e-01 0.154000 2.59e-01 3.35e-01
RAF/MAP kinase cascade 247 4.97e-09 3.52e-08 0.2370 -1.14e-01 -0.207000 2.07e-03 1.91e-08
MAPK1/MAPK3 signaling 253 3.16e-09 2.38e-08 0.2360 -1.12e-01 -0.208000 2.18e-03 1.12e-08
Nuclear Envelope (NE) Reassembly 73 3.68e-03 7.01e-03 0.2360 -1.85e-01 -0.147000 6.33e-03 2.94e-02
Infectious disease 733 5.37e-25 1.67e-23 0.2360 -2.15e-01 -0.097200 2.82e-23 7.16e-06
Diseases of metabolism 213 3.97e-09 2.92e-08 0.2360 1.83e-01 -0.149000 4.06e-06 1.86e-04
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) 16 2.86e-01 3.47e-01 0.2350 -9.50e-02 -0.215000 5.10e-01 1.36e-01
Surfactant metabolism 19 2.32e-01 2.91e-01 0.2350 -2.00e-01 -0.123000 1.31e-01 3.51e-01
Downstream signaling of activated FGFR2 26 1.15e-01 1.55e-01 0.2350 -4.51e-03 -0.235000 9.68e-01 3.79e-02
PI-3K cascade:FGFR4 16 2.62e-01 3.21e-01 0.2350 2.64e-03 -0.235000 9.85e-01 1.04e-01
Signaling by FGFR3 in disease 20 2.00e-01 2.55e-01 0.2350 -4.73e-02 -0.230000 7.14e-01 7.49e-02
Signaling by FGFR3 point mutants in cancer 20 2.00e-01 2.55e-01 0.2350 -4.73e-02 -0.230000 7.14e-01 7.49e-02
Polo-like kinase mediated events 16 2.47e-01 3.06e-01 0.2350 -6.68e-02 0.225000 6.43e-01 1.19e-01
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding 30 6.83e-02 9.81e-02 0.2350 -2.09e-01 0.108000 4.80e-02 3.07e-01
Cellular responses to stimuli 680 9.62e-25 2.94e-23 0.2350 -2.35e-01 0.003420 1.35e-25 8.79e-01
Signaling by FGFR 78 2.76e-03 5.43e-03 0.2340 -1.85e-01 -0.145000 4.82e-03 2.73e-02
Cleavage of the damaged purine 28 8.05e-02 1.14e-01 0.2340 -1.87e-01 0.141000 8.65e-02 1.98e-01
Depurination 28 8.05e-02 1.14e-01 0.2340 -1.87e-01 0.141000 8.65e-02 1.98e-01
Recognition and association of DNA glycosylase with site containing an affected purine 28 8.05e-02 1.14e-01 0.2340 -1.87e-01 0.141000 8.65e-02 1.98e-01
Regulation of TP53 Activity 155 9.01e-06 3.16e-05 0.2340 -1.84e-01 -0.144000 7.67e-05 1.90e-03
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) 13 3.14e-01 3.76e-01 0.2340 -1.14e-01 0.204000 4.76e-01 2.03e-01
Activation of BH3-only proteins 29 8.86e-02 1.23e-01 0.2330 1.88e-02 -0.233000 8.61e-01 3.01e-02
Inactivation of CSF3 (G-CSF) signaling 25 1.44e-01 1.90e-01 0.2330 -2.19e-01 -0.079800 5.77e-02 4.90e-01
G beta:gamma signalling through PLC beta 15 3.10e-01 3.72e-01 0.2330 -2.23e-01 -0.067900 1.35e-01 6.49e-01
Presynaptic function of Kainate receptors 15 3.10e-01 3.72e-01 0.2330 -2.23e-01 -0.067900 1.35e-01 6.49e-01
Post-translational protein phosphorylation 85 5.22e-04 1.22e-03 0.2320 1.66e-01 -0.162000 7.97e-03 9.67e-03
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks 51 1.93e-02 3.19e-02 0.2320 -2.23e-01 -0.066100 5.91e-03 4.14e-01
FGFR2c ligand binding and activation 10 4.59e-01 5.15e-01 0.2320 2.24e-01 0.061100 2.20e-01 7.38e-01
Gap-filling DNA repair synthesis and ligation in TC-NER 64 3.46e-03 6.65e-03 0.2320 -1.84e-01 0.142000 1.10e-02 4.96e-02
Signaling by ERBB2 TMD/JMD mutants 20 2.00e-01 2.55e-01 0.2320 -1.63e-02 -0.232000 8.99e-01 7.29e-02
MyD88 deficiency (TLR2/4) 14 3.33e-01 3.95e-01 0.2320 4.57e-02 0.228000 7.67e-01 1.40e-01
Cyclin A/B1/B2 associated events during G2/M transition 25 1.20e-01 1.61e-01 0.2320 -2.25e-01 0.055600 5.11e-02 6.30e-01
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models 20 2.26e-01 2.85e-01 0.2320 -1.29e-01 -0.193000 3.18e-01 1.36e-01
Neurodegenerative Diseases 20 2.26e-01 2.85e-01 0.2320 -1.29e-01 -0.193000 3.18e-01 1.36e-01
G alpha (q) signalling events 152 1.07e-05 3.68e-05 0.2320 -9.22e-02 -0.212000 4.96e-02 6.10e-06
Phospholipase C-mediated cascade; FGFR4 11 4.42e-01 5.00e-01 0.2310 1.24e-01 0.195000 4.75e-01 2.63e-01
HDR through MMEJ (alt-NHEJ) 10 4.34e-01 4.92e-01 0.2310 2.26e-01 -0.047300 2.16e-01 7.96e-01
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest 18 2.36e-01 2.95e-01 0.2310 4.73e-03 0.231000 9.72e-01 9.02e-02
Transcriptional regulation by RUNX2 115 1.17e-04 3.14e-04 0.2300 -2.30e-01 -0.019500 2.10e-05 7.18e-01
Synthesis of glycosylphosphatidylinositol (GPI) 18 2.10e-01 2.66e-01 0.2300 1.95e-01 -0.122000 1.51e-01 3.70e-01
PI-3K cascade:FGFR2 19 2.10e-01 2.67e-01 0.2300 3.20e-02 -0.228000 8.09e-01 8.55e-02
Synthesis of IP3 and IP4 in the cytosol 24 1.49e-01 1.95e-01 0.2300 -6.57e-03 -0.230000 9.56e-01 5.15e-02
tRNA modification in the nucleus and cytosol 43 2.51e-02 4.05e-02 0.2290 -1.26e-01 0.191000 1.52e-01 3.04e-02
Glycogen metabolism 26 1.14e-01 1.54e-01 0.2290 7.88e-02 -0.215000 4.87e-01 5.83e-02
Purine catabolism 17 2.95e-01 3.57e-01 0.2280 1.50e-01 0.172000 2.83e-01 2.20e-01
Antigen processing-Cross presentation 96 3.24e-04 8.00e-04 0.2280 -2.11e-01 0.086600 3.43e-04 1.42e-01
Cytokine Signaling in Immune system 596 8.21e-19 1.85e-17 0.2280 -1.72e-01 -0.150000 6.83e-13 3.93e-10
Interferon gamma signaling 78 2.96e-03 5.79e-03 0.2280 -2.20e-01 -0.060100 7.89e-04 3.59e-01
Presynaptic depolarization and calcium channel opening 11 4.57e-01 5.13e-01 0.2280 1.69e-01 0.152000 3.32e-01 3.82e-01
Cleavage of the damaged pyrimidine 33 6.27e-02 9.11e-02 0.2270 -2.00e-01 0.108000 4.68e-02 2.83e-01
Depyrimidination 33 6.27e-02 9.11e-02 0.2270 -2.00e-01 0.108000 4.68e-02 2.83e-01
Recognition and association of DNA glycosylase with site containing an affected pyrimidine 33 6.27e-02 9.11e-02 0.2270 -2.00e-01 0.108000 4.68e-02 2.83e-01
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release 19 2.36e-01 2.95e-01 0.2260 -2.25e-01 -0.017900 8.94e-02 8.92e-01
Phase 2 - plateau phase 13 3.92e-01 4.50e-01 0.2260 2.10e-01 0.083400 1.91e-01 6.03e-01
Signaling by NOTCH3 46 2.91e-02 4.62e-02 0.2250 1.07e-02 -0.224000 9.00e-01 8.43e-03
Intraflagellar transport 39 6.35e-02 9.19e-02 0.2240 2.03e-01 0.095300 2.81e-02 3.03e-01
Senescence-Associated Secretory Phenotype (SASP) 71 3.18e-03 6.20e-03 0.2240 -2.02e-01 0.097300 3.30e-03 1.56e-01
Immune System 1611 9.35e-47 1.37e-44 0.2240 -1.02e-01 -0.199000 7.38e-12 5.32e-41
Homologous DNA Pairing and Strand Exchange 42 5.44e-02 8.02e-02 0.2240 1.89e-01 0.120000 3.45e-02 1.77e-01
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation 15 3.55e-01 4.16e-01 0.2230 -1.91e-01 -0.116000 2.01e-01 4.38e-01
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects 17 2.51e-01 3.11e-01 0.2230 1.87e-01 -0.120000 1.81e-01 3.90e-01
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) 17 2.51e-01 3.11e-01 0.2230 1.87e-01 -0.120000 1.81e-01 3.90e-01
ATF6 (ATF6-alpha) activates chaperones 12 4.36e-01 4.94e-01 0.2230 -1.97e-01 -0.104000 2.38e-01 5.31e-01
Hedgehog ‘off’ state 95 6.08e-04 1.41e-03 0.2230 -2.15e-01 0.056300 2.86e-04 3.43e-01
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 13 3.72e-01 4.33e-01 0.2220 2.09e-02 -0.221000 8.96e-01 1.67e-01
TAK1 activates NFkB by phosphorylation and activation of IKKs complex 25 1.82e-01 2.35e-01 0.2220 -1.76e-01 -0.136000 1.28e-01 2.38e-01
Activation of GABAB receptors 35 8.83e-02 1.23e-01 0.2220 -9.52e-02 -0.201000 3.30e-01 3.97e-02
GABA B receptor activation 35 8.83e-02 1.23e-01 0.2220 -9.52e-02 -0.201000 3.30e-01 3.97e-02
Gene expression (Transcription) 1368 1.52e-39 1.11e-37 0.2220 -1.95e-01 -0.107000 7.29e-34 2.23e-11
Synthesis of bile acids and bile salts via 24-hydroxycholesterol 12 3.80e-01 4.40e-01 0.2220 -1.88e-01 0.117000 2.58e-01 4.81e-01
Anti-inflammatory response favouring Leishmania parasite infection 106 3.70e-04 8.98e-04 0.2220 1.06e-02 -0.221000 8.51e-01 8.24e-05
Leishmania parasite growth and survival 106 3.70e-04 8.98e-04 0.2220 1.06e-02 -0.221000 8.51e-01 8.24e-05
FRS-mediated FGFR3 signaling 18 2.76e-01 3.36e-01 0.2210 -4.08e-02 -0.217000 7.65e-01 1.10e-01
Metabolism of steroids 136 7.84e-05 2.18e-04 0.2210 -6.75e-02 -0.210000 1.74e-01 2.26e-05
B-WICH complex positively regulates rRNA expression 52 1.67e-02 2.82e-02 0.2200 -1.95e-01 0.102000 1.50e-02 2.02e-01
Transport of vitamins, nucleosides, and related molecules 35 6.73e-02 9.69e-02 0.2200 6.69e-02 -0.210000 4.94e-01 3.17e-02
Disorders of transmembrane transporters 153 2.32e-05 7.26e-05 0.2200 -2.14e-01 -0.053000 5.02e-06 2.58e-01
Signaling by Interleukins 384 1.14e-11 1.30e-10 0.2200 -1.48e-01 -0.163000 6.13e-07 4.15e-08
Gluconeogenesis 29 1.02e-01 1.40e-01 0.2200 1.90e-01 -0.111000 7.70e-02 3.01e-01
G beta:gamma signalling through BTK 14 3.85e-01 4.44e-01 0.2200 -2.03e-01 -0.084800 1.89e-01 5.83e-01
Regulation of TNFR1 signaling 35 8.26e-02 1.16e-01 0.2200 -2.18e-01 -0.027300 2.56e-02 7.80e-01
Kinesins 39 5.59e-02 8.22e-02 0.2190 2.06e-02 -0.218000 8.23e-01 1.82e-02
RHO GTPases activate PKNs 52 3.07e-02 4.85e-02 0.2190 -1.98e-01 -0.093200 1.36e-02 2.45e-01
Heme degradation 11 4.23e-01 4.82e-01 0.2180 -1.57e-01 0.150000 3.66e-01 3.88e-01
PD-1 signaling 16 3.52e-01 4.14e-01 0.2180 1.34e-01 0.172000 3.54e-01 2.34e-01
Sensory processing of sound by inner hair cells of the cochlea 57 1.30e-02 2.26e-02 0.2180 8.48e-02 -0.200000 2.68e-01 8.83e-03
Signaling by Insulin receptor 71 6.92e-03 1.27e-02 0.2170 -1.72e-02 -0.216000 8.02e-01 1.61e-03
Phase 4 - resting membrane potential 16 3.44e-01 4.06e-01 0.2170 -7.60e-02 -0.203000 5.99e-01 1.60e-01
Telomere C-strand (Lagging Strand) Synthesis 34 1.10e-01 1.49e-01 0.2160 1.91e-01 0.100000 5.39e-02 3.11e-01
Nucleotide Excision Repair 110 2.62e-04 6.70e-04 0.2160 -1.94e-01 0.093000 4.24e-04 9.17e-02
Activated point mutants of FGFR2 13 4.21e-01 4.81e-01 0.2150 2.07e-01 0.059000 1.97e-01 7.13e-01
DNA Double Strand Break Response 52 3.13e-02 4.94e-02 0.2150 -2.09e-01 -0.049900 9.23e-03 5.33e-01
Assembly of collagen fibrils and other multimeric structures 50 2.30e-02 3.74e-02 0.2140 1.73e-01 -0.127000 3.48e-02 1.19e-01
Metalloprotease DUBs 24 1.94e-01 2.48e-01 0.2140 -2.13e-01 -0.018700 7.03e-02 8.74e-01
Cell recruitment (pro-inflammatory response) 23 2.33e-01 2.92e-01 0.2140 -1.26e-01 -0.173000 2.96e-01 1.50e-01
Purinergic signaling in leishmaniasis infection 23 2.33e-01 2.92e-01 0.2140 -1.26e-01 -0.173000 2.96e-01 1.50e-01
tRNA processing 124 9.58e-05 2.61e-04 0.2140 -1.25e-01 0.174000 1.66e-02 8.40e-04
Transcriptional regulation by RUNX1 184 6.54e-06 2.35e-05 0.2140 -2.03e-01 -0.065200 1.92e-06 1.27e-01
RHO GTPases Activate NADPH Oxidases 20 2.45e-01 3.05e-01 0.2130 2.83e-02 -0.211000 8.27e-01 1.02e-01
PIWI-interacting RNA (piRNA) biogenesis 24 1.66e-01 2.16e-01 0.2130 -1.59e-01 0.142000 1.78e-01 2.28e-01
RHO GTPase Effectors 254 1.36e-07 7.12e-07 0.2120 -1.07e-01 -0.184000 3.33e-03 4.56e-07
SHC-mediated cascade:FGFR3 16 3.09e-01 3.71e-01 0.2120 1.05e-01 -0.184000 4.67e-01 2.02e-01
Meiotic recombination 45 4.57e-02 6.89e-02 0.2120 -1.57e-02 0.211000 8.55e-01 1.43e-02
mitochondrial fatty acid beta-oxidation of saturated fatty acids 10 5.41e-01 6.00e-01 0.2110 1.46e-01 0.153000 4.24e-01 4.02e-01
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 95 9.66e-04 2.13e-03 0.2110 1.32e-01 -0.164000 2.59e-02 5.58e-03
Detoxification of Reactive Oxygen Species 30 1.18e-01 1.59e-01 0.2110 -7.20e-02 0.198000 4.95e-01 6.02e-02
SHC-mediated cascade:FGFR1 18 3.12e-01 3.74e-01 0.2100 -3.57e-02 -0.207000 7.93e-01 1.28e-01
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function 56 2.54e-02 4.09e-02 0.2100 -2.09e-01 -0.019100 6.72e-03 8.04e-01
Biosynthesis of DHA-derived SPMs 13 3.89e-01 4.48e-01 0.2100 -1.37e-01 0.159000 3.94e-01 3.20e-01
Diseases of DNA repair 34 1.18e-01 1.59e-01 0.2100 1.98e-01 0.069200 4.56e-02 4.85e-01
Chromosome Maintenance 109 6.48e-04 1.49e-03 0.2100 -1.99e-02 0.209000 7.20e-01 1.66e-04
Collagen biosynthesis and modifying enzymes 58 1.65e-02 2.80e-02 0.2100 1.92e-01 -0.085000 1.16e-02 2.63e-01
Nicotinate metabolism 29 1.46e-01 1.92e-01 0.2100 2.10e-01 0.001500 5.08e-02 9.89e-01
Innate Immune System 838 3.33e-22 9.38e-21 0.2090 -1.07e-01 -0.180000 1.39e-07 6.82e-19
Presynaptic phase of homologous DNA pairing and strand exchange 39 9.33e-02 1.29e-01 0.2090 1.82e-01 0.103000 4.93e-02 2.66e-01
Tight junction interactions 19 2.76e-01 3.36e-01 0.2090 3.15e-02 -0.206000 8.12e-01 1.19e-01
G1/S Transition 131 1.08e-04 2.91e-04 0.2090 -8.09e-02 0.192000 1.10e-01 1.45e-04
Neuronal System 326 3.89e-10 3.56e-09 0.2080 2.80e-02 -0.207000 3.84e-01 1.38e-10
Chemokine receptors bind chemokines 22 2.63e-01 3.22e-01 0.2080 9.19e-02 0.187000 4.56e-01 1.29e-01
Inhibition of replication initiation of damaged DNA by RB1/E2F1 13 4.25e-01 4.83e-01 0.2080 2.07e-01 -0.012700 1.96e-01 9.37e-01
Plasma lipoprotein clearance 29 1.36e-01 1.80e-01 0.2070 1.94e-01 -0.072600 7.02e-02 4.99e-01
Translation of Structural Proteins 29 1.56e-01 2.03e-01 0.2070 -1.40e-02 -0.207000 8.96e-01 5.38e-02
Base-Excision Repair, AP Site Formation 35 8.56e-02 1.20e-01 0.2070 -1.59e-01 0.132000 1.03e-01 1.77e-01
Metabolism of lipids 643 1.22e-17 2.42e-16 0.2060 -3.95e-02 -0.202000 8.72e-02 1.67e-18
Metabolism of nitric oxide: NOS3 activation and regulation 15 4.01e-01 4.60e-01 0.2060 -5.92e-02 -0.197000 6.91e-01 1.86e-01
RNA Polymerase II Transcription 1234 7.75e-31 3.34e-29 0.2060 -1.80e-01 -0.098400 8.96e-27 5.31e-09
Glycerophospholipid biosynthesis 110 1.74e-03 3.61e-03 0.2050 -1.38e-01 -0.152000 1.24e-02 5.81e-03
Pyruvate metabolism 28 1.99e-01 2.54e-01 0.2040 -1.65e-01 -0.120000 1.30e-01 2.70e-01
Signaling by NOTCH4 81 4.55e-03 8.62e-03 0.2040 -1.93e-01 0.067300 2.67e-03 2.95e-01
Chaperonin-mediated protein folding 83 8.32e-03 1.51e-02 0.2040 -1.73e-01 -0.109000 6.50e-03 8.62e-02
Sensory processing of sound 62 1.56e-02 2.65e-02 0.2040 8.63e-02 -0.185000 2.40e-01 1.18e-02
Generic Transcription Pathway 1116 2.74e-27 1.00e-25 0.2030 -1.70e-01 -0.111000 6.46e-22 2.99e-10
Mitotic Metaphase and Anaphase 229 4.59e-07 2.18e-06 0.2030 -1.99e-01 0.040400 2.22e-07 2.92e-01
Purine salvage 12 4.55e-01 5.12e-01 0.2020 7.01e-02 -0.190000 6.74e-01 2.55e-01
FGFR3 mutant receptor activation 10 5.53e-01 6.09e-01 0.2020 1.97e-01 0.045400 2.81e-01 8.04e-01
Signaling by activated point mutants of FGFR3 10 5.53e-01 6.09e-01 0.2020 1.97e-01 0.045400 2.81e-01 8.04e-01
Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function 24 2.57e-01 3.15e-01 0.2010 1.79e-01 0.092900 1.30e-01 4.31e-01
Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function 24 2.57e-01 3.15e-01 0.2010 1.79e-01 0.092900 1.30e-01 4.31e-01
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function 24 2.57e-01 3.15e-01 0.2010 1.79e-01 0.092900 1.30e-01 4.31e-01
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function 24 2.57e-01 3.15e-01 0.2010 1.79e-01 0.092900 1.30e-01 4.31e-01
Diseases of DNA Double-Strand Break Repair 24 2.57e-01 3.15e-01 0.2010 1.79e-01 0.092900 1.30e-01 4.31e-01
Mitotic Anaphase 228 6.05e-07 2.80e-06 0.2010 -1.97e-01 0.039800 2.84e-07 3.00e-01
Transmission across Chemical Synapses 212 1.91e-06 7.82e-06 0.2010 2.83e-02 -0.199000 4.77e-01 5.83e-07
TRAF6-mediated induction of TAK1 complex within TLR4 complex 16 4.13e-01 4.72e-01 0.2010 -1.42e-01 -0.142000 3.25e-01 3.27e-01
Defective Intrinsic Pathway for Apoptosis 22 2.94e-01 3.55e-01 0.2000 -1.74e-01 -0.099500 1.59e-01 4.19e-01
SLC-mediated transmembrane transport 196 5.87e-06 2.13e-05 0.1990 4.05e-02 -0.195000 3.28e-01 2.60e-06
IL-6-type cytokine receptor ligand interactions 16 3.54e-01 4.15e-01 0.1980 1.52e-01 -0.127000 2.91e-01 3.79e-01
Termination of translesion DNA synthesis 32 1.68e-01 2.18e-01 0.1980 7.01e-02 0.185000 4.93e-01 6.97e-02
GABA receptor activation 45 7.46e-02 1.06e-01 0.1970 -2.17e-02 -0.196000 8.02e-01 2.27e-02
Early Phase of HIV Life Cycle 13 4.53e-01 5.10e-01 0.1970 -1.92e-01 0.043800 2.31e-01 7.84e-01
IRAK4 deficiency (TLR2/4) 15 4.44e-01 5.00e-01 0.1970 8.73e-02 0.176000 5.58e-01 2.38e-01
Telomere Maintenance 84 6.86e-03 1.26e-02 0.1960 -2.67e-02 0.194000 6.72e-01 2.10e-03
Initiation of Nuclear Envelope (NE) Reformation 19 3.59e-01 4.20e-01 0.1950 -1.81e-01 -0.073000 1.72e-01 5.82e-01
G2/M Transition 181 1.76e-05 5.73e-05 0.1950 -1.80e-01 0.073800 2.92e-05 8.67e-02
GPCR downstream signalling 420 2.62e-11 2.95e-10 0.1950 3.28e-02 -0.192000 2.48e-01 1.48e-11
Binding and Uptake of Ligands by Scavenger Receptors 31 1.90e-01 2.43e-01 0.1940 1.81e-01 0.070700 8.09e-02 4.96e-01
Signaling by GPCR 474 1.38e-12 1.80e-11 0.1940 3.01e-02 -0.192000 2.62e-01 7.40e-13
Protein folding 89 8.20e-03 1.49e-02 0.1940 -1.87e-01 -0.052600 2.33e-03 3.91e-01
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein 76 1.88e-02 3.11e-02 0.1940 -9.25e-02 -0.170000 1.63e-01 1.02e-02
CASP8 activity is inhibited 10 5.56e-01 6.11e-01 0.1930 4.07e-02 -0.189000 8.24e-01 3.00e-01
Dimerization of procaspase-8 10 5.56e-01 6.11e-01 0.1930 4.07e-02 -0.189000 8.24e-01 3.00e-01
Regulation by c-FLIP 10 5.56e-01 6.11e-01 0.1930 4.07e-02 -0.189000 8.24e-01 3.00e-01
Metabolism of proteins 1731 1.62e-36 8.49e-35 0.1930 -1.44e-01 -0.128000 1.33e-23 5.62e-19
mTORC1-mediated signalling 24 2.86e-01 3.47e-01 0.1910 -5.51e-02 -0.182000 6.40e-01 1.22e-01
Transcriptional Regulation by TP53 356 1.29e-08 8.39e-08 0.1900 -1.80e-01 -0.061900 5.14e-09 4.48e-02
Nervous system development 522 8.27e-12 9.77e-11 0.1900 -1.19e-01 -0.149000 3.47e-06 5.53e-09
Mitotic G2-G2/M phases 183 2.48e-05 7.69e-05 0.1900 -1.74e-01 0.076600 4.85e-05 7.39e-02
FGFR2 mutant receptor activation 29 1.78e-01 2.30e-01 0.1900 -1.43e-01 0.126000 1.84e-01 2.42e-01
Cell Cycle Checkpoints 260 2.55e-07 1.27e-06 0.1890 -1.46e-01 0.121000 5.16e-05 8.03e-04
Mitochondrial calcium ion transport 22 3.34e-01 3.96e-01 0.1880 -1.70e-01 -0.082200 1.68e-01 5.04e-01
SHC-mediated cascade:FGFR2 19 3.32e-01 3.94e-01 0.1880 1.26e-01 -0.139000 3.41e-01 2.95e-01
Norepinephrine Neurotransmitter Release Cycle 16 4.44e-01 5.00e-01 0.1870 -1.82e-01 -0.045500 2.08e-01 7.53e-01
Disease 1437 1.81e-29 6.97e-28 0.1870 -9.45e-02 -0.162000 1.73e-09 6.57e-25
BBSome-mediated cargo-targeting to cilium 21 3.56e-01 4.17e-01 0.1870 -7.95e-02 -0.169000 5.28e-01 1.79e-01
ADORA2B mediated anti-inflammatory cytokines production 81 1.23e-02 2.16e-02 0.1870 3.66e-02 -0.183000 5.69e-01 4.42e-03
Processing of SMDT1 15 4.51e-01 5.08e-01 0.1860 -1.86e-01 0.013600 2.13e-01 9.27e-01
Activation of HOX genes during differentiation 81 1.76e-02 2.94e-02 0.1860 -1.80e-01 -0.047000 5.08e-03 4.64e-01
Activation of anterior HOX genes in hindbrain development during early embryogenesis 81 1.76e-02 2.94e-02 0.1860 -1.80e-01 -0.047000 5.08e-03 4.64e-01
Signaling by NOTCH 193 1.05e-04 2.84e-04 0.1860 -1.55e-01 -0.102000 2.01e-04 1.42e-02
Signaling by FGFR2 in disease 39 1.44e-01 1.90e-01 0.1850 -1.81e-01 -0.036300 5.05e-02 6.95e-01
Glyoxylate metabolism and glycine degradation 25 2.92e-01 3.53e-01 0.1840 -1.79e-01 -0.042800 1.21e-01 7.11e-01
DNA Damage/Telomere Stress Induced Senescence 51 8.34e-02 1.17e-01 0.1840 -1.77e-01 -0.050000 2.86e-02 5.36e-01
Formation of the beta-catenin:TCF transactivating complex 52 8.92e-02 1.24e-01 0.1840 -1.19e-01 -0.140000 1.38e-01 8.01e-02
Neurotransmitter release cycle 47 1.11e-01 1.51e-01 0.1830 -8.60e-02 -0.162000 3.08e-01 5.50e-02
Amino acid transport across the plasma membrane 29 2.40e-01 2.99e-01 0.1830 -2.85e-02 -0.181000 7.91e-01 9.19e-02
Response of Mtb to phagocytosis 22 3.50e-01 4.12e-01 0.1830 -5.97e-02 -0.173000 6.28e-01 1.60e-01
Cellular Senescence 152 8.17e-04 1.84e-03 0.1830 -1.66e-01 -0.077000 4.13e-04 1.01e-01
Neutrophil degranulation 406 3.72e-09 2.77e-08 0.1820 -3.08e-02 -0.179000 2.86e-01 5.29e-10
Mitochondrial tRNA aminoacylation 21 3.80e-01 4.39e-01 0.1820 -8.30e-02 -0.162000 5.10e-01 2.00e-01
Intrinsic Pathway for Apoptosis 53 6.79e-02 9.76e-02 0.1810 2.14e-02 -0.180000 7.88e-01 2.32e-02
Global Genome Nucleotide Excision Repair (GG-NER) 84 1.09e-02 1.93e-02 0.1810 -1.50e-01 0.102000 1.78e-02 1.04e-01
RMTs methylate histone arginines 42 1.21e-01 1.61e-01 0.1810 -1.81e-01 0.015200 4.29e-02 8.65e-01
Basigin interactions 23 3.12e-01 3.74e-01 0.1810 2.53e-02 -0.179000 8.34e-01 1.37e-01
Translesion Synthesis by POLH 18 3.83e-01 4.42e-01 0.1810 -1.52e-01 0.096900 2.63e-01 4.77e-01
Cardiac conduction 107 3.57e-03 6.85e-03 0.1800 9.28e-02 -0.154000 9.71e-02 5.88e-03
Sema4D in semaphorin signaling 24 3.29e-01 3.93e-01 0.1800 -5.34e-02 -0.172000 6.51e-01 1.45e-01
Phospholipase C-mediated cascade; FGFR2 14 5.42e-01 6.00e-01 0.1780 1.38e-01 0.113000 3.70e-01 4.66e-01
Beta-oxidation of very long chain fatty acids 10 6.35e-01 6.85e-01 0.1780 1.71e-01 0.050700 3.50e-01 7.81e-01
Developmental Biology 843 2.54e-16 4.43e-15 0.1780 -8.61e-02 -0.155000 2.07e-05 1.55e-14
Formation of Senescence-Associated Heterochromatin Foci (SAHF) 16 4.95e-01 5.53e-01 0.1770 -8.16e-02 -0.157000 5.72e-01 2.76e-01
Extension of Telomeres 51 1.12e-01 1.52e-01 0.1770 1.24e-01 0.126000 1.26e-01 1.19e-01
ABC-family proteins mediated transport 97 7.92e-03 1.44e-02 0.1770 -1.64e-01 0.064600 5.15e-03 2.72e-01
Post-chaperonin tubulin folding pathway 20 3.88e-01 4.47e-01 0.1760 -5.37e-03 0.176000 9.67e-01 1.72e-01
Dectin-2 family 14 5.47e-01 6.05e-01 0.1760 1.46e-01 0.099400 3.45e-01 5.20e-01
Glycogen storage diseases 14 5.42e-01 6.00e-01 0.1760 1.60e-01 0.073600 2.99e-01 6.33e-01
Activation of kainate receptors upon glutamate binding 24 3.62e-01 4.23e-01 0.1760 -1.21e-01 -0.128000 3.07e-01 2.79e-01
Axon guidance 500 1.60e-09 1.28e-08 0.1730 -1.12e-01 -0.132000 1.62e-05 4.32e-07
SHC-mediated cascade:FGFR4 16 4.55e-01 5.12e-01 0.1730 1.15e-01 -0.129000 4.28e-01 3.71e-01
Activation of SMO 18 4.78e-01 5.35e-01 0.1730 -1.28e-01 -0.115000 3.45e-01 3.97e-01
Diseases of programmed cell death 61 5.11e-02 7.61e-02 0.1720 -1.32e-01 0.110000 7.37e-02 1.37e-01
RIPK1-mediated regulated necrosis 27 3.30e-01 3.93e-01 0.1720 -1.47e-01 -0.090000 1.87e-01 4.18e-01
Regulation of necroptotic cell death 27 3.30e-01 3.93e-01 0.1720 -1.47e-01 -0.090000 1.87e-01 4.18e-01
Post-translational modification: synthesis of GPI-anchored proteins 63 5.57e-02 8.20e-02 0.1720 1.70e-01 -0.026700 1.97e-02 7.14e-01
Oxidative Stress Induced Senescence 82 2.85e-02 4.53e-02 0.1720 -1.70e-01 -0.022300 7.68e-03 7.26e-01
FRS-mediated FGFR4 signaling 18 4.62e-01 5.18e-01 0.1710 -3.23e-02 -0.168000 8.12e-01 2.16e-01
FRS-mediated FGFR2 signaling 21 3.94e-01 4.52e-01 0.1710 -7.09e-04 -0.171000 9.96e-01 1.74e-01
Interleukin-37 signaling 21 3.79e-01 4.39e-01 0.1710 4.17e-02 -0.166000 7.41e-01 1.88e-01
Transcriptional regulation of testis differentiation 11 5.92e-01 6.44e-01 0.1710 8.81e-02 -0.146000 6.13e-01 4.00e-01
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex 13 5.95e-01 6.47e-01 0.1710 -1.17e-01 -0.124000 4.64e-01 4.39e-01
Mitotic G1 phase and G1/S transition 147 9.65e-04 2.13e-03 0.1700 -9.14e-02 0.144000 5.56e-02 2.62e-03
Peroxisomal protein import 59 7.12e-02 1.02e-01 0.1700 2.69e-02 -0.168000 7.21e-01 2.58e-02
G alpha (s) signalling events 92 1.54e-02 2.62e-02 0.1700 4.28e-02 -0.164000 4.78e-01 6.43e-03
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane 10 6.74e-01 7.20e-01 0.1670 -5.88e-02 -0.156000 7.48e-01 3.93e-01
Adrenaline,noradrenaline inhibits insulin secretion 23 3.88e-01 4.47e-01 0.1660 -1.29e-02 -0.166000 9.15e-01 1.69e-01
Infection with Mycobacterium tuberculosis 24 3.84e-01 4.44e-01 0.1650 -3.16e-02 -0.162000 7.89e-01 1.69e-01
Nucleotide salvage 21 4.31e-01 4.89e-01 0.1650 1.63e-01 0.023200 1.95e-01 8.54e-01
Phase II - Conjugation of compounds 75 5.11e-02 7.61e-02 0.1650 3.08e-02 0.162000 6.44e-01 1.52e-02
Regulation of Complement cascade 25 3.34e-01 3.96e-01 0.1640 -1.47e-01 0.073000 2.02e-01 5.27e-01
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes 25 3.47e-01 4.09e-01 0.1640 4.33e-02 -0.158000 7.08e-01 1.72e-01
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest 14 5.40e-01 5.99e-01 0.1630 1.12e-01 -0.119000 4.67e-01 4.42e-01
Aspartate and asparagine metabolism 10 6.94e-01 7.36e-01 0.1630 1.27e-01 0.102000 4.87e-01 5.77e-01
Recognition of DNA damage by PCNA-containing replication complex 30 2.71e-01 3.30e-01 0.1630 -1.02e-01 0.127000 3.34e-01 2.29e-01
Base Excision Repair 63 7.81e-02 1.11e-01 0.1630 -1.24e-02 0.162000 8.65e-01 2.59e-02
Incretin synthesis, secretion, and inactivation 16 5.51e-01 6.08e-01 0.1620 -1.50e-01 -0.061700 2.99e-01 6.69e-01
S Phase 160 1.10e-03 2.41e-03 0.1620 -8.21e-02 0.140000 7.30e-02 2.30e-03
Branched-chain amino acid catabolism 21 4.30e-01 4.88e-01 0.1620 1.38e-02 -0.161000 9.13e-01 2.01e-01
Vitamin D (calciferol) metabolism 10 6.56e-01 7.05e-01 0.1610 7.08e-02 -0.145000 6.98e-01 4.27e-01
Telomere C-strand synthesis initiation 13 5.78e-01 6.31e-01 0.1610 8.13e-02 -0.139000 6.12e-01 3.87e-01
Class B/2 (Secretin family receptors) 70 5.68e-02 8.34e-02 0.1610 5.07e-02 -0.152000 4.63e-01 2.76e-02
Formation of tubulin folding intermediates by CCT/TriC 23 4.38e-01 4.96e-01 0.1600 -1.41e-01 -0.075900 2.41e-01 5.29e-01
Phospholipase C-mediated cascade; FGFR3 11 6.81e-01 7.25e-01 0.1600 1.11e-01 0.115000 5.25e-01 5.09e-01
Smooth Muscle Contraction 32 2.62e-01 3.21e-01 0.1590 1.05e-01 -0.120000 3.04e-01 2.40e-01
cGMP effects 14 5.60e-01 6.14e-01 0.1580 1.11e-01 -0.113000 4.73e-01 4.63e-01
Pre-NOTCH Expression and Processing 70 8.96e-02 1.25e-01 0.1580 -9.47e-02 -0.127000 1.71e-01 6.66e-02
Signaling by Hedgehog 132 7.68e-03 1.40e-02 0.1580 -1.57e-01 -0.015800 1.81e-03 7.54e-01
Phase 0 - rapid depolarisation 28 3.61e-01 4.22e-01 0.1560 1.56e-01 0.014000 1.54e-01 8.98e-01
Visual phototransduction 70 6.90e-02 9.87e-02 0.1560 4.02e-02 -0.150000 5.61e-01 2.96e-02
M Phase 370 1.70e-06 6.98e-06 0.1540 -1.53e-01 0.013800 3.94e-07 6.49e-01
Muscle contraction 159 2.29e-03 4.60e-03 0.1530 9.71e-02 -0.118000 3.46e-02 1.02e-02
The phototransduction cascade 26 4.04e-01 4.63e-01 0.1530 -9.93e-03 -0.152000 9.30e-01 1.78e-01
Apoptosis 169 4.71e-03 8.88e-03 0.1520 -9.73e-02 -0.117000 2.90e-02 8.60e-03
Programmed Cell Death 195 1.99e-03 4.06e-03 0.1520 -8.13e-02 -0.129000 5.01e-02 1.94e-03
Transport of inorganic cations/anions and amino acids/oligopeptides 90 4.90e-02 7.33e-02 0.1510 -2.23e-02 -0.149000 7.15e-01 1.42e-02
Transcriptional Regulation by VENTX 38 2.71e-01 3.30e-01 0.1500 -1.50e-01 0.007890 1.10e-01 9.33e-01
Recycling of bile acids and salts 13 6.63e-01 7.10e-01 0.1500 1.35e-01 0.065300 3.99e-01 6.83e-01
Serotonin Neurotransmitter Release Cycle 17 5.82e-01 6.35e-01 0.1490 -1.43e-01 -0.041800 3.08e-01 7.66e-01
Sema4D induced cell migration and growth-cone collapse 20 5.40e-01 5.99e-01 0.1480 -6.69e-02 -0.132000 6.05e-01 3.05e-01
G0 and Early G1 27 4.42e-01 5.00e-01 0.1480 1.14e-01 0.095000 3.06e-01 3.93e-01
Prostacyclin signalling through prostacyclin receptor 15 6.26e-01 6.77e-01 0.1480 -1.39e-01 -0.049400 3.50e-01 7.40e-01
The canonical retinoid cycle in rods (twilight vision) 16 6.11e-01 6.62e-01 0.1470 5.69e-02 0.136000 6.94e-01 3.46e-01
TP53 Regulates Transcription of Death Receptors and Ligands 11 6.76e-01 7.21e-01 0.1470 1.13e-01 -0.093800 5.15e-01 5.90e-01
Voltage gated Potassium channels 32 3.26e-01 3.90e-01 0.1470 6.63e-02 -0.131000 5.16e-01 1.99e-01
Plasma lipoprotein assembly, remodeling, and clearance 55 1.43e-01 1.88e-01 0.1470 1.12e-01 -0.094600 1.50e-01 2.25e-01
Glutamate Neurotransmitter Release Cycle 23 5.05e-01 5.63e-01 0.1470 -1.19e-01 -0.085000 3.21e-01 4.80e-01
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol 20 5.53e-01 6.09e-01 0.1470 -1.18e-01 -0.086600 3.60e-01 5.02e-01
Transport of small molecules 598 4.33e-09 3.14e-08 0.1470 1.29e-02 -0.146000 5.90e-01 1.01e-09
Peroxisomal lipid metabolism 27 3.90e-01 4.49e-01 0.1460 9.05e-02 -0.114000 4.16e-01 3.05e-01
Homology Directed Repair 111 4.04e-02 6.18e-02 0.1440 6.39e-02 0.129000 2.45e-01 1.89e-02
Mitotic Spindle Checkpoint 109 2.66e-02 4.27e-02 0.1440 -1.31e-01 0.059000 1.79e-02 2.87e-01
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) 105 4.46e-02 6.76e-02 0.1440 3.78e-02 0.139000 5.03e-01 1.41e-02
Transcription of E2F targets under negative control by DREAM complex 19 5.85e-01 6.39e-01 0.1430 9.89e-02 0.104000 4.56e-01 4.34e-01
E2F mediated regulation of DNA replication 22 5.35e-01 5.94e-01 0.1420 5.83e-02 0.130000 6.36e-01 2.93e-01
Caspase activation via Death Receptors in the presence of ligand 15 6.09e-01 6.60e-01 0.1420 8.98e-02 -0.110000 5.47e-01 4.62e-01
HDR through Single Strand Annealing (SSA) 37 3.63e-01 4.24e-01 0.1410 1.16e-01 0.079200 2.21e-01 4.04e-01
Processing of DNA double-strand break ends 72 9.61e-02 1.33e-01 0.1410 -1.05e-01 0.093700 1.24e-01 1.69e-01
Collagen chain trimerization 37 3.06e-01 3.69e-01 0.1400 1.25e-01 -0.063500 1.87e-01 5.04e-01
Killing mechanisms 11 7.05e-01 7.45e-01 0.1400 1.27e-01 -0.060200 4.67e-01 7.30e-01
WNT5:FZD7-mediated leishmania damping 11 7.05e-01 7.45e-01 0.1400 1.27e-01 -0.060200 4.67e-01 7.30e-01
TP53 Regulates Metabolic Genes 85 9.11e-02 1.26e-01 0.1400 -1.36e-01 -0.033000 3.04e-02 5.99e-01
Gamma carboxylation, hypusine formation and arylsulfatase activation 36 3.33e-01 3.95e-01 0.1400 2.98e-02 -0.136000 7.57e-01 1.57e-01
Removal of the Flap Intermediate from the C-strand 17 6.06e-01 6.59e-01 0.1390 2.08e-03 -0.139000 9.88e-01 3.20e-01
Complement cascade 31 3.73e-01 4.34e-01 0.1390 -1.04e-01 0.092600 3.18e-01 3.72e-01
Regulation of TP53 Activity through Association with Co-factors 12 6.89e-01 7.31e-01 0.1390 5.41e-02 -0.128000 7.45e-01 4.43e-01
RHO GTPases Activate Formins 118 4.49e-02 6.81e-02 0.1390 -1.01e-01 -0.095100 5.84e-02 7.42e-02
Constitutive Signaling by NOTCH1 HD Domain Mutants 15 6.58e-01 7.06e-01 0.1380 -2.83e-02 -0.135000 8.49e-01 3.64e-01
Signaling by NOTCH1 HD Domain Mutants in Cancer 15 6.58e-01 7.06e-01 0.1380 -2.83e-02 -0.135000 8.49e-01 3.64e-01
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway 16 6.08e-01 6.60e-01 0.1380 -6.88e-02 0.120000 6.34e-01 4.07e-01
Signaling by Retinoic Acid 37 3.60e-01 4.20e-01 0.1380 -1.35e-01 -0.029700 1.56e-01 7.55e-01
Protein localization 158 9.55e-03 1.71e-02 0.1370 -1.31e-01 0.037600 4.34e-03 4.15e-01
TP53 Regulates Transcription of Cell Death Genes 43 3.33e-01 3.95e-01 0.1340 -1.25e-01 -0.049200 1.56e-01 5.77e-01
G alpha (i) signalling events 194 4.58e-03 8.65e-03 0.1340 2.06e-02 -0.133000 6.20e-01 1.45e-03
Inactivation, recovery and regulation of the phototransduction cascade 25 5.27e-01 5.87e-01 0.1340 -4.42e-02 -0.127000 7.02e-01 2.74e-01
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon 17 6.11e-01 6.62e-01 0.1330 -6.34e-02 0.117000 6.51e-01 4.02e-01
Cyclin D associated events in G1 45 3.31e-01 3.94e-01 0.1330 -6.83e-02 -0.114000 4.28e-01 1.85e-01
G1 Phase 45 3.31e-01 3.94e-01 0.1330 -6.83e-02 -0.114000 4.28e-01 1.85e-01
Dual Incision in GG-NER 41 3.31e-01 3.94e-01 0.1320 -1.62e-02 0.131000 8.58e-01 1.46e-01
Transcriptional regulation of pluripotent stem cells 30 4.43e-01 5.00e-01 0.1310 3.36e-02 -0.127000 7.50e-01 2.29e-01
Synthesis of bile acids and bile salts 30 4.89e-01 5.46e-01 0.1310 -5.86e-02 -0.117000 5.79e-01 2.69e-01
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal 92 9.34e-02 1.29e-01 0.1300 -1.30e-01 0.004050 3.07e-02 9.47e-01
Amplification of signal from the kinetochores 92 9.34e-02 1.29e-01 0.1300 -1.30e-01 0.004050 3.07e-02 9.47e-01
Common Pathway of Fibrin Clot Formation 14 6.81e-01 7.25e-01 0.1300 5.60e-02 -0.117000 7.17e-01 4.47e-01
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) 14 7.22e-01 7.61e-01 0.1300 -8.37e-02 -0.099500 5.88e-01 5.19e-01
Resolution of Sister Chromatid Cohesion 105 7.97e-02 1.13e-01 0.1290 -1.26e-01 -0.028400 2.58e-02 6.15e-01
Ion channel transport 152 1.60e-02 2.72e-02 0.1290 7.76e-02 -0.103000 9.86e-02 2.83e-02
Aggrephagy 21 5.66e-01 6.19e-01 0.1290 -7.50e-02 0.104000 5.52e-01 4.08e-01
Triglyceride metabolism 26 5.31e-01 5.91e-01 0.1280 -9.47e-03 -0.127000 9.33e-01 2.61e-01
Metabolic disorders of biological oxidation enzymes 28 5.27e-01 5.87e-01 0.1270 1.17e-01 0.049700 2.83e-01 6.49e-01
Arachidonic acid metabolism 37 3.77e-01 4.38e-01 0.1270 -6.51e-02 0.109000 4.93e-01 2.50e-01
Regulation of FZD by ubiquitination 21 6.14e-01 6.65e-01 0.1270 -3.52e-02 -0.122000 7.80e-01 3.33e-01
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation 13 7.34e-01 7.72e-01 0.1270 1.26e-01 0.013100 4.32e-01 9.35e-01
Regulation of TP53 Activity through Phosphorylation 91 1.21e-01 1.61e-01 0.1270 -1.24e-01 -0.026200 4.12e-02 6.65e-01
Amino acids regulate mTORC1 51 3.08e-01 3.71e-01 0.1260 -1.24e-01 -0.023200 1.27e-01 7.74e-01
Acyl chain remodelling of PG 11 7.87e-01 8.18e-01 0.1260 -1.02e-01 -0.072500 5.56e-01 6.77e-01
Telomere Extension By Telomerase 23 5.90e-01 6.43e-01 0.1250 -1.24e-01 -0.018500 3.05e-01 8.78e-01
EML4 and NUDC in mitotic spindle formation 96 1.14e-01 1.54e-01 0.1250 -1.22e-01 -0.025100 3.85e-02 6.71e-01
Aberrant regulation of mitotic cell cycle due to RB1 defects 36 4.64e-01 5.20e-01 0.1210 2.65e-02 0.118000 7.83e-01 2.19e-01
Xenobiotics 14 7.20e-01 7.59e-01 0.1200 1.05e-01 -0.058800 4.98e-01 7.03e-01
ROS and RNS production in phagocytes 31 5.45e-01 6.03e-01 0.1190 6.53e-02 0.099400 5.29e-01 3.38e-01
Sensory Perception 173 1.97e-02 3.25e-02 0.1180 5.70e-02 -0.104000 1.96e-01 1.84e-02
Chaperone Mediated Autophagy 17 7.23e-01 7.61e-01 0.1170 -9.89e-02 -0.063200 4.80e-01 6.52e-01
TRAF6 mediated NF-kB activation 23 6.48e-01 6.98e-01 0.1170 -8.65e-02 -0.078900 4.73e-01 5.12e-01
Apoptosis induced DNA fragmentation 12 7.68e-01 8.01e-01 0.1170 -4.54e-02 0.108000 7.85e-01 5.19e-01
Fertilization 15 7.41e-01 7.78e-01 0.1170 1.91e-02 0.115000 8.98e-01 4.40e-01
Metabolism of vitamins and cofactors 171 2.38e-02 3.86e-02 0.1160 7.39e-02 -0.088800 9.53e-02 4.50e-02
Nicotinamide salvaging 18 6.88e-01 7.31e-01 0.1150 1.13e-01 -0.022400 4.06e-01 8.70e-01
Nucleotide catabolism 31 5.71e-01 6.25e-01 0.1150 8.42e-02 0.077900 4.17e-01 4.53e-01
Na+/Cl- dependent neurotransmitter transporters 11 7.90e-01 8.20e-01 0.1140 6.39e-02 -0.094600 7.13e-01 5.87e-01
Biosynthesis of specialized proresolving mediators (SPMs) 14 7.44e-01 7.80e-01 0.1140 -5.87e-02 0.097500 7.04e-01 5.28e-01
RA biosynthesis pathway 17 7.46e-01 7.82e-01 0.1120 6.25e-02 0.092600 6.55e-01 5.09e-01
Transcriptional regulation of granulopoiesis 50 4.25e-01 4.84e-01 0.1110 -6.11e-02 -0.092900 4.55e-01 2.56e-01
Biological oxidations 150 6.39e-02 9.23e-02 0.1110 2.43e-03 0.111000 9.59e-01 1.93e-02
Synthesis of PC 26 6.28e-01 6.78e-01 0.1110 -2.00e-02 -0.109000 8.60e-01 3.37e-01
ERBB2 Activates PTK6 Signaling 11 8.35e-01 8.57e-01 0.1090 -5.86e-02 -0.091800 7.36e-01 5.98e-01
G2/M DNA damage checkpoint 69 2.79e-01 3.38e-01 0.1080 -1.03e-01 0.033600 1.41e-01 6.29e-01
Formation of Fibrin Clot (Clotting Cascade) 24 6.76e-01 7.21e-01 0.1080 -9.80e-02 -0.044700 4.06e-01 7.05e-01
Apoptotic factor-mediated response 19 7.40e-01 7.77e-01 0.1070 -8.40e-02 -0.066900 5.26e-01 6.14e-01
Activation of G protein gated Potassium channels 23 6.54e-01 7.03e-01 0.1070 -9.88e-02 0.041300 4.12e-01 7.31e-01
G protein gated Potassium channels 23 6.54e-01 7.03e-01 0.1070 -9.88e-02 0.041300 4.12e-01 7.31e-01
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits 23 6.54e-01 7.03e-01 0.1070 -9.88e-02 0.041300 4.12e-01 7.31e-01
Nitric oxide stimulates guanylate cyclase 18 7.18e-01 7.57e-01 0.1070 4.39e-02 -0.097400 7.47e-01 4.75e-01
Class C/3 (Metabotropic glutamate/pheromone receptors) 13 7.98e-01 8.25e-01 0.1060 -1.19e-02 0.105000 9.41e-01 5.10e-01
TP53 Regulates Transcription of Caspase Activators and Caspases 11 8.23e-01 8.48e-01 0.1050 -3.46e-02 0.099400 8.43e-01 5.68e-01
Interconversion of nucleotide di- and triphosphates 29 5.98e-01 6.50e-01 0.1050 -3.74e-02 0.098300 7.27e-01 3.59e-01
Metabolism of porphyrins 22 7.14e-01 7.54e-01 0.1050 5.42e-02 0.089800 6.60e-01 4.66e-01
SUMOylation of DNA methylation proteins 16 7.54e-01 7.90e-01 0.1050 -9.65e-02 0.040500 5.04e-01 7.79e-01
FGFR3 ligand binding and activation 11 8.29e-01 8.53e-01 0.1040 1.02e-01 -0.022000 5.59e-01 9.00e-01
FGFR3c ligand binding and activation 11 8.29e-01 8.53e-01 0.1040 1.02e-01 -0.022000 5.59e-01 9.00e-01
Pyroptosis 24 6.60e-01 7.08e-01 0.1030 5.60e-02 -0.086200 6.35e-01 4.65e-01
Eicosanoid ligand-binding receptors 12 8.23e-01 8.48e-01 0.1020 -1.02e-01 0.012500 5.42e-01 9.40e-01
Regulation of PLK1 Activity at G2/M Transition 87 2.53e-01 3.12e-01 0.1020 -1.02e-01 0.001150 9.89e-02 9.85e-01
Regulated Necrosis 51 4.78e-01 5.35e-01 0.1020 -5.13e-02 -0.088300 5.26e-01 2.75e-01
Downregulation of ERBB2 signaling 27 6.80e-01 7.25e-01 0.1020 -5.57e-02 -0.084900 6.16e-01 4.45e-01
Cytosolic sulfonation of small molecules 21 7.01e-01 7.42e-01 0.1010 6.75e-02 -0.075600 5.92e-01 5.48e-01
Transferrin endocytosis and recycling 30 6.43e-01 6.93e-01 0.1010 9.66e-02 0.030700 3.60e-01 7.71e-01
Tryptophan catabolism 12 8.45e-01 8.67e-01 0.1010 6.39e-02 0.078200 7.01e-01 6.39e-01
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 16 7.97e-01 8.25e-01 0.1010 8.57e-02 0.053400 5.53e-01 7.12e-01
Termination of O-glycan biosynthesis 17 7.56e-01 7.92e-01 0.1000 5.85e-02 -0.081100 6.76e-01 5.63e-01
Stimuli-sensing channels 84 2.54e-01 3.13e-01 0.1000 5.48e-02 -0.083600 3.85e-01 1.85e-01
Sealing of the nuclear envelope (NE) by ESCRT-III 29 6.28e-01 6.78e-01 0.0992 4.85e-02 -0.086500 6.51e-01 4.20e-01
Striated Muscle Contraction 26 7.08e-01 7.48e-01 0.0980 5.59e-02 0.080500 6.22e-01 4.77e-01
Metabolism of water-soluble vitamins and cofactors 117 1.62e-01 2.12e-01 0.0973 6.44e-02 -0.072900 2.28e-01 1.73e-01
Peptide ligand-binding receptors 100 2.75e-01 3.35e-01 0.0960 8.71e-02 0.040500 1.32e-01 4.84e-01
Olfactory Signaling Pathway 21 7.66e-01 7.99e-01 0.0956 4.75e-02 0.082900 7.06e-01 5.11e-01
Cell Cycle, Mitotic 512 6.83e-04 1.56e-03 0.0954 -9.02e-02 0.031100 4.71e-04 2.27e-01
Pre-NOTCH Transcription and Translation 54 4.99e-01 5.57e-01 0.0954 -3.51e-02 -0.088700 6.55e-01 2.60e-01
TNFs bind their physiological receptors 19 7.71e-01 8.03e-01 0.0950 -1.17e-03 0.095000 9.93e-01 4.74e-01
Diseases associated with the TLR signaling cascade 27 6.89e-01 7.31e-01 0.0940 -9.22e-02 0.018400 4.07e-01 8.69e-01
Diseases of Immune System 27 6.89e-01 7.31e-01 0.0940 -9.22e-02 0.018400 4.07e-01 8.69e-01
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 76 3.52e-01 4.14e-01 0.0936 9.11e-02 -0.021600 1.70e-01 7.45e-01
Downregulation of ERBB2:ERBB3 signaling 13 8.50e-01 8.71e-01 0.0932 -2.52e-02 -0.089700 8.75e-01 5.75e-01
Phospholipase C-mediated cascade: FGFR1 13 8.35e-01 8.57e-01 0.0929 -8.51e-02 0.037200 5.95e-01 8.16e-01
Sensory perception of sweet, bitter, and umami (glutamate) taste 19 7.96e-01 8.25e-01 0.0926 -8.29e-02 -0.041200 5.32e-01 7.56e-01
TP53 Regulates Transcription of Cell Cycle Genes 48 5.64e-01 6.18e-01 0.0911 -2.52e-02 -0.087600 7.63e-01 2.94e-01
Insulin receptor recycling 24 7.64e-01 7.98e-01 0.0904 6.42e-02 0.063600 5.86e-01 5.90e-01
Cytochrome P450 - arranged by substrate type 42 5.74e-01 6.27e-01 0.0898 7.25e-02 -0.053000 4.16e-01 5.52e-01
Plasma lipoprotein remodeling 22 7.48e-01 7.84e-01 0.0896 5.19e-02 -0.073000 6.73e-01 5.53e-01
AURKA Activation by TPX2 72 4.12e-01 4.72e-01 0.0878 -8.25e-02 0.030000 2.26e-01 6.60e-01
LGI-ADAM interactions 11 8.71e-01 8.90e-01 0.0872 6.96e-02 -0.052600 6.89e-01 7.63e-01
Organelle biogenesis and maintenance 272 6.12e-02 8.94e-02 0.0868 -6.94e-02 -0.052100 4.88e-02 1.39e-01
Fatty acid metabolism 146 1.67e-01 2.17e-01 0.0865 6.41e-02 -0.058100 1.81e-01 2.25e-01
Cell Cycle 636 6.30e-04 1.46e-03 0.0860 -8.01e-02 0.031500 5.57e-04 1.74e-01
Maturation of nucleoprotein 11 8.83e-01 8.98e-01 0.0860 6.35e-03 -0.085700 9.71e-01 6.22e-01
Diseases of mitotic cell cycle 38 6.73e-01 7.19e-01 0.0847 1.74e-02 0.082900 8.52e-01 3.77e-01
Intrinsic Pathway of Fibrin Clot Formation 14 8.51e-01 8.72e-01 0.0842 7.55e-02 -0.037300 6.25e-01 8.09e-01
DNA Damage Bypass 47 6.11e-01 6.62e-01 0.0830 -8.29e-02 0.004000 3.25e-01 9.62e-01
Acyl chain remodelling of PC 19 8.06e-01 8.32e-01 0.0830 -5.25e-02 0.064300 6.92e-01 6.27e-01
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain 13 8.78e-01 8.95e-01 0.0820 8.16e-02 0.008720 6.11e-01 9.57e-01
Acetylcholine Neurotransmitter Release Cycle 15 8.71e-01 8.90e-01 0.0817 -6.39e-02 -0.051000 6.68e-01 7.32e-01
Pregnenolone biosynthesis 10 9.02e-01 9.14e-01 0.0816 8.06e-02 -0.012400 6.59e-01 9.46e-01
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template 38 7.05e-01 7.46e-01 0.0803 2.59e-02 0.076000 7.82e-01 4.18e-01
NOTCH3 Activation and Transmission of Signal to the Nucleus 25 7.80e-01 8.11e-01 0.0780 4.26e-02 -0.065300 7.12e-01 5.72e-01
Advanced glycosylation endproduct receptor signaling 11 8.98e-01 9.12e-01 0.0773 4.03e-02 -0.065900 8.17e-01 7.05e-01
Generation of second messenger molecules 27 7.98e-01 8.25e-01 0.0765 7.25e-02 0.024400 5.14e-01 8.26e-01
Inwardly rectifying K+ channels 28 7.66e-01 7.99e-01 0.0761 -5.93e-02 0.047700 5.87e-01 6.62e-01
Loss of Nlp from mitotic centrosomes 69 5.48e-01 6.05e-01 0.0749 -7.40e-02 0.011900 2.88e-01 8.65e-01
Loss of proteins required for interphase microtubule organization from the centrosome 69 5.48e-01 6.05e-01 0.0749 -7.40e-02 0.011900 2.88e-01 8.65e-01
MASTL Facilitates Mitotic Progression 10 9.25e-01 9.35e-01 0.0732 1.52e-02 0.071600 9.34e-01 6.95e-01
DNA Repair 297 7.92e-02 1.12e-01 0.0726 -6.10e-02 0.039400 7.02e-02 2.43e-01
Sensory perception of taste 24 8.18e-01 8.44e-01 0.0718 -6.35e-02 0.033700 5.90e-01 7.75e-01
TRP channels 18 8.60e-01 8.80e-01 0.0714 4.51e-02 -0.055300 7.40e-01 6.85e-01
Other interleukin signaling 22 8.49e-01 8.71e-01 0.0705 -7.04e-02 -0.004390 5.68e-01 9.72e-01
GPCR ligand binding 261 1.21e-01 1.61e-01 0.0705 4.38e-02 -0.055200 2.23e-01 1.24e-01
Metabolism of steroid hormones 28 7.99e-01 8.26e-01 0.0699 5.86e-02 -0.038200 5.92e-01 7.26e-01
GABA synthesis, release, reuptake and degradation 18 8.78e-01 8.95e-01 0.0692 1.82e-04 -0.069200 9.99e-01 6.11e-01
Potassium Channels 81 5.57e-01 6.11e-01 0.0689 3.52e-03 -0.068800 9.56e-01 2.84e-01
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation 10 9.26e-01 9.36e-01 0.0681 -5.19e-02 0.044100 7.76e-01 8.09e-01
Nucleotide-like (purinergic) receptors 12 9.27e-01 9.36e-01 0.0659 6.44e-02 0.014000 6.99e-01 9.33e-01
Metabolism of folate and pterines 16 9.04e-01 9.15e-01 0.0630 5.97e-02 -0.020300 6.80e-01 8.88e-01
Mitotic Prometaphase 186 3.52e-01 4.14e-01 0.0610 -6.10e-02 0.001350 1.51e-01 9.75e-01
Interleukin-10 signaling 32 8.37e-01 8.59e-01 0.0603 6.00e-02 -0.005160 5.57e-01 9.60e-01
Meiotic synapsis 49 7.85e-01 8.16e-01 0.0586 -5.66e-02 -0.015100 4.93e-01 8.55e-01
Metabolism 1856 4.20e-04 1.00e-03 0.0570 -5.01e-02 -0.027000 3.24e-04 5.24e-02
Class A/1 (Rhodopsin-like receptors) 178 4.43e-01 5.00e-01 0.0530 4.49e-02 -0.028300 3.01e-01 5.15e-01
Amyloid fiber formation 59 7.88e-01 8.18e-01 0.0527 9.52e-03 0.051800 8.99e-01 4.91e-01
Suppression of phagosomal maturation 13 9.46e-01 9.53e-01 0.0519 -1.13e-02 0.050700 9.44e-01 7.52e-01
NRIF signals cell death from the nucleus 16 9.40e-01 9.48e-01 0.0486 -3.83e-02 0.029800 7.91e-01 8.36e-01
Phase I - Functionalization of compounds 71 7.61e-01 7.96e-01 0.0483 -3.16e-02 0.036500 6.45e-01 5.94e-01
DNA Double-Strand Break Repair 140 6.63e-01 7.10e-01 0.0461 2.52e-02 0.038600 6.06e-01 4.30e-01
Reproduction 90 7.59e-01 7.93e-01 0.0459 8.07e-03 0.045100 8.95e-01 4.59e-01
Trafficking and processing of endosomal TLR 11 9.69e-01 9.73e-01 0.0458 -2.64e-02 -0.037500 8.80e-01 8.30e-01
Keratinization 46 8.82e-01 8.98e-01 0.0434 4.23e-02 0.009620 6.20e-01 9.10e-01
Processive synthesis on the C-strand of the telomere 19 9.44e-01 9.51e-01 0.0428 2.98e-02 -0.030600 8.22e-01 8.17e-01
Regulation of BACH1 activity 11 9.73e-01 9.76e-01 0.0414 8.60e-03 0.040500 9.61e-01 8.16e-01
Vitamin B5 (pantothenate) metabolism 17 9.60e-01 9.65e-01 0.0414 1.90e-02 0.036700 8.92e-01 7.93e-01
Anchoring of the basal body to the plasma membrane 97 7.98e-01 8.25e-01 0.0411 2.23e-02 0.034500 7.04e-01 5.57e-01
Glucagon-type ligand receptors 22 9.44e-01 9.51e-01 0.0408 1.19e-02 -0.039000 9.23e-01 7.52e-01
FGFR1 ligand binding and activation 12 9.74e-01 9.76e-01 0.0401 -2.96e-02 -0.027100 8.59e-01 8.71e-01
Diseases associated with N-glycosylation of proteins 17 9.59e-01 9.65e-01 0.0390 1.34e-02 -0.036600 9.24e-01 7.94e-01
Bile acid and bile salt metabolism 37 9.14e-01 9.25e-01 0.0387 1.78e-02 -0.034400 8.52e-01 7.18e-01
Cilium Assembly 181 6.84e-01 7.27e-01 0.0366 8.87e-03 -0.035500 8.37e-01 4.09e-01
Acyl chain remodelling of PE 19 9.65e-01 9.70e-01 0.0363 1.45e-02 0.033200 9.13e-01 8.02e-01
Iron uptake and transport 55 8.99e-01 9.12e-01 0.0347 3.17e-02 -0.014100 6.84e-01 8.57e-01
Centrosome maturation 81 8.75e-01 8.93e-01 0.0320 -1.25e-02 0.029500 8.46e-01 6.46e-01
Recruitment of mitotic centrosome proteins and complexes 81 8.75e-01 8.93e-01 0.0320 -1.25e-02 0.029500 8.46e-01 6.46e-01
Meiosis 75 8.97e-01 9.11e-01 0.0316 5.86e-03 0.031000 9.30e-01 6.42e-01
Metabolism of nucleotides 90 8.86e-01 9.01e-01 0.0297 -2.46e-03 0.029500 9.68e-01 6.28e-01
Recruitment of NuMA to mitotic centrosomes 80 9.12e-01 9.23e-01 0.0268 -2.46e-02 0.010600 7.03e-01 8.69e-01
Lysine catabolism 12 9.87e-01 9.87e-01 0.0261 5.58e-03 -0.025400 9.73e-01 8.79e-01
Acyl chain remodelling of PS 15 9.85e-01 9.86e-01 0.0247 1.24e-02 -0.021300 9.34e-01 8.86e-01
Transcriptional Regulation by E2F6 34 9.75e-01 9.76e-01 0.0233 -1.12e-02 -0.020400 9.10e-01 8.36e-01
Carboxyterminal post-translational modifications of tubulin 37 9.73e-01 9.76e-01 0.0223 -3.69e-03 -0.022000 9.69e-01 8.17e-01


Detailed Gene set reports


CLEC7A (Dectin-1) induces NFAT activation

CLEC7A (Dectin-1) induces NFAT activation
metric value
setSize 11
pMANOVA 3.38e-06
p.adjustMANOVA 1.31e-05
s.dist 0.897
s.KO -0.308
s.drug -0.842
p.KO 0.077
p.drug 1.3e-06




Top 20 genes
Gene KO drug
ITPR1 -11523 -11275
NFATC1 -9218 -9228
NFATC3 -8816 -9310
ITPR2 -7642 -10382
NFATC2 -11381 -6299
PPP3CB -8974 -7138
PPP3R1 -5334 -9996

Click HERE to show all gene set members

All member genes
KO drug
AHCYL1 5721 -10813
CALM1 11329 -6948
ITPR1 -11523 -11275
ITPR2 -7642 -10382
ITPR3 969 -10878
NFATC1 -9218 -9228
NFATC2 -11381 -6299
NFATC3 -8816 -9310
PPP3CA 10840 -10652
PPP3CB -8974 -7138
PPP3R1 -5334 -9996



Cohesin Loading onto Chromatin

Cohesin Loading onto Chromatin
metric value
setSize 10
pMANOVA 1.94e-05
p.adjustMANOVA 6.18e-05
s.dist 0.865
s.KO -0.196
s.drug -0.842
p.KO 0.283
p.drug 3.98e-06




Top 20 genes
Gene KO drug
PDS5A -11384 -10144
RAD21 -8210 -10188
MAU2 -8939 -8256
STAG2 -6812 -10112
PDS5B -5114 -8962
WAPL -2614 -10812

Click HERE to show all gene set members

All member genes
KO drug
MAU2 -8939 -8256
NIPBL 4834 -10197
PDS5A -11384 -10144
PDS5B -5114 -8962
RAD21 -8210 -10188
SMC1A 1268 -9163
SMC3 9009 -7428
STAG1 10689 -8263
STAG2 -6812 -10112
WAPL -2614 -10812



MET activates RAP1 and RAC1

MET activates RAP1 and RAC1
metric value
setSize 11
pMANOVA 1.26e-05
p.adjustMANOVA 4.27e-05
s.dist 0.856
s.KO -0.399
s.drug -0.758
p.KO 0.022
p.drug 1.35e-05




Top 20 genes
Gene KO drug
CRKL -11456 -9981
CRK -11328 -8779
RAPGEF1 -9306 -9048
RAP1B -8213 -8902
GRB2 -6137 -10524
GAB1 -6660 -8223
RAC1 -7472 -3724
HGF -5157 -4177
RAP1A -1904 -6372

Click HERE to show all gene set members

All member genes
KO drug
CRK -11328 -8779
CRKL -11456 -9981
DOCK7 10605 -10745
GAB1 -6660 -8223
GRB2 -6137 -10524
HGF -5157 -4177
MET 10796 -11047
RAC1 -7472 -3724
RAP1A -1904 -6372
RAP1B -8213 -8902
RAPGEF1 -9306 -9048



Syndecan interactions

Syndecan interactions
metric value
setSize 19
pMANOVA 5.07e-10
p.adjustMANOVA 4.45e-09
s.dist 0.844
s.KO 0.216
s.drug -0.816
p.KO 0.104
p.drug 7.21e-10




Top 20 genes
Gene KO drug
ITGB3 12688 -11286
SDC4 12322 -10633
PRKCA 12366 -10396
ITGB5 12503 -10104
ITGB4 12465 -8452
THBS1 12626 -7518
ITGA2 8062 -11213
ACTN1 8122 -10816
SDC1 12230 -7104
SDC3 12401 -6760
ITGAV 144 -11011

Click HERE to show all gene set members

All member genes
KO drug
ACTN1 8122 -10816
CASK -5732 -8641
FGF2 -5091 -5204
ITGA2 8062 -11213
ITGA6 -7384 -11184
ITGAV 144 -11011
ITGB1 -3655 -11215
ITGB3 12688 -11286
ITGB4 12465 -8452
ITGB5 12503 -10104
PRKCA 12366 -10396
SDC1 12230 -7104
SDC2 -6754 -5737
SDC3 12401 -6760
SDC4 12322 -10633
TGFB1 -3526 -8816
THBS1 12626 -7518
TNC -10537 -10838
TRAPPC4 -10355 -4660



Peptide chain elongation

Peptide chain elongation
metric value
setSize 87
pMANOVA 2.79e-43
p.adjustMANOVA 3.4e-41
s.dist 0.83
s.KO -0.422
s.drug 0.715
p.KO 9.35e-12
p.drug 8.26e-31




Top 20 genes
Gene KO drug
RPL22L1 -10448 12221
RPL9 -9659 12806
RPS17 -10534 11631
RPL34 -9357 12996
RPL12 -9329 12992
RPL26L1 -9387 12770
RPS13 -9450 12652
RPS25 -9371 12690
RPL37A -9347 12675
RPS18 -9122 12984
RPL17 -8989 12909
RPL31 -8781 13131
RPS6 -9225 12405
RPS15A -8754 12989
RPL36 -8818 12868
FAU -8610 13102
RPL26 -8797 12658
RPLP2 -8225 12999
RPL11 -8529 12382
RPL35 -8027 13097

Click HERE to show all gene set members

All member genes
KO drug
EEF1A1 -9758 -7439
EEF2 -6416 -8810
FAU -8610 13102
RPL10 -3821 1598
RPL10A -9707 -8212
RPL11 -8529 12382
RPL12 -9329 12992
RPL13 -3469 12598
RPL13A -6854 6955
RPL14 -6386 13137
RPL15 -786 12153
RPL17 -8989 12909
RPL18 -6672 12800
RPL18A -6976 11926
RPL19 3924 12911
RPL21 -6322 5141
RPL22 -5554 9520
RPL22L1 -10448 12221
RPL23 5769 12922
RPL23A 11361 -5257
RPL24 -4591 12995
RPL26 -8797 12658
RPL26L1 -9387 12770
RPL27 6735 11625
RPL27A -7818 13051
RPL28 -5809 12962
RPL29 -4515 12915
RPL3 -6827 -4536
RPL30 -3907 11096
RPL31 -8781 13131
RPL32 -5028 12983
RPL34 -9357 12996
RPL35 -8027 13097
RPL35A -1449 12789
RPL36 -8818 12868
RPL36A -4480 13010
RPL36AL -8216 12702
RPL37 -4624 13134
RPL37A -9347 12675
RPL38 1558 13140
RPL39 -6168 11962
RPL39L -6608 -6269
RPL3L -510 7904
RPL4 11351 12558
RPL41 -4616 -6075
RPL5 4679 12075
RPL6 -6903 12730
RPL7 -3327 -8789
RPL7A -6163 11708
RPL8 -7572 10323
RPL9 -9659 12806
RPLP0 -1504 -7331
RPLP1 9026 12731
RPLP2 -8225 12999
RPS10 -8384 10665
RPS11 -7725 12935
RPS12 -7872 11600
RPS13 -9450 12652
RPS14 -1180 12428
RPS15 -7430 12908
RPS15A -8754 12989
RPS16 -3844 12941
RPS17 -10534 11631
RPS18 -9122 12984
RPS19 -7633 12888
RPS2 -10222 8916
RPS20 -4961 13095
RPS21 -3001 13022
RPS23 6940 11907
RPS24 2369 13034
RPS25 -9371 12690
RPS26 -2615 13114
RPS27 651 11270
RPS27A 5357 6464
RPS27L 7330 12750
RPS28 2716 12485
RPS29 -652 9078
RPS3 -7756 12135
RPS3A -9170 5257
RPS4X -8542 12239
RPS5 -6283 -7965
RPS6 -9225 12405
RPS7 5142 12976
RPS8 -5812 12745
RPS9 -8815 10189
RPSA 292 11576
UBA52 -6807 11639



Viral mRNA Translation

Viral mRNA Translation
metric value
setSize 87
pMANOVA 3.07e-43
p.adjustMANOVA 3.46e-41
s.dist 0.83
s.KO -0.42
s.drug 0.715
p.KO 1.17e-11
p.drug 7.1e-31




Top 20 genes
Gene KO drug
RPL22L1 -10448 12221
RPL9 -9659 12806
RPS17 -10534 11631
RPL34 -9357 12996
RPL12 -9329 12992
RPL26L1 -9387 12770
RPS13 -9450 12652
RPS25 -9371 12690
RPL37A -9347 12675
RPS18 -9122 12984
RPL17 -8989 12909
RPL31 -8781 13131
RPS6 -9225 12405
RPS15A -8754 12989
RPL36 -8818 12868
FAU -8610 13102
RPL26 -8797 12658
RPLP2 -8225 12999
RPL11 -8529 12382
RPL35 -8027 13097

Click HERE to show all gene set members

All member genes
KO drug
DNAJC3 -2895 -7549
FAU -8610 13102
GRSF1 -11152 -7843
RPL10 -3821 1598
RPL10A -9707 -8212
RPL11 -8529 12382
RPL12 -9329 12992
RPL13 -3469 12598
RPL13A -6854 6955
RPL14 -6386 13137
RPL15 -786 12153
RPL17 -8989 12909
RPL18 -6672 12800
RPL18A -6976 11926
RPL19 3924 12911
RPL21 -6322 5141
RPL22 -5554 9520
RPL22L1 -10448 12221
RPL23 5769 12922
RPL23A 11361 -5257
RPL24 -4591 12995
RPL26 -8797 12658
RPL26L1 -9387 12770
RPL27 6735 11625
RPL27A -7818 13051
RPL28 -5809 12962
RPL29 -4515 12915
RPL3 -6827 -4536
RPL30 -3907 11096
RPL31 -8781 13131
RPL32 -5028 12983
RPL34 -9357 12996
RPL35 -8027 13097
RPL35A -1449 12789
RPL36 -8818 12868
RPL36A -4480 13010
RPL36AL -8216 12702
RPL37 -4624 13134
RPL37A -9347 12675
RPL38 1558 13140
RPL39 -6168 11962
RPL39L -6608 -6269
RPL3L -510 7904
RPL4 11351 12558
RPL41 -4616 -6075
RPL5 4679 12075
RPL6 -6903 12730
RPL7 -3327 -8789
RPL7A -6163 11708
RPL8 -7572 10323
RPL9 -9659 12806
RPLP0 -1504 -7331
RPLP1 9026 12731
RPLP2 -8225 12999
RPS10 -8384 10665
RPS11 -7725 12935
RPS12 -7872 11600
RPS13 -9450 12652
RPS14 -1180 12428
RPS15 -7430 12908
RPS15A -8754 12989
RPS16 -3844 12941
RPS17 -10534 11631
RPS18 -9122 12984
RPS19 -7633 12888
RPS2 -10222 8916
RPS20 -4961 13095
RPS21 -3001 13022
RPS23 6940 11907
RPS24 2369 13034
RPS25 -9371 12690
RPS26 -2615 13114
RPS27 651 11270
RPS27A 5357 6464
RPS27L 7330 12750
RPS28 2716 12485
RPS29 -652 9078
RPS3 -7756 12135
RPS3A -9170 5257
RPS4X -8542 12239
RPS5 -6283 -7965
RPS6 -9225 12405
RPS7 5142 12976
RPS8 -5812 12745
RPS9 -8815 10189
RPSA 292 11576
UBA52 -6807 11639



APC truncation mutants have impaired AXIN binding

APC truncation mutants have impaired AXIN binding
metric value
setSize 14
pMANOVA 1.34e-06
p.adjustMANOVA 5.64e-06
s.dist 0.828
s.KO -0.348
s.drug -0.752
p.KO 0.0243
p.drug 1.1e-06




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
CSNK1A1 -9043 -10837
AXIN1 -11360 -7258
AMER1 -7397 -8126
PPP2R5A -4776 -9580
PPP2R1A -9193 -4828
PPP2R5B -8731 -4219
PPP2CA -3124 -7225
PPP2R5E -847 -10491

Click HERE to show all gene set members

All member genes
KO drug
AMER1 -7397 -8126
APC 7962 -10237
AXIN1 -11360 -7258
CSNK1A1 -9043 -10837
GSK3B 7016 -10755
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5A -4776 -9580
PPP2R5B -8731 -4219
PPP2R5C 5890 -5302
PPP2R5D -11383 -11113
PPP2R5E -847 -10491



AXIN missense mutants destabilize the destruction complex

AXIN missense mutants destabilize the destruction complex
metric value
setSize 14
pMANOVA 1.34e-06
p.adjustMANOVA 5.64e-06
s.dist 0.828
s.KO -0.348
s.drug -0.752
p.KO 0.0243
p.drug 1.1e-06




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
CSNK1A1 -9043 -10837
AXIN1 -11360 -7258
AMER1 -7397 -8126
PPP2R5A -4776 -9580
PPP2R1A -9193 -4828
PPP2R5B -8731 -4219
PPP2CA -3124 -7225
PPP2R5E -847 -10491

Click HERE to show all gene set members

All member genes
KO drug
AMER1 -7397 -8126
APC 7962 -10237
AXIN1 -11360 -7258
CSNK1A1 -9043 -10837
GSK3B 7016 -10755
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5A -4776 -9580
PPP2R5B -8731 -4219
PPP2R5C 5890 -5302
PPP2R5D -11383 -11113
PPP2R5E -847 -10491



Signaling by AMER1 mutants

Signaling by AMER1 mutants
metric value
setSize 14
pMANOVA 1.34e-06
p.adjustMANOVA 5.64e-06
s.dist 0.828
s.KO -0.348
s.drug -0.752
p.KO 0.0243
p.drug 1.1e-06




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
CSNK1A1 -9043 -10837
AXIN1 -11360 -7258
AMER1 -7397 -8126
PPP2R5A -4776 -9580
PPP2R1A -9193 -4828
PPP2R5B -8731 -4219
PPP2CA -3124 -7225
PPP2R5E -847 -10491

Click HERE to show all gene set members

All member genes
KO drug
AMER1 -7397 -8126
APC 7962 -10237
AXIN1 -11360 -7258
CSNK1A1 -9043 -10837
GSK3B 7016 -10755
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5A -4776 -9580
PPP2R5B -8731 -4219
PPP2R5C 5890 -5302
PPP2R5D -11383 -11113
PPP2R5E -847 -10491



Signaling by APC mutants

Signaling by APC mutants
metric value
setSize 14
pMANOVA 1.34e-06
p.adjustMANOVA 5.64e-06
s.dist 0.828
s.KO -0.348
s.drug -0.752
p.KO 0.0243
p.drug 1.1e-06




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
CSNK1A1 -9043 -10837
AXIN1 -11360 -7258
AMER1 -7397 -8126
PPP2R5A -4776 -9580
PPP2R1A -9193 -4828
PPP2R5B -8731 -4219
PPP2CA -3124 -7225
PPP2R5E -847 -10491

Click HERE to show all gene set members

All member genes
KO drug
AMER1 -7397 -8126
APC 7962 -10237
AXIN1 -11360 -7258
CSNK1A1 -9043 -10837
GSK3B 7016 -10755
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5A -4776 -9580
PPP2R5B -8731 -4219
PPP2R5C 5890 -5302
PPP2R5D -11383 -11113
PPP2R5E -847 -10491



Signaling by AXIN mutants

Signaling by AXIN mutants
metric value
setSize 14
pMANOVA 1.34e-06
p.adjustMANOVA 5.64e-06
s.dist 0.828
s.KO -0.348
s.drug -0.752
p.KO 0.0243
p.drug 1.1e-06




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
CSNK1A1 -9043 -10837
AXIN1 -11360 -7258
AMER1 -7397 -8126
PPP2R5A -4776 -9580
PPP2R1A -9193 -4828
PPP2R5B -8731 -4219
PPP2CA -3124 -7225
PPP2R5E -847 -10491

Click HERE to show all gene set members

All member genes
KO drug
AMER1 -7397 -8126
APC 7962 -10237
AXIN1 -11360 -7258
CSNK1A1 -9043 -10837
GSK3B 7016 -10755
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5A -4776 -9580
PPP2R5B -8731 -4219
PPP2R5C 5890 -5302
PPP2R5D -11383 -11113
PPP2R5E -847 -10491



Truncations of AMER1 destabilize the destruction complex

Truncations of AMER1 destabilize the destruction complex
metric value
setSize 14
pMANOVA 1.34e-06
p.adjustMANOVA 5.64e-06
s.dist 0.828
s.KO -0.348
s.drug -0.752
p.KO 0.0243
p.drug 1.1e-06




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
CSNK1A1 -9043 -10837
AXIN1 -11360 -7258
AMER1 -7397 -8126
PPP2R5A -4776 -9580
PPP2R1A -9193 -4828
PPP2R5B -8731 -4219
PPP2CA -3124 -7225
PPP2R5E -847 -10491

Click HERE to show all gene set members

All member genes
KO drug
AMER1 -7397 -8126
APC 7962 -10237
AXIN1 -11360 -7258
CSNK1A1 -9043 -10837
GSK3B 7016 -10755
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5A -4776 -9580
PPP2R5B -8731 -4219
PPP2R5C 5890 -5302
PPP2R5D -11383 -11113
PPP2R5E -847 -10491



Laminin interactions

Laminin interactions
metric value
setSize 23
pMANOVA 1.23e-11
p.adjustMANOVA 1.39e-10
s.dist 0.827
s.KO 0.269
s.drug -0.782
p.KO 0.0258
p.drug 8.23e-11




Top 20 genes
Gene KO drug
LAMC1 12854 -11227
LAMB2 12607 -10832
LAMA5 12583 -10447
ITGA1 12258 -10552
LAMA1 12802 -10091
ITGA3 12831 -9596
NID1 9752 -11078
ITGB4 12465 -8452
ITGA7 12807 -7517
ITGA2 8062 -11213
LAMB3 7018 -11255
LAMC2 10786 -6533
COL18A1 10348 -6371
LAMC3 11660 -2369
ITGAV 144 -11011

Click HERE to show all gene set members

All member genes
KO drug
COL18A1 10348 -6371
HSPG2 -9046 -9768
ITGA1 12258 -10552
ITGA2 8062 -11213
ITGA3 12831 -9596
ITGA6 -7384 -11184
ITGA7 12807 -7517
ITGAV 144 -11011
ITGB1 -3655 -11215
ITGB4 12465 -8452
LAMA1 12802 -10091
LAMA2 -8729 -4164
LAMA3 -11238 4464
LAMA4 -7403 -10348
LAMA5 12583 -10447
LAMB1 -9087 -10329
LAMB2 12607 -10832
LAMB3 7018 -11255
LAMC1 12854 -11227
LAMC2 10786 -6533
LAMC3 11660 -2369
NID1 9752 -11078
NID2 -11453 -7028



ERKs are inactivated

ERKs are inactivated
metric value
setSize 13
pMANOVA 4.26e-06
p.adjustMANOVA 1.6e-05
s.dist 0.821
s.KO -0.333
s.drug -0.751
p.KO 0.0374
p.drug 2.76e-06




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
MAPK1 -9173 -10906
MAPK3 -9742 -9271
VRK3 -8775 -7133
DUSP7 -4800 -10041
PPP2R1A -9193 -4828
MAPK7 -7980 -4568
PPP2CA -3124 -7225

Click HERE to show all gene set members

All member genes
KO drug
DUSP3 11933 -9367
DUSP4 2520 -11183
DUSP6 10590 -5904
DUSP7 -4800 -10041
MAPK1 -9173 -10906
MAPK3 -9742 -9271
MAPK7 -7980 -4568
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5D -11383 -11113
VRK3 -8775 -7133



Receptor Mediated Mitophagy

Receptor Mediated Mitophagy
metric value
setSize 11
pMANOVA 2.63e-05
p.adjustMANOVA 8.1e-05
s.dist 0.819
s.KO -0.776
s.drug -0.263
p.KO 8.3e-06
p.drug 0.131




Top 20 genes
Gene KO drug
CSNK2A1 -10604 -10586
CSNK2A2 -9949 -10332
SRC -11388 -7284
ULK1 -10494 -7342
ATG5 -7565 -7228
PGAM5 -10817 -4475
ATG12 -4585 -5690
MAP1LC3B -9817 -1760

Click HERE to show all gene set members

All member genes
KO drug
ATG12 -4585 -5690
ATG5 -7565 -7228
CSNK2A1 -10604 -10586
CSNK2A2 -9949 -10332
CSNK2B -9249 12011
FUNDC1 -3096 9106
MAP1LC3A -9431 8671
MAP1LC3B -9817 -1760
PGAM5 -10817 -4475
SRC -11388 -7284
ULK1 -10494 -7342



S33 mutants of beta-catenin aren’t phosphorylated

S33 mutants of beta-catenin aren’t phosphorylated
metric value
setSize 15
pMANOVA 7.71e-07
p.adjustMANOVA 3.45e-06
s.dist 0.811
s.KO -0.26
s.drug -0.768
p.KO 0.0808
p.drug 2.62e-07




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
CSNK1A1 -9043 -10837
AXIN1 -11360 -7258
AMER1 -7397 -8126
PPP2R5A -4776 -9580
PPP2R1A -9193 -4828
PPP2R5B -8731 -4219
PPP2CA -3124 -7225
PPP2R5E -847 -10491

Click HERE to show all gene set members

All member genes
KO drug
AMER1 -7397 -8126
APC 7962 -10237
AXIN1 -11360 -7258
CSNK1A1 -9043 -10837
CTNNB1 12434 -11116
GSK3B 7016 -10755
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5A -4776 -9580
PPP2R5B -8731 -4219
PPP2R5C 5890 -5302
PPP2R5D -11383 -11113
PPP2R5E -847 -10491



S37 mutants of beta-catenin aren’t phosphorylated

S37 mutants of beta-catenin aren’t phosphorylated
metric value
setSize 15
pMANOVA 7.71e-07
p.adjustMANOVA 3.45e-06
s.dist 0.811
s.KO -0.26
s.drug -0.768
p.KO 0.0808
p.drug 2.62e-07




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
CSNK1A1 -9043 -10837
AXIN1 -11360 -7258
AMER1 -7397 -8126
PPP2R5A -4776 -9580
PPP2R1A -9193 -4828
PPP2R5B -8731 -4219
PPP2CA -3124 -7225
PPP2R5E -847 -10491

Click HERE to show all gene set members

All member genes
KO drug
AMER1 -7397 -8126
APC 7962 -10237
AXIN1 -11360 -7258
CSNK1A1 -9043 -10837
CTNNB1 12434 -11116
GSK3B 7016 -10755
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5A -4776 -9580
PPP2R5B -8731 -4219
PPP2R5C 5890 -5302
PPP2R5D -11383 -11113
PPP2R5E -847 -10491



S45 mutants of beta-catenin aren’t phosphorylated

S45 mutants of beta-catenin aren’t phosphorylated
metric value
setSize 15
pMANOVA 7.71e-07
p.adjustMANOVA 3.45e-06
s.dist 0.811
s.KO -0.26
s.drug -0.768
p.KO 0.0808
p.drug 2.62e-07




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
CSNK1A1 -9043 -10837
AXIN1 -11360 -7258
AMER1 -7397 -8126
PPP2R5A -4776 -9580
PPP2R1A -9193 -4828
PPP2R5B -8731 -4219
PPP2CA -3124 -7225
PPP2R5E -847 -10491

Click HERE to show all gene set members

All member genes
KO drug
AMER1 -7397 -8126
APC 7962 -10237
AXIN1 -11360 -7258
CSNK1A1 -9043 -10837
CTNNB1 12434 -11116
GSK3B 7016 -10755
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5A -4776 -9580
PPP2R5B -8731 -4219
PPP2R5C 5890 -5302
PPP2R5D -11383 -11113
PPP2R5E -847 -10491



Signaling by CTNNB1 phospho-site mutants

Signaling by CTNNB1 phospho-site mutants
metric value
setSize 15
pMANOVA 7.71e-07
p.adjustMANOVA 3.45e-06
s.dist 0.811
s.KO -0.26
s.drug -0.768
p.KO 0.0808
p.drug 2.62e-07




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
CSNK1A1 -9043 -10837
AXIN1 -11360 -7258
AMER1 -7397 -8126
PPP2R5A -4776 -9580
PPP2R1A -9193 -4828
PPP2R5B -8731 -4219
PPP2CA -3124 -7225
PPP2R5E -847 -10491

Click HERE to show all gene set members

All member genes
KO drug
AMER1 -7397 -8126
APC 7962 -10237
AXIN1 -11360 -7258
CSNK1A1 -9043 -10837
CTNNB1 12434 -11116
GSK3B 7016 -10755
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5A -4776 -9580
PPP2R5B -8731 -4219
PPP2R5C 5890 -5302
PPP2R5D -11383 -11113
PPP2R5E -847 -10491



Signaling by GSK3beta mutants

Signaling by GSK3beta mutants
metric value
setSize 15
pMANOVA 7.71e-07
p.adjustMANOVA 3.45e-06
s.dist 0.811
s.KO -0.26
s.drug -0.768
p.KO 0.0808
p.drug 2.62e-07




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
CSNK1A1 -9043 -10837
AXIN1 -11360 -7258
AMER1 -7397 -8126
PPP2R5A -4776 -9580
PPP2R1A -9193 -4828
PPP2R5B -8731 -4219
PPP2CA -3124 -7225
PPP2R5E -847 -10491

Click HERE to show all gene set members

All member genes
KO drug
AMER1 -7397 -8126
APC 7962 -10237
AXIN1 -11360 -7258
CSNK1A1 -9043 -10837
CTNNB1 12434 -11116
GSK3B 7016 -10755
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5A -4776 -9580
PPP2R5B -8731 -4219
PPP2R5C 5890 -5302
PPP2R5D -11383 -11113
PPP2R5E -847 -10491



T41 mutants of beta-catenin aren’t phosphorylated

T41 mutants of beta-catenin aren’t phosphorylated
metric value
setSize 15
pMANOVA 7.71e-07
p.adjustMANOVA 3.45e-06
s.dist 0.811
s.KO -0.26
s.drug -0.768
p.KO 0.0808
p.drug 2.62e-07




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
CSNK1A1 -9043 -10837
AXIN1 -11360 -7258
AMER1 -7397 -8126
PPP2R5A -4776 -9580
PPP2R1A -9193 -4828
PPP2R5B -8731 -4219
PPP2CA -3124 -7225
PPP2R5E -847 -10491

Click HERE to show all gene set members

All member genes
KO drug
AMER1 -7397 -8126
APC 7962 -10237
AXIN1 -11360 -7258
CSNK1A1 -9043 -10837
CTNNB1 12434 -11116
GSK3B 7016 -10755
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5A -4776 -9580
PPP2R5B -8731 -4219
PPP2R5C 5890 -5302
PPP2R5D -11383 -11113
PPP2R5E -847 -10491



Mucopolysaccharidoses

Mucopolysaccharidoses
metric value
setSize 11
pMANOVA 1.36e-05
p.adjustMANOVA 4.58e-05
s.dist 0.799
s.KO 0.756
s.drug -0.258
p.KO 1.41e-05
p.drug 0.138




Top 20 genes
Gene KO drug
GNS 11099 -11125
GLB1 10162 -9240
ARSB 12086 -7494
IDS 8178 -10132
GALNS 11751 -6370
NAGLU 12163 -5299
HGSNAT 6442 -3959

Click HERE to show all gene set members

All member genes
KO drug
ARSB 12086 -7494
GALNS 11751 -6370
GLB1 10162 -9240
GNS 11099 -11125
GUSB 9430 8910
HGSNAT 6442 -3959
HYAL1 4794 556
IDS 8178 -10132
IDUA 11538 11620
NAGLU 12163 -5299
SGSH 11466 8231



Defective EXT1 causes exostoses 1, TRPS2 and CHDS

Defective EXT1 causes exostoses 1, TRPS2 and CHDS
metric value
setSize 13
pMANOVA 1.43e-06
p.adjustMANOVA 5.93e-06
s.dist 0.799
s.KO 0.358
s.drug -0.714
p.KO 0.0255
p.drug 8.23e-06




Top 20 genes
Gene KO drug
AGRN 12518 -11205
SDC4 12322 -10633
EXT2 11023 -9224
GPC4 11190 -8942
SDC1 12230 -7104
SDC3 12401 -6760
EXT1 10114 -6275
GPC5 7673 -3135
GPC1 1951 -7922

Click HERE to show all gene set members

All member genes
KO drug
AGRN 12518 -11205
EXT1 10114 -6275
EXT2 11023 -9224
GPC1 1951 -7922
GPC2 -3913 -3279
GPC4 11190 -8942
GPC5 7673 -3135
GPC6 -6095 -11229
HSPG2 -9046 -9768
SDC1 12230 -7104
SDC2 -6754 -5737
SDC3 12401 -6760
SDC4 12322 -10633



Defective EXT2 causes exostoses 2

Defective EXT2 causes exostoses 2
metric value
setSize 13
pMANOVA 1.43e-06
p.adjustMANOVA 5.93e-06
s.dist 0.799
s.KO 0.358
s.drug -0.714
p.KO 0.0255
p.drug 8.23e-06




Top 20 genes
Gene KO drug
AGRN 12518 -11205
SDC4 12322 -10633
EXT2 11023 -9224
GPC4 11190 -8942
SDC1 12230 -7104
SDC3 12401 -6760
EXT1 10114 -6275
GPC5 7673 -3135
GPC1 1951 -7922

Click HERE to show all gene set members

All member genes
KO drug
AGRN 12518 -11205
EXT1 10114 -6275
EXT2 11023 -9224
GPC1 1951 -7922
GPC2 -3913 -3279
GPC4 11190 -8942
GPC5 7673 -3135
GPC6 -6095 -11229
HSPG2 -9046 -9768
SDC1 12230 -7104
SDC2 -6754 -5737
SDC3 12401 -6760
SDC4 12322 -10633



Establishment of Sister Chromatid Cohesion

Establishment of Sister Chromatid Cohesion
metric value
setSize 11
pMANOVA 5.26e-05
p.adjustMANOVA 0.000153
s.dist 0.795
s.KO -0.298
s.drug -0.737
p.KO 0.0865
p.drug 2.3e-05




Top 20 genes
Gene KO drug
PDS5A -11384 -10144
RAD21 -8210 -10188
ESCO1 -7849 -9245
STAG2 -6812 -10112
PDS5B -5114 -8962
WAPL -2614 -10812
ESCO2 -5830 -3862
CDCA5 -5906 -564

Click HERE to show all gene set members

All member genes
KO drug
CDCA5 -5906 -564
ESCO1 -7849 -9245
ESCO2 -5830 -3862
PDS5A -11384 -10144
PDS5B -5114 -8962
RAD21 -8210 -10188
SMC1A 1268 -9163
SMC3 9009 -7428
STAG1 10689 -8263
STAG2 -6812 -10112
WAPL -2614 -10812



Eukaryotic Translation Termination

Eukaryotic Translation Termination
metric value
setSize 91
pMANOVA 2.19e-41
p.adjustMANOVA 1.89e-39
s.dist 0.794
s.KO -0.402
s.drug 0.684
p.KO 3.27e-11
p.drug 1.32e-29




Top 20 genes
Gene KO drug
RPL22L1 -10448 12221
RPL9 -9659 12806
RPS17 -10534 11631
RPL34 -9357 12996
RPL12 -9329 12992
RPL26L1 -9387 12770
RPS13 -9450 12652
RPS25 -9371 12690
RPL37A -9347 12675
RPS18 -9122 12984
RPL17 -8989 12909
RPL31 -8781 13131
RPS6 -9225 12405
RPS15A -8754 12989
RPL36 -8818 12868
FAU -8610 13102
RPL26 -8797 12658
RPLP2 -8225 12999
RPL11 -8529 12382
RPL35 -8027 13097

Click HERE to show all gene set members

All member genes
KO drug
APEH 9298 -8571
ETF1 -5515 -9496
FAU -8610 13102
GSPT1 -11018 -10261
GSPT2 -5509 -6727
N6AMT1 7099 10581
RPL10 -3821 1598
RPL10A -9707 -8212
RPL11 -8529 12382
RPL12 -9329 12992
RPL13 -3469 12598
RPL13A -6854 6955
RPL14 -6386 13137
RPL15 -786 12153
RPL17 -8989 12909
RPL18 -6672 12800
RPL18A -6976 11926
RPL19 3924 12911
RPL21 -6322 5141
RPL22 -5554 9520
RPL22L1 -10448 12221
RPL23 5769 12922
RPL23A 11361 -5257
RPL24 -4591 12995
RPL26 -8797 12658
RPL26L1 -9387 12770
RPL27 6735 11625
RPL27A -7818 13051
RPL28 -5809 12962
RPL29 -4515 12915
RPL3 -6827 -4536
RPL30 -3907 11096
RPL31 -8781 13131
RPL32 -5028 12983
RPL34 -9357 12996
RPL35 -8027 13097
RPL35A -1449 12789
RPL36 -8818 12868
RPL36A -4480 13010
RPL36AL -8216 12702
RPL37 -4624 13134
RPL37A -9347 12675
RPL38 1558 13140
RPL39 -6168 11962
RPL39L -6608 -6269
RPL3L -510 7904
RPL4 11351 12558
RPL41 -4616 -6075
RPL5 4679 12075
RPL6 -6903 12730
RPL7 -3327 -8789
RPL7A -6163 11708
RPL8 -7572 10323
RPL9 -9659 12806
RPLP0 -1504 -7331
RPLP1 9026 12731
RPLP2 -8225 12999
RPS10 -8384 10665
RPS11 -7725 12935
RPS12 -7872 11600
RPS13 -9450 12652
RPS14 -1180 12428
RPS15 -7430 12908
RPS15A -8754 12989
RPS16 -3844 12941
RPS17 -10534 11631
RPS18 -9122 12984
RPS19 -7633 12888
RPS2 -10222 8916
RPS20 -4961 13095
RPS21 -3001 13022
RPS23 6940 11907
RPS24 2369 13034
RPS25 -9371 12690
RPS26 -2615 13114
RPS27 651 11270
RPS27A 5357 6464
RPS27L 7330 12750
RPS28 2716 12485
RPS29 -652 9078
RPS3 -7756 12135
RPS3A -9170 5257
RPS4X -8542 12239
RPS5 -6283 -7965
RPS6 -9225 12405
RPS7 5142 12976
RPS8 -5812 12745
RPS9 -8815 10189
RPSA 292 11576
TRMT112 -5741 13057
UBA52 -6807 11639



Eukaryotic Translation Elongation

Eukaryotic Translation Elongation
metric value
setSize 92
pMANOVA 1.82e-41
p.adjustMANOVA 1.67e-39
s.dist 0.79
s.KO -0.412
s.drug 0.674
p.KO 8.16e-12
p.drug 4.97e-29




Top 20 genes
Gene KO drug
RPL22L1 -10448 12221
RPL9 -9659 12806
RPS17 -10534 11631
RPL34 -9357 12996
RPL12 -9329 12992
RPL26L1 -9387 12770
RPS13 -9450 12652
RPS25 -9371 12690
RPL37A -9347 12675
RPS18 -9122 12984
RPL17 -8989 12909
RPL31 -8781 13131
RPS6 -9225 12405
RPS15A -8754 12989
RPL36 -8818 12868
FAU -8610 13102
RPL26 -8797 12658
RPLP2 -8225 12999
RPL11 -8529 12382
RPL35 -8027 13097

Click HERE to show all gene set members

All member genes
KO drug
EEF1A1 -9758 -7439
EEF1A1P5 -2416 -8237
EEF1A2 11418 -3449
EEF1B2 -9424 8464
EEF1D -2336 11037
EEF1G -7846 -5785
EEF2 -6416 -8810
FAU -8610 13102
RPL10 -3821 1598
RPL10A -9707 -8212
RPL11 -8529 12382
RPL12 -9329 12992
RPL13 -3469 12598
RPL13A -6854 6955
RPL14 -6386 13137
RPL15 -786 12153
RPL17 -8989 12909
RPL18 -6672 12800
RPL18A -6976 11926
RPL19 3924 12911
RPL21 -6322 5141
RPL22 -5554 9520
RPL22L1 -10448 12221
RPL23 5769 12922
RPL23A 11361 -5257
RPL24 -4591 12995
RPL26 -8797 12658
RPL26L1 -9387 12770
RPL27 6735 11625
RPL27A -7818 13051
RPL28 -5809 12962
RPL29 -4515 12915
RPL3 -6827 -4536
RPL30 -3907 11096
RPL31 -8781 13131
RPL32 -5028 12983
RPL34 -9357 12996
RPL35 -8027 13097
RPL35A -1449 12789
RPL36 -8818 12868
RPL36A -4480 13010
RPL36AL -8216 12702
RPL37 -4624 13134
RPL37A -9347 12675
RPL38 1558 13140
RPL39 -6168 11962
RPL39L -6608 -6269
RPL3L -510 7904
RPL4 11351 12558
RPL41 -4616 -6075
RPL5 4679 12075
RPL6 -6903 12730
RPL7 -3327 -8789
RPL7A -6163 11708
RPL8 -7572 10323
RPL9 -9659 12806
RPLP0 -1504 -7331
RPLP1 9026 12731
RPLP2 -8225 12999
RPS10 -8384 10665
RPS11 -7725 12935
RPS12 -7872 11600
RPS13 -9450 12652
RPS14 -1180 12428
RPS15 -7430 12908
RPS15A -8754 12989
RPS16 -3844 12941
RPS17 -10534 11631
RPS18 -9122 12984
RPS19 -7633 12888
RPS2 -10222 8916
RPS20 -4961 13095
RPS21 -3001 13022
RPS23 6940 11907
RPS24 2369 13034
RPS25 -9371 12690
RPS26 -2615 13114
RPS27 651 11270
RPS27A 5357 6464
RPS27L 7330 12750
RPS28 2716 12485
RPS29 -652 9078
RPS3 -7756 12135
RPS3A -9170 5257
RPS4X -8542 12239
RPS5 -6283 -7965
RPS6 -9225 12405
RPS7 5142 12976
RPS8 -5812 12745
RPS9 -8815 10189
RPSA 292 11576
UBA52 -6807 11639



Formation of a pool of free 40S subunits

Formation of a pool of free 40S subunits
metric value
setSize 99
pMANOVA 1.26e-44
p.adjustMANOVA 1.68e-42
s.dist 0.789
s.KO -0.444
s.drug 0.652
p.KO 2.03e-14
p.drug 3.21e-29




Top 20 genes
Gene KO drug
RPL22L1 -10448 12221
RPL9 -9659 12806
RPS17 -10534 11631
RPL34 -9357 12996
RPL12 -9329 12992
RPL26L1 -9387 12770
RPS13 -9450 12652
RPS25 -9371 12690
RPL37A -9347 12675
RPS18 -9122 12984
RPL17 -8989 12909
RPL31 -8781 13131
RPS6 -9225 12405
RPS15A -8754 12989
RPL36 -8818 12868
FAU -8610 13102
RPL26 -8797 12658
RPLP2 -8225 12999
RPL11 -8529 12382
RPL35 -8027 13097

Click HERE to show all gene set members

All member genes
KO drug
EIF1AX -5479 11112
EIF3A -5233 -9195
EIF3B -4779 -8277
EIF3C -8843 11244
EIF3D -10400 -7621
EIF3E -9070 10545
EIF3F -1343 -5879
EIF3G -7655 4326
EIF3H -8110 -1879
EIF3I -7897 12235
EIF3J -4825 -4367
EIF3K -2668 9951
EIF3L -9160 -8016
EIF3M -10718 9044
FAU -8610 13102
RPL10 -3821 1598
RPL10A -9707 -8212
RPL11 -8529 12382
RPL12 -9329 12992
RPL13 -3469 12598
RPL13A -6854 6955
RPL14 -6386 13137
RPL15 -786 12153
RPL17 -8989 12909
RPL18 -6672 12800
RPL18A -6976 11926
RPL19 3924 12911
RPL21 -6322 5141
RPL22 -5554 9520
RPL22L1 -10448 12221
RPL23 5769 12922
RPL23A 11361 -5257
RPL24 -4591 12995
RPL26 -8797 12658
RPL26L1 -9387 12770
RPL27 6735 11625
RPL27A -7818 13051
RPL28 -5809 12962
RPL29 -4515 12915
RPL3 -6827 -4536
RPL30 -3907 11096
RPL31 -8781 13131
RPL32 -5028 12983
RPL34 -9357 12996
RPL35 -8027 13097
RPL35A -1449 12789
RPL36 -8818 12868
RPL36A -4480 13010
RPL36AL -8216 12702
RPL37 -4624 13134
RPL37A -9347 12675
RPL38 1558 13140
RPL39 -6168 11962
RPL39L -6608 -6269
RPL3L -510 7904
RPL4 11351 12558
RPL41 -4616 -6075
RPL5 4679 12075
RPL6 -6903 12730
RPL7 -3327 -8789
RPL7A -6163 11708
RPL8 -7572 10323
RPL9 -9659 12806
RPLP0 -1504 -7331
RPLP1 9026 12731
RPLP2 -8225 12999
RPS10 -8384 10665
RPS11 -7725 12935
RPS12 -7872 11600
RPS13 -9450 12652
RPS14 -1180 12428
RPS15 -7430 12908
RPS15A -8754 12989
RPS16 -3844 12941
RPS17 -10534 11631
RPS18 -9122 12984
RPS19 -7633 12888
RPS2 -10222 8916
RPS20 -4961 13095
RPS21 -3001 13022
RPS23 6940 11907
RPS24 2369 13034
RPS25 -9371 12690
RPS26 -2615 13114
RPS27 651 11270
RPS27A 5357 6464
RPS27L 7330 12750
RPS28 2716 12485
RPS29 -652 9078
RPS3 -7756 12135
RPS3A -9170 5257
RPS4X -8542 12239
RPS5 -6283 -7965
RPS6 -9225 12405
RPS7 5142 12976
RPS8 -5812 12745
RPS9 -8815 10189
RPSA 292 11576
UBA52 -6807 11639



Signaling by Hippo

Signaling by Hippo
metric value
setSize 20
pMANOVA 1.9e-08
p.adjustMANOVA 1.19e-07
s.dist 0.781
s.KO -0.162
s.drug -0.764
p.KO 0.209
p.drug 3.23e-09




Top 20 genes
Gene KO drug
STK4 -10071 -9177
AMOTL2 -9439 -9139
AMOTL1 -7699 -11147
CASP3 -10552 -8110
LATS1 -8149 -10122
DVL2 -9629 -6902
YAP1 -5571 -10960
MOB1B -7457 -8165
STK3 -6242 -7825
SAV1 -3497 -9467
NPHP4 -2565 -6207

Click HERE to show all gene set members

All member genes
KO drug
AMOT 7703 -10465
AMOTL1 -7699 -11147
AMOTL2 -9439 -9139
CASP3 -10552 -8110
DVL2 -9629 -6902
LATS1 -8149 -10122
LATS2 11787 -9234
MOB1A 2732 -9207
MOB1B -7457 -8165
NPHP4 -2565 -6207
SAV1 -3497 -9467
STK3 -6242 -7825
STK4 -10071 -9177
TJP1 11775 -10865
TJP2 6248 -10022
WWC1 2910 -5030
WWTR1 10572 -10736
YAP1 -5571 -10960
YWHAB 11096 -6543
YWHAE -10212 1399



Synthesis of PIPs at the early endosome membrane

Synthesis of PIPs at the early endosome membrane
metric value
setSize 16
pMANOVA 1.36e-06
p.adjustMANOVA 5.69e-06
s.dist 0.773
s.KO -0.298
s.drug -0.713
p.KO 0.0391
p.drug 7.87e-07




Top 20 genes
Gene KO drug
MTMR12 -10618 -11138
PIKFYVE -10388 -10306
VAC14 -9751 -7774
PIK3C3 -8170 -7865
INPP4A -6949 -8897
MTMR2 -6094 -9336
PIK3C2A -5604 -9519
INPP5F -6267 -8385
PI4K2A -7282 -6755
MTMR4 -4934 -8877
MTM1 -4584 -7808
PI4K2B -4371 -7468

Click HERE to show all gene set members

All member genes
KO drug
FIG4 10135 -5525
INPP4A -6949 -8897
INPP4B 7799 1151
INPP5F -6267 -8385
MTM1 -4584 -7808
MTMR10 9939 -6395
MTMR12 -10618 -11138
MTMR2 -6094 -9336
MTMR4 -4934 -8877
PI4K2A -7282 -6755
PI4K2B -4371 -7468
PIK3C2A -5604 -9519
PIK3C3 -8170 -7865
PIK3R4 9611 -9422
PIKFYVE -10388 -10306
VAC14 -9751 -7774



Synthesis of PIPs at the late endosome membrane

Synthesis of PIPs at the late endosome membrane
metric value
setSize 11
pMANOVA 0.000109
p.adjustMANOVA 0.000294
s.dist 0.771
s.KO -0.383
s.drug -0.67
p.KO 0.0278
p.drug 0.00012




Top 20 genes
Gene KO drug
PIKFYVE -10388 -10306
MTMR9 -9350 -8112
VAC14 -9751 -7774
PIK3C3 -8170 -7865
MTMR2 -6094 -9336
PIK3C2A -5604 -9519
MTMR4 -4934 -8877
MTM1 -4584 -7808

Click HERE to show all gene set members

All member genes
KO drug
FIG4 10135 -5525
MTM1 -4584 -7808
MTMR2 -6094 -9336
MTMR4 -4934 -8877
MTMR7 -5015 4886
MTMR9 -9350 -8112
PIK3C2A -5604 -9519
PIK3C3 -8170 -7865
PIK3R4 9611 -9422
PIKFYVE -10388 -10306
VAC14 -9751 -7774



HDMs demethylate histones

HDMs demethylate histones
metric value
setSize 22
pMANOVA 1.14e-08
p.adjustMANOVA 7.46e-08
s.dist 0.771
s.KO -0.358
s.drug -0.683
p.KO 0.00361
p.drug 2.94e-08




Top 20 genes
Gene KO drug
KDM7A -11295 -10173
KDM1B -9446 -10808
KDM1A -10032 -9331
KDM6A -9651 -8938
KDM2A -11020 -7679
KDM2B -10344 -8038
KDM4B -6893 -10084
KDM5C -7030 -9378
PHF8 -8404 -7628
KDM3A -9030 -6941
PHF2 -10182 -5776
JMJD6 -6552 -8458
KDM4C -2464 -10800
KDM6B -2868 -8061
KDM4D -364 -5384

Click HERE to show all gene set members

All member genes
KO drug
ARID5B 686.0 -6056.0
H3C1 -1179.0 2773.0
H3C15 2532.5 7678.5
JMJD6 -6552.0 -8458.0
KDM1A -10032.0 -9331.0
KDM1B -9446.0 -10808.0
KDM2A -11020.0 -7679.0
KDM2B -10344.0 -8038.0
KDM3A -9030.0 -6941.0
KDM3B 11164.0 -9930.0
KDM4A 9104.0 -8480.0
KDM4B -6893.0 -10084.0
KDM4C -2464.0 -10800.0
KDM4D -364.0 -5384.0
KDM5A 7125.0 -10180.0
KDM5B 4544.0 -11091.0
KDM5C -7030.0 -9378.0
KDM6A -9651.0 -8938.0
KDM6B -2868.0 -8061.0
KDM7A -11295.0 -10173.0
PHF2 -10182.0 -5776.0
PHF8 -8404.0 -7628.0



Unwinding of DNA

Unwinding of DNA
metric value
setSize 12
pMANOVA 5.5e-05
p.adjustMANOVA 0.00016
s.dist 0.77
s.KO 0.603
s.drug 0.48
p.KO 0.000299
p.drug 0.00402




Top 20 genes
Gene KO drug
MCM3 12292 11486
GINS2 11246 12341
MCM8 11436 11881
MCM5 11258 11775
CDC45 10231 12211
GINS3 9481 10673
GINS1 11040 5510
GINS4 11290 5284
MCM4 12194 780

Click HERE to show all gene set members

All member genes
KO drug
CDC45 10231 12211
GINS1 11040 5510
GINS2 11246 12341
GINS3 9481 10673
GINS4 11290 5284
MCM2 12294 -4587
MCM3 12292 11486
MCM4 12194 780
MCM5 11258 11775
MCM6 -9260 -5270
MCM7 -6963 9667
MCM8 11436 11881



Activation of RAC1

Activation of RAC1
metric value
setSize 13
pMANOVA 2.04e-05
p.adjustMANOVA 6.47e-05
s.dist 0.77
s.KO -0.34
s.drug -0.69
p.KO 0.0336
p.drug 1.63e-05




Top 20 genes
Gene KO drug
PAK1 -11464 -9735
SLIT2 -11365 -9218
NCK1 -9577 -9993
SOS1 -7259 -9921
NCK2 -10111 -6626
PAK2 -6371 -10285
PAK4 -8948 -6862
ROBO1 -4716 -10678
RAC1 -7472 -3724

Click HERE to show all gene set members

All member genes
KO drug
NCK1 -9577 -9993
NCK2 -10111 -6626
PAK1 -11464 -9735
PAK2 -6371 -10285
PAK3 9899 -7417
PAK4 -8948 -6862
PAK5 10389 -4026
PAK6 1878 388
RAC1 -7472 -3724
ROBO1 -4716 -10678
SLIT2 -11365 -9218
SOS1 -7259 -9921
SOS2 9761 -9317



Selenocysteine synthesis

Selenocysteine synthesis
metric value
setSize 91
pMANOVA 1.38e-38
p.adjustMANOVA 8.77e-37
s.dist 0.768
s.KO -0.355
s.drug 0.681
p.KO 4.6e-09
p.drug 2.66e-29




Top 20 genes
Gene KO drug
RPL22L1 -10448 12221
RPL9 -9659 12806
RPS17 -10534 11631
RPL34 -9357 12996
RPL12 -9329 12992
RPL26L1 -9387 12770
RPS13 -9450 12652
RPS25 -9371 12690
RPL37A -9347 12675
RPS18 -9122 12984
RPL17 -8989 12909
RPL31 -8781 13131
RPS6 -9225 12405
RPS15A -8754 12989
RPL36 -8818 12868
FAU -8610 13102
RPL26 -8797 12658
RPLP2 -8225 12999
RPL11 -8529 12382
RPL35 -8027 13097

Click HERE to show all gene set members

All member genes
KO drug
EEFSEC 11184 -3492
FAU -8610 13102
PSTK 5756 9314
RPL10 -3821 1598
RPL10A -9707 -8212
RPL11 -8529 12382
RPL12 -9329 12992
RPL13 -3469 12598
RPL13A -6854 6955
RPL14 -6386 13137
RPL15 -786 12153
RPL17 -8989 12909
RPL18 -6672 12800
RPL18A -6976 11926
RPL19 3924 12911
RPL21 -6322 5141
RPL22 -5554 9520
RPL22L1 -10448 12221
RPL23 5769 12922
RPL23A 11361 -5257
RPL24 -4591 12995
RPL26 -8797 12658
RPL26L1 -9387 12770
RPL27 6735 11625
RPL27A -7818 13051
RPL28 -5809 12962
RPL29 -4515 12915
RPL3 -6827 -4536
RPL30 -3907 11096
RPL31 -8781 13131
RPL32 -5028 12983
RPL34 -9357 12996
RPL35 -8027 13097
RPL35A -1449 12789
RPL36 -8818 12868
RPL36A -4480 13010
RPL36AL -8216 12702
RPL37 -4624 13134
RPL37A -9347 12675
RPL38 1558 13140
RPL39 -6168 11962
RPL39L -6608 -6269
RPL3L -510 7904
RPL4 11351 12558
RPL41 -4616 -6075
RPL5 4679 12075
RPL6 -6903 12730
RPL7 -3327 -8789
RPL7A -6163 11708
RPL8 -7572 10323
RPL9 -9659 12806
RPLP0 -1504 -7331
RPLP1 9026 12731
RPLP2 -8225 12999
RPS10 -8384 10665
RPS11 -7725 12935
RPS12 -7872 11600
RPS13 -9450 12652
RPS14 -1180 12428
RPS15 -7430 12908
RPS15A -8754 12989
RPS16 -3844 12941
RPS17 -10534 11631
RPS18 -9122 12984
RPS19 -7633 12888
RPS2 -10222 8916
RPS20 -4961 13095
RPS21 -3001 13022
RPS23 6940 11907
RPS24 2369 13034
RPS25 -9371 12690
RPS26 -2615 13114
RPS27 651 11270
RPS27A 5357 6464
RPS27L 7330 12750
RPS28 2716 12485
RPS29 -652 9078
RPS3 -7756 12135
RPS3A -9170 5257
RPS4X -8542 12239
RPS5 -6283 -7965
RPS6 -9225 12405
RPS7 5142 12976
RPS8 -5812 12745
RPS9 -8815 10189
RPSA 292 11576
SARS1 10748 -9421
SECISBP2 11207 -6517
SEPHS2 8103 -351
SEPSECS -6443 -5096
UBA52 -6807 11639



Cell-extracellular matrix interactions

Cell-extracellular matrix interactions
metric value
setSize 16
pMANOVA 2.2e-06
p.adjustMANOVA 8.89e-06
s.dist 0.766
s.KO -0.418
s.drug -0.642
p.KO 0.00377
p.drug 8.63e-06




Top 20 genes
Gene KO drug
FLNC -11176 -11224
FLNA -11044 -11244
FERMT2 -9974 -11051
PARVB -9605 -8758
PXN -9307 -8111
LIMS1 -6324 -10598
VASP -9209 -6573
ILK -8271 -6696
ITGB1 -3655 -11215
LIMS2 -5134 -4517
PARVA -2258 -6707

Click HERE to show all gene set members

All member genes
KO drug
ACTN1 8122 -10816
ARHGEF6 10171 -7583
FBLIM1 12771 -9890
FERMT2 -9974 -11051
FLNA -11044 -11244
FLNC -11176 -11224
ILK -8271 -6696
ITGB1 -3655 -11215
LIMS1 -6324 -10598
LIMS2 -5134 -4517
PARVA -2258 -6707
PARVB -9605 -8758
PXN -9307 -8111
RSU1 -5575 5754
TESK1 -10587 8733
VASP -9209 -6573



MET activates PTK2 signaling

MET activates PTK2 signaling
metric value
setSize 18
pMANOVA 6.8e-08
p.adjustMANOVA 3.72e-07
s.dist 0.765
s.KO 0.155
s.drug -0.749
p.KO 0.256
p.drug 3.71e-08




Top 20 genes
Gene KO drug
LAMC1 12854 -11227
LAMB2 12607 -10832
LAMA5 12583 -10447
LAMA1 12802 -10091
ITGA3 12831 -9596
MET 10796 -11047
ITGA2 8062 -11213
LAMB3 7018 -11255
LAMC2 10786 -6533
LAMC3 11660 -2369

Click HERE to show all gene set members

All member genes
KO drug
HGF -5157 -4177
ITGA2 8062 -11213
ITGA3 12831 -9596
ITGB1 -3655 -11215
LAMA1 12802 -10091
LAMA2 -8729 -4164
LAMA3 -11238 4464
LAMA4 -7403 -10348
LAMA5 12583 -10447
LAMB1 -9087 -10329
LAMB2 12607 -10832
LAMB3 7018 -11255
LAMC1 12854 -11227
LAMC2 10786 -6533
LAMC3 11660 -2369
MET 10796 -11047
PTK2 -9167 -10148
SRC -11388 -7284



Signaling by PDGFRA extracellular domain mutants

Signaling by PDGFRA extracellular domain mutants
metric value
setSize 12
pMANOVA 4.81e-05
p.adjustMANOVA 0.000141
s.dist 0.763
s.KO -0.263
s.drug -0.716
p.KO 0.114
p.drug 1.74e-05




Top 20 genes
Gene KO drug
PDGFRA -11424 -11082
PIK3CB -9217 -10250
STAT1 -8311 -10243
SOS1 -7259 -9921
GRB2 -6137 -10524
PIK3CA -5426 -9599
PIK3R2 -6506 -5848
NRAS -3309 -9724

Click HERE to show all gene set members

All member genes
KO drug
GRB2 -6137 -10524
HRAS -8054 12320
KRAS 12719 -8619
NRAS -3309 -9724
PDGFRA -11424 -11082
PIK3CA -5426 -9599
PIK3CB -9217 -10250
PIK3R1 10169 -9568
PIK3R2 -6506 -5848
SOS1 -7259 -9921
STAT1 -8311 -10243
STAT3 12160 -10670



Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants

Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
metric value
setSize 12
pMANOVA 4.81e-05
p.adjustMANOVA 0.000141
s.dist 0.763
s.KO -0.263
s.drug -0.716
p.KO 0.114
p.drug 1.74e-05




Top 20 genes
Gene KO drug
PDGFRA -11424 -11082
PIK3CB -9217 -10250
STAT1 -8311 -10243
SOS1 -7259 -9921
GRB2 -6137 -10524
PIK3CA -5426 -9599
PIK3R2 -6506 -5848
NRAS -3309 -9724

Click HERE to show all gene set members

All member genes
KO drug
GRB2 -6137 -10524
HRAS -8054 12320
KRAS 12719 -8619
NRAS -3309 -9724
PDGFRA -11424 -11082
PIK3CA -5426 -9599
PIK3CB -9217 -10250
PIK3R1 10169 -9568
PIK3R2 -6506 -5848
SOS1 -7259 -9921
STAT1 -8311 -10243
STAT3 12160 -10670



Beta-catenin phosphorylation cascade

Beta-catenin phosphorylation cascade
metric value
setSize 17
pMANOVA 8.19e-07
p.adjustMANOVA 3.66e-06
s.dist 0.762
s.KO -0.273
s.drug -0.711
p.KO 0.0512
p.drug 3.79e-07




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
CSNK1A1 -9043 -10837
AXIN1 -11360 -7258
AMER1 -7397 -8126
PPP2R5A -4776 -9580
PPP2R1A -9193 -4828
PPP2R5B -8731 -4219
PPP2CA -3124 -7225
FRAT2 -7878 -2844
PPP2R5E -847 -10491

Click HERE to show all gene set members

All member genes
KO drug
AMER1 -7397 -8126
APC 7962 -10237
AXIN1 -11360 -7258
CSNK1A1 -9043 -10837
CTNNB1 12434 -11116
FRAT1 208 -2333
FRAT2 -7878 -2844
GSK3B 7016 -10755
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5A -4776 -9580
PPP2R5B -8731 -4219
PPP2R5C 5890 -5302
PPP2R5D -11383 -11113
PPP2R5E -847 -10491



tRNA processing in the mitochondrion

tRNA processing in the mitochondrion
metric value
setSize 20
pMANOVA 6.21e-08
p.adjustMANOVA 3.42e-07
s.dist 0.755
s.KO 0.16
s.drug 0.738
p.KO 0.216
p.drug 1.09e-08




Top 20 genes
Gene KO drug
MT-CO1 9067 13178
MT-ATP8 9404 12604
MT-CO2 8603 13180
MT-ATP6 8420 13018
MT-CO3 8245 13176
MT-ND3 6571 13181
MT-CYB 5991 13184
MT-ND1 5209 13177
MT-ND6 4676 13045
MT-ND5 4289 13012
HSD17B10 2620 11931
MT-ND4L 2132 13172
MT-ND4 566 13174

Click HERE to show all gene set members

All member genes
KO drug
ELAC2 -9745 -1209
HSD17B10 2620 11931
MT-ATP6 8420 13018
MT-ATP8 9404 12604
MT-CO1 9067 13178
MT-CO2 8603 13180
MT-CO3 8245 13176
MT-CYB 5991 13184
MT-ND1 5209 13177
MT-ND2 -1457 13183
MT-ND3 6571 13181
MT-ND4 566 13174
MT-ND4L 2132 13172
MT-ND5 4289 13012
MT-ND6 4676 13045
MT-RNR1 -5225 13169
MT-RNR2 -1383 13168
PRORP -2649 -8367
TRMT10C -106 3998
TRNT1 -2728 -3540



Response of EIF2AK4 (GCN2) to amino acid deficiency

Response of EIF2AK4 (GCN2) to amino acid deficiency
metric value
setSize 99
pMANOVA 6.6e-41
p.adjustMANOVA 5.37e-39
s.dist 0.755
s.KO -0.423
s.drug 0.625
p.KO 3.36e-13
p.drug 5.07e-27




Top 20 genes
Gene KO drug
ASNS -10878 12349
RPL22L1 -10448 12221
RPL9 -9659 12806
RPS17 -10534 11631
RPL34 -9357 12996
RPL12 -9329 12992
RPL26L1 -9387 12770
RPS13 -9450 12652
RPS25 -9371 12690
RPL37A -9347 12675
RPS18 -9122 12984
RPL17 -8989 12909
RPL31 -8781 13131
RPS6 -9225 12405
RPS15A -8754 12989
RPL36 -8818 12868
FAU -8610 13102
RPL26 -8797 12658
RPLP2 -8225 12999
RPL11 -8529 12382

Click HERE to show all gene set members

All member genes
KO drug
ASNS -10878 12349
ATF2 -8942 -9289
ATF3 -4081 -4353
ATF4 -6768 11948
CEBPB -7116 12656
CEBPG -9940 6581
DDIT3 -9395 10987
EIF2AK4 10865 -7766
EIF2S1 -8950 -8774
EIF2S2 -10653 -6089
EIF2S3 -10174 -5022
FAU -8610 13102
GCN1 10665 -8257
IMPACT -1732 -8127
RPL10 -3821 1598
RPL10A -9707 -8212
RPL11 -8529 12382
RPL12 -9329 12992
RPL13 -3469 12598
RPL13A -6854 6955
RPL14 -6386 13137
RPL15 -786 12153
RPL17 -8989 12909
RPL18 -6672 12800
RPL18A -6976 11926
RPL19 3924 12911
RPL21 -6322 5141
RPL22 -5554 9520
RPL22L1 -10448 12221
RPL23 5769 12922
RPL23A 11361 -5257
RPL24 -4591 12995
RPL26 -8797 12658
RPL26L1 -9387 12770
RPL27 6735 11625
RPL27A -7818 13051
RPL28 -5809 12962
RPL29 -4515 12915
RPL3 -6827 -4536
RPL30 -3907 11096
RPL31 -8781 13131
RPL32 -5028 12983
RPL34 -9357 12996
RPL35 -8027 13097
RPL35A -1449 12789
RPL36 -8818 12868
RPL36A -4480 13010
RPL36AL -8216 12702
RPL37 -4624 13134
RPL37A -9347 12675
RPL38 1558 13140
RPL39 -6168 11962
RPL39L -6608 -6269
RPL3L -510 7904
RPL4 11351 12558
RPL41 -4616 -6075
RPL5 4679 12075
RPL6 -6903 12730
RPL7 -3327 -8789
RPL7A -6163 11708
RPL8 -7572 10323
RPL9 -9659 12806
RPLP0 -1504 -7331
RPLP1 9026 12731
RPLP2 -8225 12999
RPS10 -8384 10665
RPS11 -7725 12935
RPS12 -7872 11600
RPS13 -9450 12652
RPS14 -1180 12428
RPS15 -7430 12908
RPS15A -8754 12989
RPS16 -3844 12941
RPS17 -10534 11631
RPS18 -9122 12984
RPS19 -7633 12888
RPS2 -10222 8916
RPS20 -4961 13095
RPS21 -3001 13022
RPS23 6940 11907
RPS24 2369 13034
RPS25 -9371 12690
RPS26 -2615 13114
RPS27 651 11270
RPS27A 5357 6464
RPS27L 7330 12750
RPS28 2716 12485
RPS29 -652 9078
RPS3 -7756 12135
RPS3A -9170 5257
RPS4X -8542 12239
RPS5 -6283 -7965
RPS6 -9225 12405
RPS7 5142 12976
RPS8 -5812 12745
RPS9 -8815 10189
RPSA 292 11576
TRIB3 -3221 -5552
UBA52 -6807 11639



ERK/MAPK targets

ERK/MAPK targets
metric value
setSize 22
pMANOVA 2.93e-08
p.adjustMANOVA 1.77e-07
s.dist 0.751
s.KO -0.352
s.drug -0.663
p.KO 0.00427
p.drug 7.08e-08




Top 20 genes
Gene KO drug
PPP2R5D -11383 -11113
PPP2CB -11374 -10028
MAPK1 -9173 -10906
MAPK3 -9742 -9271
RPS6KA3 -8355 -9502
RPS6KA2 -8378 -9101
MAPK14 -9586 -7538
RPS6KA5 -8869 -7063
VRK3 -8775 -7133
DUSP7 -4800 -10041
PPP2R1A -9193 -4828
ELK1 -10880 -3893
MAPK7 -7980 -4568
MEF2C -8056 -4261
MEF2A -4972 -5692
PPP2CA -3124 -7225

Click HERE to show all gene set members

All member genes
KO drug
DUSP3 11933 -9367
DUSP4 2520 -11183
DUSP6 10590 -5904
DUSP7 -4800 -10041
ELK1 -10880 -3893
MAPK1 -9173 -10906
MAPK11 10678 4248
MAPK14 -9586 -7538
MAPK3 -9742 -9271
MAPK7 -7980 -4568
MEF2A -4972 -5692
MEF2C -8056 -4261
PPP2CA -3124 -7225
PPP2CB -11374 -10028
PPP2R1A -9193 -4828
PPP2R1B 6255 -5465
PPP2R5D -11383 -11113
RPS6KA1 12818 -7761
RPS6KA2 -8378 -9101
RPS6KA3 -8355 -9502
RPS6KA5 -8869 -7063
VRK3 -8775 -7133



Non-integrin membrane-ECM interactions

Non-integrin membrane-ECM interactions
metric value
setSize 41
pMANOVA 1.27e-16
p.adjustMANOVA 2.25e-15
s.dist 0.751
s.KO 0.2
s.drug -0.724
p.KO 0.0268
p.drug 1e-15




Top 20 genes
Gene KO drug
LAMC1 12854 -11227
ITGB3 12688 -11286
PDGFB 12741 -11178
AGRN 12518 -11205
LAMB2 12607 -10832
LAMA5 12583 -10447
SDC4 12322 -10633
LAMA1 12802 -10091
PRKCA 12366 -10396
ITGB5 12503 -10104
ITGB4 12465 -8452
DDR1 12660 -8206
THBS1 12626 -7518
PDGFA 12623 -7408
ITGA2 8062 -11213
ACTN1 8122 -10816
SDC1 12230 -7104
SDC3 12401 -6760
LAMB3 7018 -11255
LAMC2 10786 -6533

Click HERE to show all gene set members

All member genes
KO drug
ACTN1 8122 -10816
AGRN 12518 -11205
CASK -5732 -8641
DAG1 6148 -8573
DDR1 12660 -8206
DDR2 -9960 -7915
DMD -237 910
FGF2 -5091 -5204
HSPG2 -9046 -9768
ITGA2 8062 -11213
ITGA6 -7384 -11184
ITGAV 144 -11011
ITGB1 -3655 -11215
ITGB3 12688 -11286
ITGB4 12465 -8452
ITGB5 12503 -10104
LAMA1 12802 -10091
LAMA2 -8729 -4164
LAMA3 -11238 4464
LAMA4 -7403 -10348
LAMA5 12583 -10447
LAMB1 -9087 -10329
LAMB2 12607 -10832
LAMB3 7018 -11255
LAMC1 12854 -11227
LAMC2 10786 -6533
LAMC3 11660 -2369
NRXN1 -7510 141
NTN4 -8804 -7703
PDGFA 12623 -7408
PDGFB 12741 -11178
PRKCA 12366 -10396
SDC1 12230 -7104
SDC2 -6754 -5737
SDC3 12401 -6760
SDC4 12322 -10633
TGFB1 -3526 -8816
THBS1 12626 -7518
TNC -10537 -10838
TRAPPC4 -10355 -4660
TTR -212 1928



Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)

Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
metric value
setSize 93
pMANOVA 6.86e-38
p.adjustMANOVA 4.02e-36
s.dist 0.749
s.KO -0.424
s.drug 0.617
p.KO 1.55e-12
p.drug 6.83e-25




Top 20 genes
Gene KO drug
RPL22L1 -10448 12221
RPL9 -9659 12806
RPS17 -10534 11631
RPL34 -9357 12996
RPL12 -9329 12992
RPL26L1 -9387 12770
RPS13 -9450 12652
RPS25 -9371 12690
RPL37A -9347 12675
RPS18 -9122 12984
RPL17 -8989 12909
RPL31 -8781 13131
RPS6 -9225 12405
RPS15A -8754 12989
RPL36 -8818 12868
FAU -8610 13102
RPL26 -8797 12658
RPLP2 -8225 12999
RPL11 -8529 12382
RPL35 -8027 13097

Click HERE to show all gene set members

All member genes
KO drug
EIF4G1 9159 -10287
ETF1 -5515 -9496
FAU -8610 13102
GSPT1 -11018 -10261
GSPT2 -5509 -6727
NCBP1 -7784 -5234
NCBP2 -6378 -6281
PABPC1 -7033 -10406
RPL10 -3821 1598
RPL10A -9707 -8212
RPL11 -8529 12382
RPL12 -9329 12992
RPL13 -3469 12598
RPL13A -6854 6955
RPL14 -6386 13137
RPL15 -786 12153
RPL17 -8989 12909
RPL18 -6672 12800
RPL18A -6976 11926
RPL19 3924 12911
RPL21 -6322 5141
RPL22 -5554 9520
RPL22L1 -10448 12221
RPL23 5769 12922
RPL23A 11361 -5257
RPL24 -4591 12995
RPL26 -8797 12658
RPL26L1 -9387 12770
RPL27 6735 11625
RPL27A -7818 13051
RPL28 -5809 12962
RPL29 -4515 12915
RPL3 -6827 -4536
RPL30 -3907 11096
RPL31 -8781 13131
RPL32 -5028 12983
RPL34 -9357 12996
RPL35 -8027 13097
RPL35A -1449 12789
RPL36 -8818 12868
RPL36A -4480 13010
RPL36AL -8216 12702
RPL37 -4624 13134
RPL37A -9347 12675
RPL38 1558 13140
RPL39 -6168 11962
RPL39L -6608 -6269
RPL3L -510 7904
RPL4 11351 12558
RPL41 -4616 -6075
RPL5 4679 12075
RPL6 -6903 12730
RPL7 -3327 -8789
RPL7A -6163 11708
RPL8 -7572 10323
RPL9 -9659 12806
RPLP0 -1504 -7331
RPLP1 9026 12731
RPLP2 -8225 12999
RPS10 -8384 10665
RPS11 -7725 12935
RPS12 -7872 11600
RPS13 -9450 12652
RPS14 -1180 12428
RPS15 -7430 12908
RPS15A -8754 12989
RPS16 -3844 12941
RPS17 -10534 11631
RPS18 -9122 12984
RPS19 -7633 12888
RPS2 -10222 8916
RPS20 -4961 13095
RPS21 -3001 13022
RPS23 6940 11907
RPS24 2369 13034
RPS25 -9371 12690
RPS26 -2615 13114
RPS27 651 11270
RPS27A 5357 6464
RPS27L 7330 12750
RPS28 2716 12485
RPS29 -652 9078
RPS3 -7756 12135
RPS3A -9170 5257
RPS4X -8542 12239
RPS5 -6283 -7965
RPS6 -9225 12405
RPS7 5142 12976
RPS8 -5812 12745
RPS9 -8815 10189
RPSA 292 11576
UBA52 -6807 11639
UPF1 -10419 -10092



Complex I biogenesis

Complex I biogenesis
metric value
setSize 57
pMANOVA 8.21e-22
p.adjustMANOVA 2.23e-20
s.dist 0.74
s.KO -0.123
s.drug 0.729
p.KO 0.109
p.drug 1.49e-21




Top 20 genes
Gene KO drug
NDUFA6 -10640 12901
NDUFB10 -9687 12582
NDUFA8 -8774 12900
NDUFS3 -8653 12725
NDUFB9 -8544 12805
NDUFS8 -7989 12773
NDUFB6 -8238 12165
NDUFAB1 -10558 8746
NDUFV2 -6865 13148
NDUFC1 -7186 12437
NDUFAF4 -8760 9608
NDUFS5 -6394 13145
NDUFV3 -6779 12304
NDUFB11 -7090 11583
NDUFA1 -6222 13127
TMEM126B -8036 9815
NDUFS6 -6327 12108
NDUFA5 -6593 11094
NDUFAF2 -5167 12574
ECSIT -6333 10115

Click HERE to show all gene set members

All member genes
KO drug
ACAD9 12457 11377
COA1 11438 12298
ECSIT -6333 10115
MT-ND1 5209 13177
MT-ND2 -1457 13183
MT-ND3 6571 13181
MT-ND4 566 13174
MT-ND5 4289 13012
MT-ND6 4676 13045
NDUFA1 -6222 13127
NDUFA10 -7241 -4286
NDUFA11 9807 12851
NDUFA12 6720 13049
NDUFA13 -4424 12971
NDUFA2 5937 13125
NDUFA3 -4508 13084
NDUFA5 -6593 11094
NDUFA6 -10640 12901
NDUFA7 8872 13143
NDUFA8 -8774 12900
NDUFA9 2605 10360
NDUFAB1 -10558 8746
NDUFAF1 2883 9463
NDUFAF2 -5167 12574
NDUFAF3 10175 13112
NDUFAF4 -8760 9608
NDUFAF5 -3460 9719
NDUFAF6 -5625 10508
NDUFAF7 6751 8883
NDUFB1 8092 13163
NDUFB10 -9687 12582
NDUFB11 -7090 11583
NDUFB2 11367 12511
NDUFB3 1661 12046
NDUFB4 8888 13008
NDUFB5 -3244 -5075
NDUFB6 -8238 12165
NDUFB7 -4205 12444
NDUFB8 8367 13039
NDUFB9 -8544 12805
NDUFC1 -7186 12437
NDUFC2 -5184 11409
NDUFS1 -9609 -7041
NDUFS2 3967 -10068
NDUFS3 -8653 12725
NDUFS4 6388 3949
NDUFS5 -6394 13145
NDUFS6 -6327 12108
NDUFS7 5531 12411
NDUFS8 -7989 12773
NDUFV1 -5404 8980
NDUFV2 -6865 13148
NDUFV3 -6779 12304
NUBPL 8039 -8010
TIMMDC1 9211 -3329
TMEM126B -8036 9815
TMEM186 -8187 5086



Defective B4GALT7 causes EDS, progeroid type

Defective B4GALT7 causes EDS, progeroid type
metric value
setSize 18
pMANOVA 1.1e-07
p.adjustMANOVA 5.83e-07
s.dist 0.739
s.KO 0.371
s.drug -0.639
p.KO 0.00644
p.drug 2.71e-06




Top 20 genes
Gene KO drug
CSPG4 12459 -11273
AGRN 12518 -11205
SDC4 12322 -10633
GPC4 11190 -8942
SDC1 12230 -7104
SDC3 12401 -6760
B4GALT7 10562 -4980
BCAN 12079 -4013
GPC5 7673 -3135
BGN 11953 -1313
GPC1 1951 -7922
NCAN 3533 -1773
CSPG5 545 -3163

Click HERE to show all gene set members

All member genes
KO drug
AGRN 12518 -11205
B4GALT7 10562 -4980
BCAN 12079 -4013
BGN 11953 -1313
CSPG4 12459 -11273
CSPG5 545 -3163
GPC1 1951 -7922
GPC2 -3913 -3279
GPC4 11190 -8942
GPC5 7673 -3135
GPC6 -6095 -11229
HSPG2 -9046 -9768
NCAN 3533 -1773
SDC1 12230 -7104
SDC2 -6754 -5737
SDC3 12401 -6760
SDC4 12322 -10633
VCAN -1861 -11263



Formation of the ternary complex, and subsequently, the 43S complex

Formation of the ternary complex, and subsequently, the 43S complex
metric value
setSize 50
pMANOVA 7.28e-20
p.adjustMANOVA 1.67e-18
s.dist 0.731
s.KO -0.501
s.drug 0.532
p.KO 8.83e-10
p.drug 7.23e-11




Top 20 genes
Gene KO drug
RPS17 -10534 11631
RPS13 -9450 12652
RPS25 -9371 12690
RPS18 -9122 12984
RPS6 -9225 12405
RPS15A -8754 12989
FAU -8610 13102
RPS4X -8542 12239
RPS11 -7725 12935
EIF3C -8843 11244
RPS19 -7633 12888
EIF3M -10718 9044
EIF3I -7897 12235
RPS15 -7430 12908
EIF3E -9070 10545
RPS3 -7756 12135
RPS12 -7872 11600
RPS2 -10222 8916
RPS9 -8815 10189
RPS10 -8384 10665

Click HERE to show all gene set members

All member genes
KO drug
EIF1AX -5479 11112
EIF2S1 -8950 -8774
EIF2S2 -10653 -6089
EIF2S3 -10174 -5022
EIF3A -5233 -9195
EIF3B -4779 -8277
EIF3C -8843 11244
EIF3D -10400 -7621
EIF3E -9070 10545
EIF3F -1343 -5879
EIF3G -7655 4326
EIF3H -8110 -1879
EIF3I -7897 12235
EIF3J -4825 -4367
EIF3K -2668 9951
EIF3L -9160 -8016
EIF3M -10718 9044
FAU -8610 13102
RPS10 -8384 10665
RPS11 -7725 12935
RPS12 -7872 11600
RPS13 -9450 12652
RPS14 -1180 12428
RPS15 -7430 12908
RPS15A -8754 12989
RPS16 -3844 12941
RPS17 -10534 11631
RPS18 -9122 12984
RPS19 -7633 12888
RPS2 -10222 8916
RPS20 -4961 13095
RPS21 -3001 13022
RPS23 6940 11907
RPS24 2369 13034
RPS25 -9371 12690
RPS26 -2615 13114
RPS27 651 11270
RPS27A 5357 6464
RPS27L 7330 12750
RPS28 2716 12485
RPS29 -652 9078
RPS3 -7756 12135
RPS3A -9170 5257
RPS4X -8542 12239
RPS5 -6283 -7965
RPS6 -9225 12405
RPS7 5142 12976
RPS8 -5812 12745
RPS9 -8815 10189
RPSA 292 11576



Signaling by PDGFR in disease

Signaling by PDGFR in disease
metric value
setSize 19
pMANOVA 5.53e-07
p.adjustMANOVA 2.59e-06
s.dist 0.726
s.KO -0.198
s.drug -0.698
p.KO 0.135
p.drug 1.36e-07




Top 20 genes
Gene KO drug
PDGFRA -11424 -11082
PIK3CB -9217 -10250
STAT1 -8311 -10243
SOS1 -7259 -9921
GRB2 -6137 -10524
PIK3CA -5426 -9599
STRN -4990 -10079
FIP1L1 -10927 -4497
WDR48 -6426 -7065
PIK3R2 -6506 -5848
NRAS -3309 -9724
GOLGA4 -1644 -10260
KDR -650 -4500

Click HERE to show all gene set members

All member genes
KO drug
ETV6 10751 -5574
FIP1L1 -10927 -4497
GOLGA4 -1644 -10260
GRB2 -6137 -10524
HRAS -8054 12320
KANK1 11265 -8486
KDR -650 -4500
KRAS 12719 -8619
NRAS -3309 -9724
PDGFRA -11424 -11082
PIK3CA -5426 -9599
PIK3CB -9217 -10250
PIK3R1 10169 -9568
PIK3R2 -6506 -5848
SOS1 -7259 -9921
STAT1 -8311 -10243
STAT3 12160 -10670
STRN -4990 -10079
WDR48 -6426 -7065



MET promotes cell motility

MET promotes cell motility
metric value
setSize 29
pMANOVA 1.04e-10
p.adjustMANOVA 1.03e-09
s.dist 0.725
s.KO -0.011
s.drug -0.725
p.KO 0.919
p.drug 1.37e-11




Top 20 genes
Gene KO drug
CRKL -11456 -9981
CRK -11328 -8779
LAMB1 -9087 -10329
PTK2 -9167 -10148
RAPGEF1 -9306 -9048
SRC -11388 -7284
LAMA4 -7403 -10348
RAP1B -8213 -8902
GRB2 -6137 -10524
GAB1 -6660 -8223
ITGB1 -3655 -11215
LAMA2 -8729 -4164
RAC1 -7472 -3724
HGF -5157 -4177
RAP1A -1904 -6372

Click HERE to show all gene set members

All member genes
KO drug
CRK -11328 -8779
CRKL -11456 -9981
DOCK7 10605 -10745
GAB1 -6660 -8223
GRB2 -6137 -10524
HGF -5157 -4177
ITGA2 8062 -11213
ITGA3 12831 -9596
ITGB1 -3655 -11215
LAMA1 12802 -10091
LAMA2 -8729 -4164
LAMA3 -11238 4464
LAMA4 -7403 -10348
LAMA5 12583 -10447
LAMB1 -9087 -10329
LAMB2 12607 -10832
LAMB3 7018 -11255
LAMC1 12854 -11227
LAMC2 10786 -6533
LAMC3 11660 -2369
MET 10796 -11047
PTK2 -9167 -10148
RAC1 -7472 -3724
RAP1A -1904 -6372
RAP1B -8213 -8902
RAPGEF1 -9306 -9048
SRC -11388 -7284
TNS3 11628 -8857
TNS4 9700 3510



Regulation of gene expression by Hypoxia-inducible Factor

Regulation of gene expression by Hypoxia-inducible Factor
metric value
setSize 10
pMANOVA 0.000408
p.adjustMANOVA 0.000976
s.dist 0.721
s.KO -0.0291
s.drug -0.72
p.KO 0.874
p.drug 7.95e-05




Top 20 genes
Gene KO drug
CREBBP -10387 -10534
EP300 -9471 -10672
ARNT -9141 -10063
CA9 -11518 -7389
HIGD1A -886 -3864

Click HERE to show all gene set members

All member genes
KO drug
ARNT -9141 -10063
CA9 -11518 -7389
CITED2 7410 -11022
CREBBP -10387 -10534
EP300 -9471 -10672
EPAS1 12897 -11206
HIF1A 11458 -11105
HIF3A 672 4805
HIGD1A -886 -3864
VEGFA 12141 -7594



Deadenylation of mRNA

Deadenylation of mRNA
metric value
setSize 22
pMANOVA 1.59e-07
p.adjustMANOVA 8.27e-07
s.dist 0.72
s.KO -0.491
s.drug -0.526
p.KO 6.62e-05
p.drug 1.96e-05




Top 20 genes
Gene KO drug
TNKS1BP1 -11502 -10413
EIF4B -9005 -10529
CNOT7 -11301 -7685
CNOT8 -8665 -9856
EIF4E -10282 -8119
EIF4A2 -9799 -8479
CNOT6L -8358 -9361
PABPC1 -7033 -10406
CNOT11 -9135 -7816
PAIP1 -8427 -7081
PAN3 -4919 -4940
EIF4A1 -8156 -2754
PARN -10553 -1376
CNOT4 -2308 -5239
EIF4A3 -628 -6343

Click HERE to show all gene set members

All member genes
KO drug
CNOT1 2534 -11219
CNOT10 -9314 9295
CNOT11 -9135 -7816
CNOT2 10950 -6125
CNOT3 -10183 4663
CNOT4 -2308 -5239
CNOT6 4352 -7718
CNOT6L -8358 -9361
CNOT7 -11301 -7685
CNOT8 -8665 -9856
EIF4A1 -8156 -2754
EIF4A2 -9799 -8479
EIF4A3 -628 -6343
EIF4B -9005 -10529
EIF4E -10282 -8119
EIF4G1 9159 -10287
PABPC1 -7033 -10406
PAIP1 -8427 -7081
PAN2 -4742 11237
PAN3 -4919 -4940
PARN -10553 -1376
TNKS1BP1 -11502 -10413



Here is the session info with all the versions of packages used.

sessionInfo()
## R version 4.2.1 (2022-06-23)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.1 LTS
## 
## Matrix products: default
## BLAS:   /usr/lib/x86_64-linux-gnu/openblas-pthread/libblas.so.3
## LAPACK: /usr/lib/x86_64-linux-gnu/openblas-pthread/libopenblasp-r0.3.20.so
## 
## locale:
##  [1] LC_CTYPE=en_US.UTF-8       LC_NUMERIC=C              
##  [3] LC_TIME=en_US.UTF-8        LC_COLLATE=en_US.UTF-8    
##  [5] LC_MONETARY=en_US.UTF-8    LC_MESSAGES=en_US.UTF-8   
##  [7] LC_PAPER=en_US.UTF-8       LC_NAME=C                 
##  [9] LC_ADDRESS=C               LC_TELEPHONE=C            
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C       
## 
## attached base packages:
## [1] stats4    stats     graphics  grDevices utils     datasets  methods  
## [8] base     
## 
## other attached packages:
##  [1] pkgload_1.3.0               GGally_2.1.2               
##  [3] gtools_3.9.2.2              echarts4r_0.4.4            
##  [5] beeswarm_0.4.0              vioplot_0.3.7              
##  [7] sm_2.2-5.7                  kableExtra_1.3.4           
##  [9] topconfects_1.12.0          limma_3.52.1               
## [11] eulerr_6.1.1                mitch_1.8.0                
## [13] MASS_7.3-58                 fgsea_1.22.0               
## [15] gplots_3.1.3                DESeq2_1.36.0              
## [17] SummarizedExperiment_1.26.1 Biobase_2.56.0             
## [19] MatrixGenerics_1.8.0        matrixStats_0.62.0         
## [21] GenomicRanges_1.48.0        GenomeInfoDb_1.32.2        
## [23] IRanges_2.30.0              S4Vectors_0.34.0           
## [25] BiocGenerics_0.42.0         reshape2_1.4.4             
## [27] forcats_0.5.1               stringr_1.4.0              
## [29] dplyr_1.0.9                 purrr_0.3.4                
## [31] readr_2.1.2                 tidyr_1.2.0                
## [33] tibble_3.1.7                ggplot2_3.3.6              
## [35] tidyverse_1.3.1             zoo_1.8-10                 
## 
## loaded via a namespace (and not attached):
##   [1] readxl_1.4.0           backports_1.4.1        fastmatch_1.1-3       
##   [4] systemfonts_1.0.4      plyr_1.8.7             polylabelr_0.2.0      
##   [7] splines_4.2.1          BiocParallel_1.30.3    digest_0.6.29         
##  [10] htmltools_0.5.2        fansi_1.0.3            magrittr_2.0.3        
##  [13] memoise_2.0.1          tzdb_0.3.0             Biostrings_2.64.0     
##  [16] annotate_1.74.0        modelr_0.1.8           svglite_2.1.0         
##  [19] colorspace_2.0-3       blob_1.2.3             rvest_1.0.2           
##  [22] haven_2.5.0            xfun_0.31              crayon_1.5.1          
##  [25] RCurl_1.98-1.7         jsonlite_1.8.0         genefilter_1.78.0     
##  [28] survival_3.4-0         glue_1.6.2             polyclip_1.10-0       
##  [31] gtable_0.3.0           zlibbioc_1.42.0        XVector_0.36.0        
##  [34] webshot_0.5.3          DelayedArray_0.22.0    scales_1.2.0          
##  [37] DBI_1.1.3              Rcpp_1.0.8.3           viridisLite_0.4.0     
##  [40] xtable_1.8-4           bit_4.0.4              htmlwidgets_1.5.4     
##  [43] httr_1.4.3             RColorBrewer_1.1-3     ellipsis_0.3.2        
##  [46] farver_2.1.0           pkgconfig_2.0.3        reshape_0.8.9         
##  [49] XML_3.99-0.10          sass_0.4.1             dbplyr_2.2.1          
##  [52] locfit_1.5-9.5         utf8_1.2.2             labeling_0.4.2        
##  [55] tidyselect_1.1.2       rlang_1.0.3            later_1.3.0           
##  [58] AnnotationDbi_1.58.0   munsell_0.5.0          cellranger_1.1.0      
##  [61] tools_4.2.1            cachem_1.0.6           cli_3.3.0             
##  [64] generics_0.1.2         RSQLite_2.2.14         broom_0.8.0           
##  [67] evaluate_0.15          fastmap_1.1.0          yaml_2.3.5            
##  [70] knitr_1.39             bit64_4.0.5            fs_1.5.2              
##  [73] caTools_1.18.2         KEGGREST_1.36.2        mime_0.12             
##  [76] xml2_1.3.3             compiler_4.2.1         rstudioapi_0.13       
##  [79] png_0.1-7              reprex_2.0.1           geneplotter_1.74.0    
##  [82] bslib_0.3.1            stringi_1.7.6          highr_0.9             
##  [85] lattice_0.20-45        Matrix_1.4-1           vctrs_0.4.1           
##  [88] pillar_1.7.0           lifecycle_1.0.1        jquerylib_0.1.4       
##  [91] data.table_1.14.2      bitops_1.0-7           httpuv_1.6.5          
##  [94] R6_2.5.1               promises_1.2.0.1       KernSmooth_2.23-20    
##  [97] gridExtra_2.3          codetools_0.2-18       assertthat_0.2.1      
## [100] withr_2.5.0            GenomeInfoDbData_1.2.8 parallel_4.2.1        
## [103] hms_1.1.1              grid_4.2.1             rmarkdown_2.14        
## [106] shiny_1.7.1            lubridate_1.8.0

END of report